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SYNOPSIS 
This PhD developed a national network and research platform for the study of 
serious and uncommon disorders in early pregnancy: The UK Early Pregnancy 
Surveillance System (UKEPSS).  Using the UKEPSS platform, with an early 
pregnancy network of 86 UK hospitals and Early Pregnancy Units (EPUs), a nation-
wide prospective cohort study of caesarean scar pregnancy was performed.  
Based on the findings of this study we recommend that; 
x Women who have had a caesarean section delivery should be counselled about 
the risk of caesarean scar pregnancy (CSP). 
x Women should be informed that the estimated UK incidence of CSP is 1 per 10 
000 maternities. Age, smoking, parity and number of caesarean sections are 
strongly associated with an increased risk of developing a CSP. 
x The most common presenting feature is vaginal bleeding. The mean gestation at 
presentation is 9 weeks (range 6 – 18 weeks). 
x Transvaginal ultrasound scan is the most commonly used investigation for the 
diagnosis of CSP. 
x Women should be counselled about the different treatment options for the 
management of CSP, including expectant, medical and surgical management, 
and the benefits and risks of each approach.  
x Surgical management with dilatation and curettage is associated with a high 
success rate and early discharge and in the majority of cases should be 
considered as first line management. 
x Treatment approach should be based on a shared management plan between the 
woman and the clinician. 
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Moreover, based on the findings of the second section of this thesis which comprises 
of systematic reviews in priority questions in miscarriage management, we suggest 
that; 
 
x Women presenting with early pregnancy bleeding may benefit from progestogen 
treatment. Current evidence on the effectiveness of progestogens to reduce 
miscarriage is weak and a high quality randomised controlled trial is recommended to 
address this question. Based on the findings of this review, funding was sought from 
the NIHR HTA programme, and we were successful in being awarded £1.8 million 
(co-applicant) to conduct a multi-centre randomised controlled trial (RCT): The 
PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial.  
 
x Women with hydrosalpinx undergoing IVF treatment have an increased risk of 
miscarriage. Treatment with salpingectomy may reduce the risk of miscarriage. 
Further research is needed to assess the benefit of screening for hydrosalpinx in 
women with a history of recurrent miscarriage. 
 
x Women of Black and Asian ethnicity appear to be at increased risk of 
miscarriage when compared to women of White ethnicity, a finding demonstrated in 
spontaneous and IVF conceived pregnancies. Further research is needed to 
understand the reasons for the observed difference to allow a targeted approach to 
investigations and management.  
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INTRODUCTION  
 
Early pregnancy complications are amongst the most common reasons for 
presentation to hospital in women during pregnancy. Approximately 210,000 (21%) 
early pregnancy complications occur in an estimated 1 million pregnancies per year 
in the UK. (1) These usually occur before 12 weeks gestation and include vaginal 
bleeding, miscarriage, ectopic pregnancies, pregnancies of unknown location, 
adnexal masses and molar pregnancies.  
Any complication in pregnancy can be extremely distressing to a woman. For 
instance, miscarriage can result in substantial adverse psychological impact for 
women and studies have shown that the level of distress and the bereavement 
reaction associated with miscarriages can be equivalent to those of women who have 
suffered the stillbirth of a term baby. (1) 
The most frequent complication of pregnancy is miscarriage, affecting one in five 
pregnancies.  Another early pregnancy complication is ectopic pregnancy with an 
estimated incidence of 11 per 1000 pregnancies, and a maternal mortality of 0.2 per 
1000 estimated ectopic pregnancies. About two thirds of these deaths are associated 
with substandard care.(2)  Over the years the Confidential Enquiries into Maternal 
Deaths reports have consistently shown that young women in the UK continue to die 
in early pregnancy.(3) The triennial reports have found that these deaths are often 
related to common early pregnancy complications, but can also result from serious 
and rare disorders occurring in early pregnancy. These disorders are difficult to 
manage as they are rare and under-researched. For the care provider, it is important 
to be able to recognise early pregnancy complications and their consequences in 
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order that they may be able to counsel and treat women appropriately. Failure to 
manage early pregnancy problems appropriately can lead to a variety of adverse 
outcomes, including evacuation of a normal pregnancy, mismanagement of an 
ectopic pregnancy, maternal dissatisfaction and medico-legal action. (4) 
 
AIMS 
 
 
The primary aim of this PhD is to develop a novel approach for the study of rare early 
pregnancy disorders. Using this platform I will study caesarean scar pregnancy, a 
serious and uncommon early pregnancy condition, prioritised by a national body of 
clinicians, academics and patient representatives. Secondly, I will perform a number 
of systematic reviews to address priority questions in miscarriage management. 
 
This thesis will therefore be divided into two sections; 
Section 1: UKEPSS study of caesarean scar pregnancy 
Section 2:  Systematic reviews of priority questions in miscarriage management 
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SECTION 1: THE UNITED KINGDOM EARLY PREGNANCY SURVEILLANCE 
SERVICE CAESAREAN SCAR PREGNANCY STUDY 
Objectives 
 
1. Establish a national network of Early Pregnancy Units  
2. Develop a national platform for the study of serious and uncommon 
conditions of early pregnancy: The United Kingdom Early Pregnancy 
Surveillance Service (UKEPSS) 
3. Study the serious and rare condition of caesarean scar pregnancy  using 
the UKEPSS platform 
 
UKEPSS 
The Confidential Enquiries into Maternal Deaths (CEMD) have consistently shown 
that women die in early pregnancy, often leaving behind a young family. The most 
recent MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and 
Confidential Enquiries across the UK) report listed 8 such deaths (between 2010 and 
2012). (3) Atypical presentations or complications of early pregnancy problems led to 
these maternal deaths. Sub-standard care was reported in a majority of the cases.  
 
The maternal deaths represent the tip of the iceberg. It is estimated that there are 
over 100 ‘near misses’ for every death. (5) Although collectively the conditions that 
result in deaths and near misses place a substantial burden on families and the NHS, 
individually they are uncommon. There is paucity in published evidence on the 
diagnosis, treatment and outcomes of these conditions. Hence, clinical practice is 
rarely based on reliable evidence.  
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Uncommon disorders are difficult to study because routine information sources are 
unreliable and comprehensive studies, such as the BEST survey of eclampsia in 
1992 require a large collaboration to identify relatively few cases.(6) A national 
collaboration can enable high quality research to improve our knowledge and help us 
provide better care for women with these problems.  UKOSS (UK Obstetric 
Surveillance System) (7) and BPSU (British Paediatric Surveillance Unit) (8) are 
examples of such national collaborations that have made enormous contributions to 
improving patient care. Research recommendations from these surveillance systems 
have been vital in guiding practice and improving patient care within the NHS. Since 
2005, UKOSS has published over 30 definitive reports to guide practice on critical 
conditions such as H1N1v influenza in pregnancy, uterine rupture and eclampsia. 
Similarly, BPSU (British Paediatric Surveillance Unit) has generated over 160 
research publications through a national reporting platform for rare conditions in 
paediatrics. BPSU surveys have informed policy on antenatal screening, identified 
the risks of faulty packaging of chemistry sets(9) and investigated concerns about 
vitamin K therapy,(10) water-births (11) and variant Creutzfeldt-Jakob (CJD) in British 
children. (12) 
 
This PhD proposes a national network and research platform for early pregnancy and 
emergency gynaecological conditions: The UK Early Pregnancy Surveillance System 
(UKEPSS). UKEPSS will use well-established approaches similar to those of UKOSS 
and BPSU. The UK offers a unique setting to study early pregnancy problems as the 
country is served by dedicated Early Pregnancy Units (EPUs); in the rest of the 
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world, early pregnancy problems are generally managed in general gynaecological or 
emergency departments. (13) 
CAESAREAN SCAR PREGNANCY SURVEILLANCE STUDY 
 
Ectopic pregnancy is defined as the implantation of a pregnancy outside of the 
uterine cavity and can be broadly divided into two groups; tubal and non-tubal 
ectopics. Non-tubal ectopics are rare in incidence, and can implant in locations such 
as the ovary, cervix, in caesarean section scars or peritoneum.  
Ectopic pregnancy remains a leading cause of maternal mortality in early pregnancy 
in the UK, with two thirds of these deaths attributed to atypical presentation and 
delayed diagnosis. 
Ectopic pregnancy was therefore prioritised as the first UKEPSS surveillance study,  
focusing on the condition of caesarean scar pregnancy. This condition was  
prioritised by a national body of clinicians and patient representatives from the 
Association of Early Pregnancy Units, (14) the Early Pregnancy Clinical Studies 
Group,(15) the Miscarriage Association (16) and the Ectopic Pregnancy Trust (17). 
Whilst the number of deliveries in NHS hospitals have decreased in the past year 
(from 671,255 in 2012-13, to 646,904 in 2013-2014), the NHS Maternity Statistics for 
England, 2013-14, have shown a rise in the caesarean section rate by 0.7 per cent, 
to 26.2 per cent or 166,081caesarean sections in 2013-14. Specifically, there has 
been an increase in the number of elective caesareans (2.5 per cent) while 
emergency caesarean rates are down 1.8 per cent. This continues the trend 
observed over recent years of increasing elective caesarean rates but a drop in the 
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emergency caesarean rates. (18)Women are routinely counselled about a number of 
complications that are associated with caesarean deliveries, however, one of the 
risks that clinicians and patients appear to be facing increasingly in recent years is 
that of caesarean scar pregnancy.  
 
Caesarean scar pregnancy is a rare and serious condition, which can be mistaken for 
a cervical pregnancy or a miscarriage, with the consequence of delayed diagnosis 
and life-threatening haemorrhage. (19) The study will look at the presentation, 
diagnosis, key management strategies and outcomes associated with this condition. 
 
The specific questions I will attempt to address are: 
1. What is the incidence of the condition? 
2. What are the presenting features of the condition?  
3. How is the condition diagnosed? 
4. What are the risk factors associated with caesarean scar pregnancy? For 
example, are age, ethnicity or number of previous caesarean sections 
associated with an increased risk of the condition 
5. How is the condition typically managed?  
6. What are the important variations in management? 
7. What are the outcomes? 
8. What are the factors associated with poor outcomes? 
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SECTION 2: SYSTEMATIC REVIEWS OF PRIORITY QUESTIONS IN 
MISCARRIAGE MANAGEMENT 
 
The Royal College of Obstetricians and Gynaecologists(20)  defines miscarriage as; 
 ‘..the spontaneous loss of pregnancy before the fetus reaches viability. The term 
therefore includes all pregnancy losses from the time of conception until 24 weeks of 
gestation. It should be noted that advances in neonatal care have resulted in a small 
number of babies surviving birth before 24 weeks of gestation.’ 
 
Through systematic reviews of the literature and meta-analyses of available data, I 
aim to address the following questions: 
 
PRIORITY QUESTION 1:  PROGESTOGEN FOR THE TREATMENT OF 
THREATENED MISCARRIAGE  
 
Objectives 
1. To determine the effectiveness of progestogens to reduce miscarriage in women 
presenting with early pregnancy bleeding 
2. To identify adverse effects associated with progestogen use 
 
Background 
Threatened miscarriage is a very common first-trimester problem occurring in up to 
one-third of pregnancies. (13) This is a clinical diagnosis defined as vaginal bleeding 
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in the first trimester with or without abdominal pain. 
 
 One in 5 pregnancies miscarry. Early pregnancy loss accounts for over 50,000 
admissions in the UK annually. (2) Miscarriage has the potential to cause both 
psychological and physical harm, including severe haemorrhage, infection, 
perforation of the womb during surgery for miscarriage, and occasionally death. 
(1;21;22) 
 
In December 2012, the National Institute of Health and Care Excellence (NICE) 
launched a national guideline on “Ectopic pregnancy and Miscarriage” (CG154) (2) in 
which they called for a key clinical trial on the effects of progesterone in preventing 
miscarriage in women with early pregnancy bleeding, stating “A very large 
multicentre randomised controlled trial of women treated with either 
progesterone/progestogen or placebo should be conducted.” The aim of this chapter 
is to evaluate the effectiveness of progestogen treatment to reduce miscarriage by 
systematically reviewing trials of the use of progestogens in women with early 
pregnancy bleeding. 
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PRIORITY QUESTION 2:  THE EFFECT OF PRESENCE AND MANAGEMENT OF 
HYDROSALPINX ON MISCARRIAGE RISK 
 
Objectives 
1. To determine the relationship between presence of hydrosalpinx and miscarriage  
2. To evaluate the benefit of management of hydrosalpinx in reducing miscarriage 
risk 
 
Background 
Hydrosalpinx is a fluid-filled distension of the fallopian tube in the presence of distal 
tubal occlusion. The incidence of hydrosalpinx within infertile women is between 10 
to 13% when diagnosed by ultrasound.  This figure increases to 30% with the use of 
hysterosalpingogram or laparoscopy. (23) The most common pathogen associated 
with tubal damage is Chlamydia trachomatis. In vitro fertilization was first introduced 
as a method to overcome tubal infertility. (24)  
 
It has been established that the presence of hydrosalpinx is associated with lower 
implantation and pregnancy rates.(25-27) Moreover, studies have demonstrated that 
treatment for hydrosalpinx can improve clinical pregnancy and live birth rate. (28;29) 
However, the question whether hydrosalpinx has a detrimental effect on an already 
established pregnancy, that is, when an intrauterine pregnancy is seen on 
ultrasonography is yet to be addressed. Moreover, it is not known whether treatment 
is beneficial in reducing miscarriage risk in these women. The aim of this review is to 
assess the effect of the presence and treatment of hydrosalpinx on miscarriage rate. 
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PRIORITY QUESTION 3:  THE EFFECT OF ETHNICITY ON MISCARRIAGE 
 
Objectives 
1. To determine the relationship between ethnicity and miscarriage risk 
2. To identify potentially at risk groups  
 
The most common cause of early miscarriages is chromosomal abnormalities, 
occurring in about half of all early miscarriages. (30) Other factors associated with 
miscarriage risk include female age, anti-phospholipid syndrome (APS), previous 
miscarriage, thrombophilia, infection and uterine anomalies. (31-34) A link between 
ethnicity and miscarriage risk has been previously suggested. (35) Ethnicity has been 
associated with many adverse pregnancy outcomes. For instance, spontaneous 
preterm birth and fetal growth restriction have been shown to differ significantly in 
women of different ethnic backgrounds. (36-38) 
No reviews to date have evaluated the effect of ethnicity on miscarriage. The aim of 
this chapter is to systematically review studies of ethnicity and pregnancy outcomes 
in early pregnancy.  
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 Chapter number 
Title Population Intervention  Comparison or 
reference 
standard 
Outcome (s) Research Design 
SECTION 1:  The UK Early Pregnancy Surveillance Service  study of caesarean scar pregnancy 
2 Establishing the 
UKEPSS network 
Early Pregnancy 
units 
Develop an early  
pregnancy  network 
None  Number and 
distribution of EPUs 
A national network of 
Early Pregnancy 
Units 
3 Ectopic pregnancy 
in a caesarean scar: 
a systematic review  
Women with 
caesarean scar 
pregnancy 
Surgical management Expectant and 
Medical 
management 
Successful treatment 
of CSP 
Complications 
 
Systematic review 
and meta-analysis  
 
4 
 
 
 
 
 
 
 
Caesarean scar 
pregnancy 
surveillance 
methodology 
Early Pregnancy 
Units 
 
Women with 
caesarean scar 
pregnancy 
Development of  the 
methodology for the 
study of caesaraen 
scar pregnancy 
using a national 
research platform  
  A national 
surveillance platform 
for the study of 
serious and 
uncommon early 
pregnancy disorders 
5 Surveillance 
findings 
Women with 
caesarean scar 
pregnancy 
Expectant, medical or 
surgical treatment 
Women with no 
CSP 
Expectant vs 
Medical vs 
Surgical 
Successful treatment 
of CSP 
Complications 
Time to discharge 
 
Cohort study 
SECTION 2:  Systematic reviews of priority questions in miscarriage management 
6  Progestogen for the 
treatment of 
threatened 
miscarriage 
 
Women presenting 
with early 
pregnancy bleeding 
Progestogen Placebo or no 
treatment 
Miscarriage  Systematic review 
and meta-analysis  
 
Survey 
7 The effect of 
presence and 
management of 
hydrosalpinx on 
miscarriage   
 
Women with 
hydrosalpinx 
undergoing IVF 
treatment 
Salpingectomy or tubal 
clipping 
Women without 
hydrosalpinx 
undergoing IVF 
 
No treatment 
Miscarriage 
 
Systematic review 
and meta-analysis  
8 Ethnicity and 
miscarriage  
Women of Black 
and Asian ethnicity 
None Women of white 
ethnicity 
Miscarriage Cohort study 
Systematic review 
and meta-analysis  
Table 1. Summary of chapters included in this thesis 
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SECTION 1: 
UKEPSS CAESAREAN SCAR PREGNANCY 
SURVEILLANCE STUDY 
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CHAPTER 2 
ESTABLISHING THE UNITED KINGDOM EARLY 
PREGNANCY SURVEILLANCE SERVICE (UKEPSS) 
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OBJECTIVES  
 
1.  Identify the number and geographical distribution of Early Pregnancy Units 
(EPUs) serving the UK 
2. Establish a national network of Early Pregnancy Units  
3. Develop the methodology for the study of serious and uncommon conditions 
of early pregnancy units through a national surveillance platform (UKEPSS) 
 
ESTABLISHING THE UKEPSS NETWORK 
 
Background 
 
Early pregnancy care has undergone radical changes over the years. The wide use 
of ultrasonography and the introduction of early pregnancy units (EPU) has brought 
about a shift from the inpatient admission of women with early pregnancy problems 
to general gynaecological wards, to outpatient management in specialist clinics. Early 
pregnancy assessment units have been established to facilitate the streamlining of 
patient care and to provide an effective service for the management of early 
pregnancy disorders.  Women who are found to have normal pregnancies are given 
reassurance, whilst those diagnosed with complications such as an ectopic 
pregnancy or miscarriage are given counselling and are managed as appropriate. 
(2;13;39) 
The earliest reported established Early Pregnancy Assessment Unit was in 1991 in 
the United Kingdom.  It demonstrated an improvement in the quality of care, whilst 
reducing the number of admissions and average length of stay with significant cost 
  
  
 
36 
 
 
savings.(13) For example, the administration of intravenous fluids and anti-emetics in 
an outpatient clinic setting has reduced the need for women having to be hospitalised 
for supportive treatment. Moreover, EPU, which are often lead by nurse specialists 
offer a setting for psychological support and follow up.  
Early pregnancy care has been revolutionised by the incorporation of ultrasound 
examination allowing women with ectopic pregnancy and other early pregnancy 
disorders to be assessed and followed up without the need for immediate 
intervention or admission. (40)  Scanning can be performed by trained 
gynaecologists, sonographers and specialist nurses, and the setting also provides 
supervised training opportunities for trainees and nurses.  
There is currently a lack of accurate information on the number and distribution of 
EPUs in the UK. The structure of the units varies from one unit to another and across 
regions. An overview of the EPUs registered with the Association of Early Pregnancy 
Units (AEPU) shows regional variations, with large numbers in the South East but 
comparatively few in the North Eastern areas. It is, therefore, not clear if access to 
EPU services is adequate across the regions, and what impact this may have on 
clinical outcomes. The information on the distribution of EPUs may facilitate service 
planning and policy, and may improve outcomes by identifying regions that require 
investment. Due to constant changes in practice and emerging evidence, a national 
network of early pregnancy units could facilitate the rapid dissemination and uptake 
of guidelines and recommendations, including those developed through UKEPSS 
studies. 
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Building the network 
 
I used multiple methods to identify and invite EPUs to join the UKEPSS network. 
These included: 
 Approaching units on the AEPU registry 
 Direct communication with all NHS hospitals in the UK 
 Contact via Early Pregnancy Clinical Studies Group (EPCSG), Miscarriage 
Association (MA) and Early Pregnancy Trust (EPT). 
 Announcement at the national AEPU conferences (2012, 2013, 2014) 
 Self-registration through UKEPSS website 
 Contact through obstetric units (on the UK Obstetric Surveillance System 
[UKOSS] network) 
 
Eighty six UK Early Pregnancy Units (EPUs) have registered with UKEPSS (Figure 
1). Each EPU is represented within the UKEPSS network by a nominated clinician, 
nurse and a sonographer, and there are currently 133 early pregnancy practitioners 
registered and active in the participation with UKEPSS. The UKEPSS Network 
collected details of EPUs in the UK with names of lead clinicians, nurses and 
sonographers. This information can be used nationally by service planners and policy 
makers, for instance, the Department of Health to gather data on geographical 
spread of early pregnancy services. One of the anticipated outputs of the UKEPSS 
network is the rapid dissemination of guidelines and uptake of evidence, which can 
have the potential to improve care and outcomes for patients. Details of the network 
are made available on the UKEPSS website (http://www.birmingham.ac.uk/ukepss) 
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for use by clinicians, researchers and patients. It is anticipated that the UKEPSS 
Network will be an enduring legacy and a platform for future research beyond the 
PhD programme.
    
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
London and Southeast  
Barts Health NHS Foundation Trust 
Buckinghamshire Healthcare NHS Trust 
Brighton and Sussex University Hospitals NHS Trust 
Chelsea and Westminster Hospital 
Colchester General Hospital 
Conquest Hospital, East Sussex Healthcare 
Darant Valley Hosiptal, Dartford, Kent 
Epsom General Hospital Surrey 
Royal Hampshire County Hospital EPU 
Heatherwood Hospital EPU 
Homerton Hospital EPAU, London 
King's College Hospital NHS Foundation Trust 
Kettering General Hospital 
Newham General Hospital 
North Middlesex University Hospital 
Queen Charlotte's and Chelsea Hospital 
Royal Berkshire Hospital 
St Peters Hospital, Chertsey 
University College Hospital, London 
West Middlesex University Hospital EPAU 
Whittington Hospital 
Wexham Park Hospital, Slough 
 
East Midlands and East Anglia  
Bedford Hospital 
EastDarant Valley Hospital  
Luton & Dunstable Hospital 
Milton Keynes General Hospital Trust EPU 
Nottingham University Hospitals NHS Trust EPAU 
Nurture Fertility, Nottingham University Hospitals NHS Trust 
Rosie Hospital, Cambridge University Hospitals FT 
Royal Berkshire Hospital 
Royal Derby Hospital GAU 
Peterborough City Hospital EPU 
 
Southwest  
Derriford Hospital Plymouth 
Dorset County Hospital 
Musgrove Park Hospital Taunton 
St Michael’s University Hospital 
Princess Anne Hospital, Southampton 
Poole Hospital EPU  
Royal Devon & Exeter Hospital Centre For Womens Health 
Salisbury NHS Foundation Trust EPU 
 
North West 
Blackpool Teaching Hospitals NHS Trust 
Blackpool Victoria Hospital EPAU 
Central Manchester University Hospitals 
Countess of Chester NHS Foundation Trust 
East Lancashire Hospitals Trust, Burnley General 
EPAU/GAU 
ELHT EPAU/Lancashire Womens Hospital 
Liverpool Women's NHS Foundation Trust 
Maternity Unit, Cumberland Infirmary 
North Cumbria University Hospitals NHS Trust 
Pennine Acute Hospitals NHS Trust 
Preston Lancashire Teaching Hospitals NHS 
Foundation Trust  
Southport & Ormskirk NHS Trust 
St Helens & Knowsley Hospital/Whiston Hospital 
Whiston  
St Mary's Hospital, Manchester 
Southport & Ormskirk NHS Trust 
West Cumberland Hospital, Whitehaven, Cumbria 
Whiston Hospital 
Wrightington, Wigan and Leigh Foundation NHS 
Trust 
 
 
North and North East 
Bradford Teaching Hospitals NHS Trust 
Calderdale & Huddersfield NHS Foundation Trust 
Harrogate District Hospital EPAU 
LIFE Newcastle Hospitals NHS Foundation Trust 
Newcastle upon Tyne Hospitals NHS Trust 
North Tyneside General Hospital 
QE Gateshead Health Foundation Trust 
St James University Hospital EPU 
Sunderland Royal Hospital 
University Hospital of North Durham 
York Hospital EPAU 
 Northern Ireland 
Belfast Health and 
 Social Care Trust 
Ulster Hospital, 
  Dundonald 
 
Wales 
Princess Of Wales  
Hospital  
 
Scotland 
Aberdeen Maternity Hospital Early Pregnancy Services 
Ayrshire Maternity Unit, University Hospital Crosshouse 
Dr Gray's Hospital (Elgin), NHS Grampian 
Forth Valley Royal Hospital 
Ninewells Hospital Dundee 
Pregnancy Support Centre, Edinburgh 
The MRC Centre for Reproductive Health, University of 
Edinburgh 
 
 
Figure 1.  UK EARLY PREGNANCY 
SURVEILLANCE SERVICE NETWORK 
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DEVELOPMENT OF THE METHODOLOGY FOR SURVEILLANCE  
 
 
UKEPSS collaboration 
The development of the UKEPSS network was described earlier in this chapter. 
Each EPU member was provided with access to a secure online database to report 
data on the conditions under surveillance.  
 
Monthly electronic cards (e-cards) 
Cases are collected through monthly electronic cards (e-cards) emailed monthly to 
a nominated clinician, nurse and ultrasonographer in each participating EPU. The e-
card asks the reporting clinician to indicate whether there has been a case of 
caesarean scar pregnancy in their unit using a simple tick box. It contains a “nothing 
to report” check box to positively verify there have not been any cases, which is 
important for determination of denominators and calculation of rates. The response 
is recorded on the Electronic Data Capture (EDC) system, which also identifies 
units which have not returned their cards. A reminder is sent after 7 days and in the 
situation where there is still no response, a follow-up email or telephone call will be 
made.  
 
Gathering data using Case Report Forms (CRFs) 
If a case is reported on e-card, the reporting practitioner is asked to complete an 
electronic case report form (CRF). The CRF asks for core information that is 
collected on all women and condition-specific information to confirm diagnosis, and 
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collect data on presentation, risk factors, treatment and outcomes. UKEPSS does 
not collect any personally identifiable information, such as names, addresses or 
hospital numbers. Reporting practitioners are asked to keep their own record of the 
names of women they have reported so that they can retrieve the case notes in 
case additional information is required. If a case is reported, but no CRF is 
completed and returned, 3 electronic reminders are sent, followed by two telephone 
reminders. 
 
DEVELOPING THE DATA CAPTURE SYSTEM 
 
UKOSS have successfully collected data for more than 30 studies using a paper 
based system; this system requires reporting clinicians to mail a monthly return 
card, which is received by a co-ordinating team who send out a case report form 
(CRF) for every positive case reported. The CRF then needs to be completed by 
reporting clinicians and once again returned to the UKOSS co-ordinating centre. For 
UKEPSS, this system was developed to an electronic data capture (EDC) system to 
facilitate the reporting process, and to achieve significant time and cost savings, as 
well as efficiency, and quality gains. 
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DESIGN 
UKEPSS Database  
The first step was to design the UKEPSS database, working closely with 
MedSciNet,  a company based at King’s College University (London) who have over 
10 years’ experience in supporting 38 clinical trials, 17 registries, and 9 resource 
centres, including international databases for the World Health Organisation (WHO). 
The database is an Electronic Data Capture (EDC) system that has been developed 
and delivered to ISO 9001:2000 standards and in compliance with FDA CRF21:11 
requirements.  
A unique interface (Figure 2) was developed to facilitate the registration of UKEPSS 
centres, communication and participation in UKEPSS studies. Predefined validation 
rules, custom rules and extensive repository of standard components were used to 
develop an efficient and secure database structure. 
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Figure 2. The UKEPSS database home page  
 
 
 
Case report form (CRF) 
 
The next step was to create the electronic CRF (Figure 3) based on pre-defined 
research questions, which were developed by performing an extensive review of the 
literature. Moreover, each section was discussed in detail at the UKEPSS Study 
Steering Committee meeting held at the Royal College of Obstetricians and 
Gynaecologists. The group consists of early pregnancy clinicians, nurses and 
academics, such as the Director of UKOSS,  Professor Marian Knight, who has 
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extensive experience in conducting studies of rare conditions. A list of the UKEPSS 
Study Steering Committee is included in the Appendix for reference.  The UKEPSS 
Study Steering Committee approved the final version of the CRF. Numerous 
iterations of the electronic case report forms were created to develop a reporting 
system which is clear and simple to use.  
 
A test site was created and circulated for use by participating clinicians to test the 
ease and functionality of the interface. After agreement, the database and study 
eCRF were launched on the 7th of February 2014 and the database 
(http://www.medscinet.com/ukepss/) was active for reporting over a 12 month 
surveillance period.. 
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Figure 3. Caesarean scar pregnancy surveillance CRF 
 
 
Data Collection  
 
Every month UKEPSS electronic case notification cards are sent to nominated 
reporting clinicians in each hospital in the UK with a consultant-led early pregnancy 
unit, with a simple box to indicate whether they have seen a woman with CSP. They 
are also asked to return cards indicating a ‘‘nil report‘‘, in order that I could monitor 
card return rates and confirm the denominator to calculate the incidence rate. If a 
clinician returns a card indicating a case, they are then asked to complete an online 
data collection form asking for details on presentation, investigations, management 
and outcomes. 
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Figure 4. UKEPSS electronic case notification cards 
 
 
 
 
 
Monitoring 
 
To monitor monthly engagement, a function was been added to maintain global 
monitoring of response from units by returned cards. Centres that do not respond to 
the first UKEPSS e-card are sent a reminder one week later. The system then 
identifies those centres which have not responded to the reminder and a list is 
created of the units to contact by direct email or telephone. 
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Data regulation 
 
The secure online Electronic Data Capture (EDC) system has been developed and 
delivered to ISO 9001:2000 standards and in compliance with FDA CRF21:11 
requirements. 
 
Alert system for data completion  
 
Alerts provide an efficient way for global monitoring. A comprehensive alert system 
was incorporated to detect incomplete data sets and missing forms (Figure 5).  
 
Figure 5.  Alert system for data completion  
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LAUNCH METHODOLOGY AND NETWORK ENGAGEMENT STRATEGIES 
 
Multiple strategies were employed to introduce the national early pregnancy and 
gynaecology community to UKEPSS.  
 
1. Invitation emails:  Prior to launching, I designed e-leaflets (figure 6) which were 
disseminated to clinicians and EPAU units nationally.  
 
Figure 6. UKEPSS e-leaflet invitation  
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2. Presentations at national and regional conferences: I presented at multiple 
local and national meetings including the Annual Association of Early Pregnancy 
Units Conference (2012, 2013, 2014) the Ectopic Pregnancy Trust, Early Pregnancy 
Meeting (Scotland), and the Birmingham Women’s annual Research and 
Development meeting.   
 
3. Electronic launch announcement:  an e-flyer (figure 7) was sent to all contacts, 
registered units and obstetrics and gynaecology nurses and clinicians, identified 
through the AEPU registry, and by direct contact with every hospital in the UK with 
an obstetric and gynaecology unit.  
      Figure 7. UKEPSS electronic launch 
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4. UKEPSS WEBSITE: http://www.birmingham.ac.uk/ukepss, provides updates on 
study progress. Announcements were also made by supporting organisations 
online. 
 
Figure 8. Ectopic Pregnancy Trust announcement of UKEPSS launch 
 
 
 
 
 
 
 
 
 
 
 
5. Social media: A facebook page was set up to provide regular updates to 
participating units, followers and patients. 
 
6. Direct email and telephone correspondence: Queries are promptly addressed 
using the UKEPSS central email (ukepss@contacts.bham.ac.uk) 
 
7. TOG column: A commentary (figure 9) was submitted to The Obstetrician and 
Gynaecology (TOG) journal and was published in July 2014. Moreover, UKEPSS 
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has been invited to report biannually in the TOG journal. This will provide a key 
route to engagement of UK obstetrics and gynaecology clinicians and units, and will 
facilitate dissemination of findings nationally. 
COMMENTARY 
 
Figure 9. TOG publication on UKEPSS 
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CHAPTER 3 
MANAGEMENT OF CAESAREAN SCAR PREGNANCY: A 
SYSTEMATIC REVIEW AND META-ANALYSIS 
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OBJECTIVES 
 
1. To systematically review the literature to identify management approaches 
currently used for the treatment of caesarean scar pregnancy 
2. To systematically review, and if possible, to meta-analyse data from the 
literature to determine the management approach associated with treatment 
success 
3. To systematically review, and if possible, to meta-analyse data from the 
literature to  identify adverse outcomes associated with each management 
approach 
4. To use the findings of this review to develop the specific case report forms 
for the caesarean scar pregnancy surveillance study 
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ABSTRACT 
 
 
Objective 
To determine the effectiveness of the different management approaches for the 
treatment of caesarean scar pregnancy. 
Methods 
Studies were identified without language restrictions from MEDLINE (1966-2015), 
EMBASE (1980-2015), Cochrane Library, and manual searching of bibliographies of 
known primary and review articles. Studies were selected if treatment was given to 
women presenting with caesarean scar pregnancy and if studies reported outcomes 
of interest. Observational studies and case series were included in the absence of 
randomised trials. Data were extracted on study characteristics, quality and the 
outcome. Relative risks from individual studies were meta-analysed using random 
and fixed effects models. Heterogeneity was evaluated graphically using forest plots 
and statistically using the I2 statistic. 
 
Results  
The search identified 12 case series comprising 274 women. Meta-analysis of these 
12 studies showed that there was no difference between medical and surgical 
treatment for the outcome of successful treatment (RR 0.85, 95% CI: 0.70 to 1.04, 
p= 0.12; I2 = 12%, p=0.33). However, additional intervention was more likely to be 
performed in women undergoing medical management when compared to surgical 
management (RR 2.50, 95% CI: 1.10 to 5.65, p=0.03; I2= 15%, p=0.31). No 
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difference was found in complication rates including haemorrhage, need for 
emergency hysterectomy, persistent myometrial defects requiring repair, or rupture. 
 
Conclusion 
There is some evidence to suggest that surgical treatment is associated with less 
need for additional interventions, although no difference was found in overall 
treatment success. This review was limited by the quality, number and size of 
included studies. A prospective national surveillance may facilitate the study of this 
rare condition and enable recommendations for practice and further research.  
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INTRODUCTION 
 
In a caesarean scar pregnancy (CSP), the ectopic pregnancy is partially or 
completely surrounded by myometrium and fibrous tissue of the scar of the prior 
lower uterine segment. The incidence of caesarean scar pregnancy is currently 
unknown; Jurkovic et al estimated a prevalence of 1:1800 in their local population, 
whilst in their case series, Seow at al found an incidence of 1: 1226 of all 
pregnancies. (19;41)  The number of reported cases has increased over recent 
years, possibly reflecting the rising number of caesareans being performed and the 
more widespread use of transvaginal ultrasonography. 
 
Differentiating between spontaneous miscarriage, cervical pregnancy and 
caesarean scar pregnancy can be difficult. Several potential predisposing factors 
have been suggested in the literature, including a history of dilatation and curettage, 
placental pathology, ectopic pregnancy, uterine closure and IVF require further 
investigation.(42) There are currently no validated criteria for the diagnosis of 
caesarean scar pregnancy. 
 
There is currently no agreement on the management for caesarean scar 
pregnancies. Various treatment modalities for caesarean scar pregnancy have been 
described in the literature. There are three predominant treatment approaches: 
expectant, medical and surgical management. Delivery of a live term baby following 
expectant management has been reported in a number of cases but often with 
severe consequences to the mother, including massive haemorrhage and the need 
for a hysterectomy.(43) Medical management includes local or systemic 
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methotrexate, uterine artery embolization, and the injection of local potassium 
chloride in heterotopic pregnancies. Surgical treatment in the way of dilatation and 
curettage, hysteroscopic resection, laparoscopic excision and hysterectomy has 
been reported with varying success. A combined approach has also been 
described, such as the local administration of methotrexate followed by surgical 
dilatation and curettage. Other more novel techniques have also been reported, 
such as chemoembolization of the uterine arteries.  
 
The aim of this review is to systematically review the available literature to assess 
outcomes associated with the various treatment approaches for the management of 
this condition. This information may be useful for the counselling and management 
of affected women. 
 
METHODS 
 
Identification of literature 
The following electronic databases were searched: MEDLINE (1985 to January 
2014), EMBASE (1985 to January 2015), Science Direct (1985 to January 2015), 
Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science 
(1985 to January 2015). A search strategy was carried out based on the following 
key words and/or medical subject heading (MeSH) terminology: ‘caesarean scar 
pregnancy’; ‘caesarean scar’; ‘ectopic pregnancy’, ‘caesarean scar complications’; 
‘caesarean scar ectopic pregnancy’; ‘caesarean scar implantations’; pregnancy; 
caesarean; pregnancy; scar; ectopic;  and ‘previous caesarean scar’, caesarean, 
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cesarean, pregnancy, scar, ectopic. Key words were combined using AND/OR. In 
addition, references from all identified articles were checked. If necessary, 
additional information was sought from the authors of the primary studies. The 
search was not restricted by language. The searches were conducted 
independently by me and two other reviewers, BW and MS.  
 
STUDY SELECTION  
 
Studies were selected if the target population were women reported to have a 
caesarean scar pregnancy. The primary outcome was successful treatment of 
caesarean scar pregnancy. Successful treatment was defined as resolution of 
caesarean scar pregnancy following primary management. Secondary outcomes 
included the need for additional interventions and complications. Studies were 
selected in a two-stage process. First, the titles and abstracts from the electronic 
searches were scrutinized by two reviewers independently (HH and BW) and full 
manuscripts of all citations that were likely to meet the predefined selection criteria 
were obtained. Secondly, final inclusion or exclusion decisions were made on 
examination of the full manuscripts. In cases of duplicate publication, the most 
recent and complete versions were selected. We excluded case reports, 
commentaries and letters. Any disagreements about inclusion were resolved by 
consensus or arbitration by a third reviewer (MS). Data extraction was performed in 
duplicate by HH and BW.  
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Methodological quality assessment 
All manuscripts meeting the selection criteria were assessed for their 
methodological quality. I used the MINORS checklist for the quality assessment of 
case series. The scale assesses for reliability, consistency and validity. A score 
between 0 and 2 is given for the adequacy of reporting; items are scored 0 if not 
reported, 1 where reported but inadequate, or 2 if reported and adequate. The 
overall ideal score is 16 for non-comparative studies and 24 for comparative 
studies.  
 
Data extraction 
I designed a data extraction form to extract relevant data. A second reviewer (BW) 
extracted data using the agreed form. Any discrepancies were resolved by 
discussion.  
 
SYNTHESIS 
I carried out relative effectiveness meta-analyses of treatment approaches using the 
Review Manager software (RevMan 5.3).  Relative risks with 95% confidence 
intervals from each study were combined for meta-analysis using the Mantel-
Haenszel method. The random-effect model was used as default for combining data 
from observational studies where it was reasonable to assume that studies were 
estimating the same underlying treatment effect: i.e. where trials are examining the 
same intervention, and the trials’ populations and methods were judged sufficiently 
similar.  
Heterogeneity was assessed graphically using forest plot and statistically using I2 
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test.  To detect publication and related biases, I undertook funnel plot analysis using 
Egger’s tests to evaluate for asymmetry.  
 
RESULTS 
The search strategy (figure 10) yielded 638 publications (634 from electronic 
searches; 4 from reference lists of relevant publications). There were no 
randomised controlled trials identified. From the title and abstract, 420 studies were 
excluded as it was clear that they did not fulfil the selection criteria or were in a 
foreign language. For the remaining 214 articles, I obtained full manuscripts, and 
following scrutiny of these, we excluded 202 studies for the following reasons: 178 
were case reports, 16 were literature reviews or opinion articles, 6 studies contained 
duplicate data, and in 7 studies treatment was combined. Therefore the total 
number of studies included in this review is 12. 
 
Study characteristics 
The 12 studies (44-55) included a total of 274 women and were all case series. The 
study characteristics, including number of women, study design, age, caesarean 
section history, symptoms and signs at presentation, method of diagnosis, BhCG at 
presentation, primary treatment used, treatment success, complications, follow up 
duration and future pregnancy are summarized in Tables 2.1 and 2.2.  
 
Quality of included studies 
The quality of the included studies is summarised in Table 3.
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Author 
 
Study 
Design 
 
Population 
 
 
 
Age 
 
(median) 
 
Pregnancy 
history 
 
Symptoms and 
gestation 
at presentation 
 
Method of 
diagnosis and 
findings 
 
BhCG at 
presentati
on 
(median) 
Ben Nagi, 2007 
 
(n=40) 
Case series Women treated for CSP 
at King’s College 
Hospital, London 
between 1999-2005 
36 years 
(range 27-43 
years) 
(Median) 
Vaginal birth=0; 
CS=2; 
Miscarriage=1; 
Ectopic=0; 
TOP=0 
Not reported TV USS NR 
Bignardi, 2010 
 
(n=7) 
 Case series  Women treated for CSP 
at EPU, Nepan Hospital, 
Sydney between 2006-
2008 
34 years 
(range 23-41 
years) 
1 CS n= 6/7 
2 CS n=1/7 
Vaginal bleeding 
n=3/7; Vaginal 
bleeding + abdo pain 
n=1/7; Asymptomatic 
n= 3/7 
Other: Following 
IVF= 2/7 
Median GA= 44 
TV USS 
 
Cardiac activity 
present y= 4/7 
 
1563 
Deans, 2010 
 
(n=6) 
Case series Women diagnosed with 
CSP at Royal Hospital 
for Women, Sydney 
between 2004-2007 
41 years 
(range 33-41 
years) 
Previous CS: 
1 CS n= 4/6 
2 CS n= 2/6 
Median GA= 6.5 
weeks 
TV USS 
Cardiac activity 
y= 3/6 
 294  
Halperin, 2009 
 
(n=6) 
 
Case series Women diagnosed with 
CSP at Assaf Harofe 
Medical Centre, Tek-
Aviv between 2004-
2007 
35 years 
(range 27-44 
years) 
2 previous CS  
n= 6/6 
Median GA= 
14weeks 
 
TV and TA USS  
 
Not 
reported 
Ko, 2014 
 
Case series Women diagnosed with 
CSP at Queen Mary 
Hospital, China over a 
34.1 years 
 +/- 4.1 years 
Previous CS 
1 CS= 17/22 
Vaginal bleeding 
n=19/22; abdo pain 
n=2/22 
TV USS 
 
28 943 IU/L 
(range 346 
– 139 653) 
Table 2.1. Characteristics of included studies of CSP showing patient demographics and presenting signs and symptoms 
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(n=22) 10 year period (2004-2013) 2 CS= 5/22 
 
Median interval 
CS to CSP = 2 
years (range 
6mths-11 years) 
Spontaneous 
preg n=19/22; 
ART n=3/22 
Median GA= 6.7 
weeks (range 4.7 – 
11.8 weeks) 
 
 
 
 
Heterogenous 
mass n=22/22;  
GS n=18/22;  
Cardiac activity 
n=12/22;  
Median 
myometrial 
thickness 1.5mm 
(range 1-8mm) 
Li, 2014 
 
(n=39) 
 
 
 Case series Women treated for CSP 
at Peking Union Medical 
College Hospital from 
2005-2012 
33 years 
+/- 5 years 
Previous CS: 
1 CS =not 
reported;2 CS= 
5/39 
Median interval 
from CS – CSP 
=4years 
Vaginal bleeding 
n=35/39 
TV USS: Cystic 
solid or solid 
mass with mixed 
echoes in the 
lower anterior 
uterine wall, 
surrounded by 
peritrophoblastic 
vasculature 
 
Michener, 2009 
 
(n=13) 
Case series Cases of CSP seen at 
the King Edward 
Memorial Hospital, 
Australia 
34 years (IQR 
32.2, 35.2) 
Median parity=2 
(IQR 1,3) 
Previous CS: 
1 CS= 9/13 
2 CS= 2/13  
3 CS= 1; 4 CS = 1 
Median interval 
between CS and 
CSP = 2 years 
(IQR 1.75, 4.6) 
Vaginal bleeding 
n=9/13 
 
Median GA 6.8 
weeks (range 5.5-
11.5) 
TV USS n=9/13 
 
Cardiac activity 
n= 5/13 
Median= 
9035 
Ong, 2014 
 
Case series All women diagnosed 
and treated for CSP at 
KK Women’s and 
30 years 
(range 21-34 
years) 
Previous CS: 
1 CS= 2/5 
Vaginal spotting= 2/5 
Vaginal 
spotting+pain= 3/5 
TV USS Median= 
1792.5 
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(n=5) Children’s Hospital, Singapore between 
2012 and 2013 
2 CS= 3/5 
 
Shi, 2014 
 
(n=57) 
Case series All women undergoing 
treatment for CSP at 
Affiliated Hospital of 
Hebei University, China 
between 2011 and 2013 
Not extractable Not extractable Not extractable Not extractable Not 
extractable 
Tagore, 2010 
 
(n=6) 
Case series  Women managed for 
CSP at KK Women’s 
and Children’s Hospital, 
Singapore between 
2004 - 2008 
 32.5 years  
(range 27-41 
years) 
Previous CS 
1 CS= 3/6 
2 CS= 3/6 
Not reported TV USS 
 
Cardiac activity 
n=2/6 
 8647.5 
Uysal, 2013 
 
(n=7) 
Case series Women managed for 
CSP at Konak Women’s 
Health and Maternity 
Hospital, Turkey  
28 years 
(range 22-41) 
Previous C/S  
1 CS=5/7 
2 CS= 2/7 
Interval between 
CS and CSP= 
6mths-10 mths 
Previous CSP = 
1/7 
Amenorrhoea n=7/7 
 
 
 
TV USS 
 
Cardiac activity= 
3/7 
5978 
Yang, 2010 
 
(n=66) 
Case series Women diagnosed with 
CSP at West China 
Second University  
Hospital of Sichuan 
University, China 
between 2003 and 2008 
31.6 years  
(range 19-48 
years) 
Range 1-3 
previous CS 
 
Median time from 
previous CS to 
CSP = 3.3years 
Abdominal pain n= 
28/66; 
 
Vaginal bleeding 
n=34/66 
TV USS and 
Doppler 
 440-
129520 
NR= Not reported;  TV USS= Transvaginal Ultrasound Scan; BhCG = Beta Beta-Human Chorionic Gonadotropin; GA= Gestational Age; D&C= Diltation and 
Curettage; KCL= Potassium chloride; MTX= Methotrexate;  NR = Not reported; Post op= Postoperative; UAE= Uterine Artey Embolisation 
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Author 
 
 
Primary treatment 
 
 
Treatment success 
 
 
Complication and Follow-
up 
 
 
 
Future pregnancy 
Ben Nagi, 2007 
 
(n=40) 
Surgical evacuation = 28/40; 
Medical management 9/40; 
Expectant management=3/40 
 
Surgical=28/28 
Medical= 6/9 
Expectant=0/3 (emergency 
hysterectomy= 2; miscarriage 
at 17 weeks, n=1) 
NR F/U data available 
for 29/38; 24/29 
attempted 
pregnancy, of which 
21/24 conceived. 
1/20 had recurrent 
CSP 
Bignardi, 2010 
 
(n=7) 
TRS (transrectal guided) 
surgical evacuation n=5/7 
 
MTX n=2/7 
Surgical= 5/5 
 
Medical n=1/2; 3rd dose of 
MTX failed, TRS-guided 
aspiration performed 
Surgical n= 0/5 
 
Medical n=1/2 – lap repair of 
persistent myometrial defect 
 
NR 
Deans, 2010 
 
(n=6) 
Hysteroscopy and resection 
n= 4/6; 
Medical n=1/6; combined n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
=1/6 
Surgery n=4/4; medical n=1/1; 
combined 1/1 
Surgical n=1/4 
haemorrhage, ergometrine 
and foley catheter used;
 
Medical n=1/1 pesistent pain 
and haematoma 
Of those planning for 
pregnancy n=2/4 
Table 2.2  Characteristics of included studies of CSP showing treatment outcome 
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Halperin, 2009 
 
(n=6) 
 
Surgical, D+C n=4 
 
Medical n=2;  
- UAE and MTX = 1 
-MTX = 1 
 
 
 
Surgery 4/4 
 
Medical 0/2 
Surgery=  blood transfusions 
n=2; DIC n=1 
 
Medical: Rupture n=1, pt 
required laparotomy and 
excision, had bladder injury. 
Heavy bleeding  n=1, 
laparotomy and excision 
performed 
NR 
Ko, 2014 
 
(n=22) 
Expectant= 4; 
 
Medical =12, of which 
MTX=9, MTX+KCL=3 
 
Surgical = 4, of which US 
guided suction evacuation n= 
3, Laparotomy n=1 
 
2 transferred to another 
centre- outcomes unknown 
Expectant= 4/4 
Medical =9/12 
Surgical = 3/4 
BhCG to normalise 
mean=10 weeks (range 2-20 
weeks) 
 
Time to complete resolution 
= 4 months (range 1-15 
months)  
4/ (denominator NR) 
Li, 2014 
 
(n=39) 
 
 
Medical n=3, all MTX. 
 
Surgical n= 35: 
D+C n=16; 
Lap excision n= 15; 
TA hysterectomy n=4 
MTX= 2/3 
D+C= 11/16 
Lap excision =15/15 
TAH= 4/4 
Not reported NR 
Michener, 2009 
 
(n=13) 
Methotrexate n=8 
 
Surgical n=5: 
Emergency hysterectomy n=1 
Suction curettage n=2 
Elective hysterectomy=2   
Medical n=5/8 
 
Surgical n=5/5 
Medical= life threatening 
bleeding, required 
emergency hysterectomy 
and HDU care 
Pt who had Emergency 
hysterectomy at presentation 
required HDU care 
4/? 
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Ong, 2014 
 
(n=5) 
Medical: Methotrexate = 3/5 
 
Surgical: Suction curettage= 
2/5 
Medical= 0/3 
 
Surgical= 2/2 
Medical-2 required suction 
curettage, 1 needed lap 
adhesiolysis and repair of 
defect + suction curettage 
BhCG to normalise in wks: 
4, 4, 3,6, 3 
NR 
Shi, 2014 
 
(n=57) 
Medical: Embolisation= 22  
Surgical: 
D+C= 12 
Laparotomy= 8 
TV debridement= 15  
Embolisation n=19/22 
D+C= 12/12 
Laparotomy= 7/8 
Transvaginal debridement= 
13/15 
NR NR 
Tagore, 2010 
 
(n=6) 
Medical- MTX n =3/6 
Surgical- hysterotomy n=1/6 
Laparotomy and excision 
n=1/6 
Laparoscopy and excision= 
1/6 
Medical= 3/3 
Surgical= 2/3- subtotal 
hysterectomy for massive 
bleeding following attempted 
hysterotomy 
Surgical= 1/3- subtotal 
hysterectomy for massive 
bleeding following attempted 
hysterotomy 
 
Uysal, 2013 
 
(n=7) 
Medical- MTX n= 2/7 
Intrasac KCL n=1/7 
Surgical- D&C 3/7 
Laparotomy and excision 
n=1/7 
Medical- 1/3 
 
Surgical n=4/4 
 
Medical- vaginal bleeding 
n=2, curettage performed 
n=2 
Surgical- bleeding following 
hysterotomy; cervical 
cerclage suturing and 
bilateral hypogastric artery 
ligation performed 
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D&C= Diltation and Curettage; KCL= Potassium chloride; MTX= Methotrexate;  NR = Not reported; Post op= Postoperative; UAE= Uterine Artey 
Embolisation
Yang, 2010 
 
(n=66) 
Medical: 
Systemic MTX- n=17/66 
Surgical: 
D&C n=11/66 
Combined 
UAE+ local MTX n=38/66 
 
Medical n= 9/17 
 
Surgical n=3/11 
Medical- massive 
haemorrhage n=7/17- 2 
needed hysterectomy; 5 
needed extra MTX or D&C 
for failed treatment  
D&C- severe haemorrhage 
n=8/11- 3 needed 
hysterectomy, 1 wedge 
resection of pregnancy; 
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Figure 10. Study selection process for systematic review of management of caesarean scar 
pregnancy 
 Total number of citations retrieved from electronic searches and from examination  
of reference lists of primary and review articles : n =  638 
Citations excluded after screening title and/or abstracts: n =  420 
Full manuscripts retrieved for detailed evaluation: n =  214 
Primary articles fulfilling inclusion criteria for systematic review:  n=12 
Articles excluded after review of full text with reasons. 
Case report n=  178  
Literature  review/opinion n=  16 
n=  6 Duplicate  publication 
n = 7 Combined treatment 
Total excluded n= 202 
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 Ben 
Nagi 
2007 
Bignardi 
2010 
Deans 
2010 
Halperin 
2009 
Ko 
2014 
Li  
2014 
Michener 
2009 
Ong 
2014 
Shi 
2014 
Tagore 
2010 
Uysal 
2013 
Yang  
2010 
Aim 2 2 2 1 2 2 2 2 2 2 1 2 
Inclusion of patients 2 2 2 1 1 2 2 1 2 2 1 2 
Prospective data collection 0 0 0 0 0 0 0 0 0 0 0 0 
Appropriate end points 1 1 1 2 2 1 1 2 1 2 2 1 
Unbiased end point assessment 2 0 0 1 2 0 0 2 0 2 2 0 
Appropriate follow up 1 1 1 1 2 1 1 2 1 2 2 1 
Loss of follow up <5% 1 0 1 0 1 1 1 2 1 1 1 1 
Prospective study size calculation 0 0 0 0 0 0 0 0 0 0 0 0 
Adequate control group 0 0 0 0 0 0 0 0 0 0 0 0 
Contemporary groups  0 0 0 0 0 0 0 0 0 0 0 0 
Baseline equivalence 1 1 1 1 1 1 1 1 1 1 1 1 
Statistical Analysis 1 0 0 0 0 0 0 0 0 0 0 0 
Score 11 7 8 11 11 8 8 12 8 12 10 8 
 
 
 
 
 
 
 
Table 3.  Appraisal of methodological quality (Minors checklist) of included studies of CSP 
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Primary outcome - Treatment success 
Expectant management 
Two studies reported expectant management for the treatment of caesarean scar 
pregnancy; one study compared outcome following expectant management with 
medical treatment. The other study compared expectant management with surgical 
treatment. It was therefore not possible to meta-analyse for this treatment approach. 
 
Medical vs Surgical treatment  
Pooling of results from 12 studies that compared medical treatment with surgical 
treatment as primary management for caesarean scar pregnancy showed no 
difference in treatment success (RR=0.85, 95% CI 0.70–1.04, p=0.12, Figure 11).  
The I2 value was 12% indicating little variation among the studies (p=0.33).   
 
Outcome according to intervention 
 
Methotrexate vs Surgical evacuation 
Pooling of results from 9 studies that compared methotrexate with surgical 
evacuation as primary management for caesarean scar pregnancy did not show a 
difference in successful treatment outcome (RR=0.78, 95% CI 0.55–1.02, p=0.07, 
Figure 12).  The I2 value was 0% indicating no variation among the studies (p=0.47).   
 
 
Methotrexate vs laparatomy and excision  
Pooling of results from 3 studies that compared methotrexate with laparotomy and 
excision as primary management of caesarean scar pregnancy did not show a 
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difference in successful treatment outcome (RR=0.90, 95% CI 0.51–1.59, p=0.71, 
Figure 13).  The I2 value was 0% indicating no variation among the studies (p=0.87).   
 
Methotrexate vs laparascopy and excision 
Pooling of results from 2 studies that compared methotrexate with laparoscopy and 
excision as primary management of caesarean scar pregnancy did not show a 
difference in successful treatment outcome (RR=0.73, 95% CI 0.41–1.32, p=0.30, 
Figure 14).   
 
Methotrexate vs hysteroscopic resection  
Only one study compared outcome following treatment with methotrexate and 
hysteroscopic resection as primary outcome and therefore could not be meta-
analysed (Figure 15).  
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Study 
Medical versus Surgical (all)
Ben Nagi 2007
Michener 2009
Halperin 2009
Bignardi 2010
Yang 2010
Tagore 2010
Deans 2010
Uysal 2013
Ong 2014
Ko 2014
Li 2014
Shi 2014
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 12.52, df = 11 (P = 0.33); I² = 12%
Test for overall effect: Z = 1.55 (P = 0.12)
Events
6
5
0
1
9
3
1
1
0
9
2
19
56
Total
9
8
2
2
17
3
1
3
3
12
3
22
85
Events
28
5
4
5
3
2
4
4
2
3
26
32
118
Total
28
5
4
5
11
3
4
4
2
4
31
35
136
95% CI
0.66 [0.42, 1.04]
0.67 [0.38, 1.18]
0.19 [0.01, 2.36]
0.55 [0.17, 1.73]
1.94 [0.67, 5.63]
1.40 [0.60, 3.26]
1.00 [0.43, 2.34]
0.42 [0.11, 1.53]
0.15 [0.01, 2.11]
1.00 [0.52, 1.92]
0.79 [0.35, 1.80]
0.94 [0.78, 1.15]
0.85 [0.70, 1.04]
Medical Surgical Risk Ratio Risk Ratio
Random, 95% CI
0.5 0.7 1 1.5 2
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Meta-analysis of studies of caesarean scar pregnancy for the outcome of successful treatment following  
primary management 
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Study 
Methotrexate versus surgical evacuation
Ben Nagi 2007
Halperin 2009
Michener 2009
Yang 2010
Tagore 2010
Bignardi 2010
Uysal 2013
Li 2014
Ko 2014
Ong 2014
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.62, df = 8 (P = 0.47); I² = 0%
Test for overall effect: Z = 1.84 (P = 0.07)
Events
6
0
5
9
0
1
1
2
9
0
33
Total
9
2
8
17
0
2
2
3
12
3
58
Events
28
4
2
3
0
5
3
11
2
2
60
Total
28
4
2
11
0
5
3
16
3
2
74
95% CI
0.66 [0.42, 1.04]
0.19 [0.01, 2.36]
0.73 [0.35, 1.52]
1.94 [0.67, 5.63]
Not estimable
0.55 [0.17, 1.73]
0.57 [0.17, 1.88]
0.97 [0.41, 2.30]
1.13 [0.47, 2.67]
0.15 [0.01, 2.11]
0.75 [0.55, 1.02]
Medical Surgical Risk Ratio Risk Ratio
95% CI
0.5 0.7 1 1.5 2
 
 
Figure 12. Meta-analysis of studies of caesarean scar pregnancy for the outcome of successful treatment: Methotrexate vs surgical 
evacuation 
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Study 
Methotrexate vs Laparotomy and excision
Tagore 2010
Uysal 2013
Ko 2014
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.27, df = 2 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.71)
Events
3
1
9
13
Total
3
2
12
17
Events
1
1
1
3
Total
1
1
1
3
95% CI
1.00 [0.41, 2.42]
0.67 [0.17, 2.67]
0.97 [0.41, 2.32]
0.90    [0.51, 1.59]
Medical Surgical Risk Ratio Risk Ratio
95% CI
0.5 0.7 1 1.5 2
 
 
Figure 13. Meta-analysis of studies of caesarean scar pregnancy for the outcome of successful treatment: Methotrexate vs 
Laparotomy and excision 
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Study 
Methotrexate vs laparoscopic resection
Deans 2010
Tagore 2010
Li 2014
Subtotal (95% CI)
Heterogeneity: Chi² = 0.59, df = 1 (P = 0.44); I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
Events
0
3
2
Total
0
3
3
6
Events
0
1
15
Total
0
1
15
16
95% CI
Not estimable
1.00 [0.41, 2.42]
0.65 [0.30, 1.39]
0.73 [0.41, 1.32]
Year
2010
2010
2014
Medical Surgical Risk Ratio Risk Ratio
95% CI
0.5 0.7 1 1.5 2
 
 
 
 
Figure 14. Meta-analysis of studies of caesarean scar pregnancy for the outcome of successful treatment: Methotrexate vs 
Laparoscopic excision 
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Study 
Methotrexate versus Hysteroscopic resection
Deans 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
Events
1
Total
1
1
Events
4
Total
4
4
95% CI
1.00 [0.43, 2.34]
1.00 [0.43, 2.34]
Medical Surgical Risk Ratio Risk Ratio
95% CI
0.5 0.7 1 1.5 2
  
 
 
  
 
 
Figure 15. Meta-analysis of studies of caesarean scar pregnancy for the outcome of successful treatment: Methotrexate vs 
Hysteroscopic resection 
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Secondary outcomes 
 
Need for secondary intervention 
Pooling of results from 8 studies that reported the need for secondary intervention for 
caesarean scar pregnancy showed an increase in the secondary intervention rate in 
women treated with medical treatment when compared to those treated surgically 
(RR=2.50, 95% CI 1.10–5.65, p=0.03, Figure 16)).  The I2 value was 15% indicating 
little variation among the studies (p=0.31).   
 
Complications 
Pooling of results from 8 studies that compared medical and surgical treatment as 
primary management of caesarean scar pregnancy did not show a difference in 
complication rate (RR=1.24, 95% CI 0.67–2.29, p=0.50, Figure 17).  The I2 value was 
19% indicating some variation among the studies (p=0.28).   
 
Haemorrhage  
Pooling of results from 6 studies that compared medical and surgical treatment as 
primary management of caesarean scar pregnancy did not show a difference in the 
risk of haemorrhage as a complication of treatment (RR=1.13, 95% CI 0.58–2.22, 
p=0.50).  The I2 value was 27% indicating some variation among the studies 
(p=0.28).   
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Persistent defect 
Pooling of results from 2 studies that compared medical and surgical treatment as 
primary management of caesarean scar pregnancy did not show a difference in the 
risk of persistent myometrial defect necessitating repair as a complication of 
treatment (RR=3.64, 95% CI 0.48–27.43, p=0.21).  The I2 value was 0% indicating 
consistency among the studies (p=0.63).   
 
Rupture 
Only one study reported this outcome. This was a complication which occurred 
following medical treatment of caesarean scar pregnancy. 
 
Hysterectomy 
Pooling of results from 3 studies that compared medical and surgical treatment as 
primary management of caesarean scar pregnancy did not show a difference in the 
risk of hysterectomy as a complication of treatment (RR=0.57, 95% CI 0.17–1.93, 
p=0.37).  The I2 value was 0% indicating consistency among the studies (p=0.64).   
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Study 
Ben Nagi 2007
Bignardi 2010
Halperin 2009
Michener 2009
Ong 2014
Tagore 2010
Uysal 2013
Yang 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.22; Chi² = 8.28, df = 7 (P = 0.31); I² = 15%
Test for overall effect: Z = 2.19 (P = 0.03)
Events
3
1
2
3
3
0
2
7
21
Total
9
2
2
8
3
3
3
17
47
Events
0
0
0
0
0
1
1
4
6
Total
28
5
4
5
2
3
4
11
62
95% CI
20.30 [1.15, 359.72]
6.00 [0.34, 107.42]
8.33 [0.57, 121.28]
4.67 [0.29, 75.02]
5.25 [0.41, 67.73]
0.33 [0.02, 5.97]
2.67 [0.41, 17.42]
1.13 [0.43, 2.98]
2.50 [1.10, 5.65]
Medical Surgical Risk Ratio Risk Ratio
Random, 95% CI
0.01 0.1 1 10 100
 
 
Figure 16. Meta-analysis of studies of caesarean scar pregnancy for the outcome of need for additional interventions 
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Study or Subgroup
1.2.1 Medical vs surgical (any complication)
Bignardi 2010
Deans 2010
Halperin 2009
Michener 2009
Ong 2014
Tagore 2010
Uysal 2013
Yang 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.15; Chi² = 8.69, df = 7 (P = 0.28); I² = 19%
Test for overall effect: Z = 0.67 (P = 0.50)
1.2.2 Haemorrhage
Deans 2010
Halperin 2009
Michener 2009
Tagore 2010
Uysal 2013
Yang 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.18; Chi² = 6.83, df = 5 (P = 0.23); I² = 27%
Test for overall effect: Z = 0.36 (P = 0.72)
1.2.3 Need for emergency hysterectomy
Michener 2009
Tagore 2010
Yang 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 2 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.95 (P = 0.34)
1.2.4 Persistent myometrial defect necessitating repair
Halperin 2009
Ong 2014
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.15, df = 1 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.17 (P = 0.24)
1.2.5 Rupture
Bignardi 2010
Heterogeneity: Not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Events
1
1
2
1
1
0
2
7
15
1
2
1
0
2
7
13
1
0
2
3
1
1
2
1
Total
2
1
2
8
3
3
3
17
39
1
2
8
3
3
17
34
8
3
17
28
2
3
5
2
Events
0
1
2
0
0
1
1
8
13
1
2
0
1
1
8
13
0
1
3
4
0
0
0
0
Total
5
4
4
5
2
3
4
11
38
4
4
5
3
4
11
31
5
3
11
19
4
2
6
5
95% CI
6.00 [0.34, 107.42]
2.50 [0.53, 11.89]
1.67 [0.61, 4.59]
2.00 [0.10, 41.37]
2.25 [0.13, 38.09]
0.33 [0.02, 5.97]
2.67 [0.41, 17.42]
0.57 [0.29, 1.11]
1.24 [0.67, 2.29]
2.50 [0.53, 11.89]
1.67 [0.61, 4.59]
2.00 [0.10, 41.37]
0.33 [0.02, 5.97]
2.67 [0.41, 17.42]
0.57 [0.29, 1.11]
1.13 [0.58, 2.22]
2.00 [0.10, 41.37]
0.33 [0.02, 5.97]
0.43 [0.09, 2.18]
0.54 [0.15, 1.94]
5.00 [0.29, 87.54]
2.25 [0.13, 38.09]
3.34 [0.45, 24.97]
6.00 [0.34, 107.42]
Medical Surgical Risk Ratio Risk Ratio
Random, 95% CI
0.005 0.1 1 10 200
 
Figure 17. Meta-analysis of studies of caesarean scar pregnancy for the outcome of 
complications 
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DISCUSSION 
 
This systematic review, which included 12 studies, found that medical and surgical 
treatment were equally as effective when used as primary management for 
caesarean scar pregnancy.  However, additional intervention was required more 
often in women undergoing medical treatment when compared to those that had 
surgical treatment. No difference was found in the risk of complications, including 
haemorrhage, need for emergency hysterectomy, persistent myometrial defects 
requiring repair, and rupture.  
 
There are several factors that give strength to the findings of this study. Firstly, I 
performed an extensive search strategy and used valid data synthesis methods.  
No language restrictions were placed on the search or included study. 
 
The weaknesses in the study are mainly related to the quality of the included 
studies. 9 of the included studies were of observational study design and 3 were 
case series. While there are clear limitations to the methodology of case series, the 
observation of a series of patients can add to our understanding of aetiology, 
pathogenesis, natural history, and treatment, particularly in rare diseases.  
 
A serious concern is the possibility of false positive cases being reported as 
caesarean scar pregnancies. All of the women in the included studies had 
transvaginal ultrasonography. There currently does not exist a validated ultrasound 
criteria for the diagnosis of CSP. Jurkovic (41) proposed the following criteria to aid 
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diagnosis: presence of gestational sac or placental tissue anteriorly at the level of 
the internal os, clear evidence of pregnancy invading into the myometrium, 
evidence of sustained peritrophoblastic circulation on colour Doppler examination, 
characterised by high blood-flow velocity (over 20cm/sec) and low impedance 
(PI<1) circulation, and  negative sliding organ sign (inability to displace the 
gestational sac from its position using gentle pressure with a transvaginal probe). 
Whether this criteria is used widely in practice is unknown.  
 
Magnetic Resonance Imaging (MRI) may be a useful adjunct to ultrasonography for 
the diagnosis of caesarean scar pregnancy.(56;57) MRI can provide additional 
information on the volume of the lesion and extent of myometrial involvement. (57) 
This information can potentially aid clinicians to assess the appropriateness of the 
management approach. For example, surgical management may be considered in 
women with significantly deficient myometrial scar. However, a major limitation of 
MRI is its long acquisition time and cost and may be better reserved for cases 
where TVS and colour flow doppler are inconclusive. 
 
Two of the included case series as well as several published case reports have 
reported women who were treated conservatively after diagnosis of caesarean scar 
pregnancy. In two cases, close observation with twice weekly BhCG and USS scan 
monitoring showed a resolution of pregnancy on scan and BhCG within 2 months, 
with no complications or further treatment required. Two women are reported to 
have kept scar pregnancies till 35 weeks of gestation; one woman went into pre-
term labour and required an emergency caesarean section, and the other was 
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admitted with severe abdominal pain. Both had healthy babies, but with the 
consequence of life threatening haemorrhage, resulting in disseminated 
intravascular coagulopathy with 16 units of blood transfused in one case, and both 
needed a hysterectomy.  In the remaining 6 cases, a conservative approach was 
intended, however, salvage treatment was performed due to life threatening 
haemorrhage, or persistent gestational tissue on ultrasonography. One woman had 
severe haemorrhage and underwent an emergency laparotomy and total abdominal 
hysterectomy. Another woman had a dilatation and curettage for persistent 
gestational tissue which resulted in a massive bleed necessitating a laparotomy and 
hysterectomy for uncontrollable intra-operative bleeding.  Due to persistent 
gestational tissue on scan and raised BhCG, two other women underwent surgical 
treatment; in one case, a laparoscopy was performed and was converted to a 
laparotomy, with excision of tissue and repair of the dehiscent scar. In the other, a 
laparoscopy was performed, and the pregnancy tissue was resected 
hysteroscopically.  
 
In reported cases of heterotopic pregnancies, selective embryo reduction of a 
caesarean ectopic was shown to result in the delivery of a healthy infant, but often 
with consequences of pre-term labour, haemorrhage or premature rupture of 
membranes. 
Given the quality of the included studies and concerns regarding reporting bias and 
the potential of false positive cases being reported, firm inferences cannot be drawn 
from the findings of this review. A nationwide collaboration to study this rare 
condition could enable higher quality prospective research to improve our 
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knowledge on best management of this condition, and to guide further research in 
this area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
86 
 
 
 
 
 
 
 
 
CHAPTER 4: 
 
CAESAREAN SCAR PREGNANCY SURVEILLANCE 
PROTOCOL 
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AIM  
To use the UK Early Pregnancy Surveillance Service (UKEPSS) network to study 
caesarean scar Pregnancy. 
 
 
OBJECTIVES 
 
1. To establish the incidence of caesarean scar pregnancy 
2. To identify the presenting features of caesarean scar pregnancy. 
3. To identify the risk factors associated with this condition. 
4. To evaluate additional diagnostic information gained from 3D Ultrasound, 
Doppler, MRI and CT over the reference standard of greyscale 2D 
ultrasonography.  
5. To explore the variations in management and outcomes for this condition. 
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BACKGROUND 
In this condition the pregnancy is partially or completely surrounded by myometrium 
and fibrous tissue of the scar of the prior lower uterine segment. It is estimated to 
occur in 0.15% of women with a history of at least one caesarean delivery. (19) 
Audit from a large tertiary unit (University College London) showed an incidence of 
1:400 (0.25%) after one caesraean section and 1:50 (2%) after two or more 
Caesarean deliveries. The number of published case reports has increased over 
recent years, possibly reflecting the rising number of caesareans being performed 
or the more widespread use of transvaginal ultrasonography. 
 
CLINICAL DILEMMAS: WHY A STUDY IS NEEDED 
 
Diagnosis 
Differentiating between spontaneous miscarriage, cervical pregnancy and 
caesarean scar pregnancy can be difficult. The majority of caesarean scar 
pregnancies fail spontaneously early in the first trimester. In the minority of cases a 
live foetus develops and the pregnancy could progress beyond the first trimester. In 
these cases a delay in diagnosis and treatment can lead to life threatening 
haemorrhage, hysterectomy or rupture of the uterus.(19;58;59)  Early diagnosis is 
considered effective at reducing these risks. Through this study, we will study the 
application of the existing ultrasound diagnostic criteria and assess the role of 3D 
ultrasound scanning and 3D Power Doppler in providing additional diagnostic 
information. Furthermore, the use of magnetic resonance imaging (MRI) as an 
adjunct will be examined. 
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Risk factors 
The risk of recurrence and the effect of interval between the previous caesarean 
delivery and a caesarean scar pregnancy is currently unknown.  An increased risk 
has been reported in women having caesarean breech deliveries. (58) Potential 
predisposing factors such as a history of dilatation and curettage, placental 
pathology, ectopic pregnancy, uterine closure and IVF require further investigation. 
This information will aid early detection and counselling for women at risk. 
 
Management 
There is currently no agreement on the management for caesarean scar 
pregnancies. Delivery of a live term baby following expectant management has 
been reported in a few cases but with severe consequences to the mother. For this 
study we intend to compare expectant, medical and surgical management, 
investigating outcomes in terms of resolution of pregnancy, complications and 
length of follow up. Specifically, we will explore the effect of treatment with 
methotrexate, comparing systemic administration with local injection. Outcomes of 
different surgical techniques, including laparotomy with wedge resection, operative 
laparoscopy, and hysteroscopic approaches will be compared. Furthermore, 
combined medical and surgical treatment (such as local injection of methotrexate 
with transcervical aspiration of the pregnancy) will be studied. The use of selective 
uterine artery embolisation also requires further assessment. This information will 
be used to develop follow-up protocols and guidelines on management. 
RESEARCH QUESTIONS AND DESIGNS 
Using the UK Early Pregnancy Surveillance Service to identify cases of caesarean 
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scar pregnancy the following non-interventional descriptive studies will be 
conducted: 
1) Case-control study: the aim is to identify risk factors for caesarean scar 
pregnancy, with a particular focus on modifiable risk factors. For instance, is the 
method of uterine closure (with single or double layer suturing) associated with 
caesarean scar pregnancy? Is the number of previous caesarean sections 
associated with caesarean scar pregnancy? Is BMI associated with caesarean 
scar pregnancy? The control group will consist of women who have a history of 
at least one previous caesarean section, but no caesarean scar pregnancy. For 
each case of caesarean scar pregnancy reported, two controls will be sought 
from the reporting hospital.  
2) Study of additional information gained from added tests: The standard 
method for diagnosis is ultrasound; in this study we will evaluate the additional 
test information gained from three-dimensional ultrasonography, magnetic 
resonance imaging and computer tomography (CT) scanning.  
3) Cohort study: Treatment methods and outcomes will be gathered and reported. 
Expectant, medical and/or surgical treatment is possible, and we will report 
outcomes by different treatment methods, and subgroups of patients. 
 
5. CASE IDENTIFICATION 
 
Cases will be identified through the monthly mailing of the UK Early Pregnancy 
Surveillance Service, comprising of early pregnancy units, acute gynaecology and 
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obstetric units. The cases will be women in the UK diagnosed as having a 
caesarean scar pregnancy. Given the recognised variability in ultrasound 
experience as well as the lack of a universally agreed diagnostic criteria, the 
UKEPSS study steering committee has adopted the sonographic criteria developed 
by Jurkovic et al (Figure 18), which will be distributed to all participating units, as a  
guide to objectively assess whether submitted cases are true cases of caesarean 
scar pregnancy. It is possible that units may have a different criteria for diagnosis 
and the CRF has been left open to allow centres to report other scan findings which 
may aid in the diagnosis of this condition. Therefore the proposed criteria is a guide 
but is not definitive. Centres will also be encouraged to submit anonymised 
ultrasound images for assessment by the study steering committee.  
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Based on criteria developed by Jurkovic et al. and adopted by the UKEPSS Study Management Group for the purpose of this   
study. 
 
 
Ultrasound diagnostic criteria 
x Presence of gestational sac or placental tissue anteriorly at the level of the internal os 
x Clear evidence of pregnancy invading into the myometrium 
x Evidence of sustained peritrophoblastic circulation on colour Doppler examination, characterised by high blood-
flow velocity (over 20cm/sec) and low impedance (PI<1) circulation 
x Negative sliding organ sign (inability to displace the gestational sac from its position using gentle pressure with a 
transvaginal probe)  
Figure 18.  Sonographic criteria for the diagnosis of caesarean scar pregnancy 
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SONOGRAPHIC IMAGES OF CSP  (Images (19-24) included and used with permission from Mr Davor Jurkovic, FRCOG, University 
College London) 
Why does a scar pregnancy 
occur?  
The gestational sac implants into a 
deficient lower segment uterine 
caesarean section scar.  
There is a lack of decidua at the 
level of scar which facilitates 
trophoblast invasion into the 
myometrium and development of 
abnormally adherent placenta 
Figure 19: Gestational sac implantation in 
deficient CS scar 
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Figure 20: Implantation into the anterior uterine wall (transducer bottom of the image) 
 
 
 
 
 
 
 
     C – uterine cavity, CX – cervix, B- urinary bladder, GS – gestational sac) 
              Take a note of uterine version/flexion in order to correctly identify anterior and uterine walls. 
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Pregnancy located outside the uterine cavity (C) and extending beyond endometrial-myometrial junction at or below the level 
of the internal os 
Figure 21: Pregnancy outside of the uterine cavity 
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Figure 22: Myometrial involvement 
         Gestational sac (GS) outside the uterine cavity (C) completely embedded into the myometrium 
 
 
 
 
 
Anterior herniation towards the bladder (arrow) confirms thediagnosis of myometrial implantation 
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Figure 23: Peri-trophoblastic flow 
Colour Doppler demonstrates high vascularity adjacent to the anterior aspect of the gestational sac (GS), uterine cavity (C) 
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Figure 24: Using Doppler to avoid false positive 
diagnosis 
• Gestational sac overlying the scar (arrow), but Doppler 
shows posterior implantation away from the scar 
• Gestational sac overlying the scar (arrow) but blood 
supply indicates implantation inside the uterine cavity 
which is suggestive of uncomplicatedmiscarriage 
• Inevitable miscarriage – although the cardiac action is 
still maintained the lack of peri-trophoblastic flow and 
high cord insertion (arrow) are suggestive of cervical 
phase of miscarriage 
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Previous caesarean 
section 
Woman Presents in 
early pregnancy  to 
Early Pregnancy 
Unit or 
Gynaecological 
Assessment 
Unit/Ward  with 
bleeding/ pain/or 
for a routine scan 
USS performed 
+/- other 
diagnostic tests 
CSP SUSPECTED 
Treatment 
Expectant / 
Medical/ 
Surgical/Combined  
Outcome 
 and resolution 
 
 
 
 
 
Figure 25.    Expected care pathway for women presenting with caesarean scar pregnancy 
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CONTROL IDENTIFICATION 
Controls will be women with a history of at least one previous caesarean section 
delivery, of approximately the same gestation as the case, diagnosed with an 
intrauterine pregnancy on early pregnancy scan (i.e not a CSP, seen for other 
symptoms). The clinician reporting each case will be asked to supply data for two 
control women seen at their unit.   
 
DATA GATHERING 
 
Monthly electronic cards and case reporting forms will be sent to nominated reporting 
clinicians to collect anonymised information using a secure electronic data capture 
system. The case report form will seek to confirm that the reported case meets the 
case definition and will collect information on each woman’s presenting features, risk 
factors, diagnosis, management and outcomes. No personally identifiable 
information, such as names, date of birth, addresses, or hospital numbers will be 
collected by UKEPSS. All information sought will be anonymous and will be 
completed by the clinical team from the woman's case notes, without requiring 
reference to any other sources of information. Each unit will be advised to keep a 
centre specific case ID number for each case reported, such that if further 
information is needed the relevant data can be sought. The study thus involves 
provision of information only. The woman’s management will not be changed in any 
way by inclusion of her data in the study, and patients will not be contacted directly at 
any point either by the central research team or by local collaborating clinicians. 
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CONSENT 
This is a non-interventional (descriptive) study only. The study seeks to describe the 
disease and will collect information only. The central team will not seek to collect any 
names, addresses, dates of birth, hospital or NHS numbers in order that none of the 
participants are individually identifiable. Patients will be managed by their usual 
clinical team and will receive the usual management for their care at hospital. 
Information will be collected from the clinical team responsible for each patient after 
the initial diagnosis. The management of each woman participating will not be altered 
in any way by participation in the study. The anonymous information will be used to 
calculate incidence rates, and to study variation in management and outcome, to 
further improve patient care.  
 
STUDY SIZE 
We will study all cases gathered in one year from the start of surveillance (February 
2014). In 2008, 147 726 caesarean section (C/S) deliveries were performed. Based 
on the reported incidence of caesarean scar pregnancy of 0.15%, data on 
approximately 225 cases could be collected over a one year surveillance period.  
 
DATA STORAGE 
Anonymised data will be acquired and stored on a secure online Electronic Data 
Capture (EDC) system that will be developed and delivered to ISO 9001:2000 
standards and in compliance with FDA CRF21:11 requirements. The system will be 
designed, developed and maintained by MedSciNet, based at King’s College 
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University (London), who have over 10 years’ experience in supporting 38 clinical 
trials, 17 registries, and 9 resource centres, including international databases for 
WHO. 
 
STATISTICAL ANALYSIS 
For descriptive studies, we will report frequencies and proportions with confidence 
intervals. For test performance, we will report additional cases identified by other 
tests, and the extra information they provided. For studies examining associations 
between various factors and successful outcome, we will report crude and adjusted 
odds ratios. 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
This study has been approved by the North Wales REC (Central & East) (REC 
reference 13/WA/0318).  
 
PROJECT MANAGEMENT 
Day-to-day management of the project will be carried out by me. The overall conduct 
of the study will be monitored by the Steering Committee of the UK Early Pregnancy 
Surveillance System. Beyond this study, applications will be invited from clinicians 
and researchers for inclusion of suitable studies into the surveillance system. These 
will be considered by the UKEPSS steering committee.  Potential studies will be lead 
by the applicants with the support of the UKEPSS steering committee, and will be 
considered against the following criteria: 
1- The condition is an important cause of maternal morbidity and/or mortality. 
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2- The condition is an uncommon disorder of pregnancy, thus inclusion within the 
study programme of UKEPSS will not impose too great a burden on reporting 
clinicians (usually no more than one case per 2000 pregnancies 
annually in the UK). 
3- The research questions posed by the study can be suitably addressed using the 
UKEPSS methodology (prospective descriptive, cohort or case–control studies). 
4- Other sources of information exist to enhance and/or assess completeness of data 
collection.  
 
DISSEMINATION AND PUBLICATION 
UKEPSS has been proposed to address important clinical and public health issues 
concerning serious disorders of early pregnancy. The key aim of UKEPSS is to 
provide information which can be used to improve prevention, diagnosis, treatment 
and service planning for the NHS and policy makers. Furthermore, it will be important 
to feedback the outcomes of the study to the clinicians who participated in providing 
information. We will achieve this through a comprehensive dissemination strategy: 
Guidelines: The information is expected to be rapidly incorporated into guidelines by 
AEPU, RCOG and NICE, and disseminated to Early Pregnancy Units for 
implementation. 
Patient information resources: Production of lay information with links to appropriate 
patient support groups, including Miscarriage Association and Ectopic Pregnancy 
Trust. 
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Conferences: Patients and patient representative groups regularly attend the 
Association of Early Pregnancy Units (AEPU) conferences. Results will be presented 
annually at the AEPU conferences and at other appropriate conferences. 
Key Research Findings Memos: These memos will be distributed to all reporting 
clinicians, steering committee members, Directors of Public Health in Strategic Health 
Authorities and Health Boards, Chief Medical Officers, Voluntary Groups in the early 
pregnancy field, the UK Department of Health, and the Patient Safety Observatory. 
Newsletters: Quarterly newsletters on the progress of UKEPSS studies will be 
published and widely distributed to all stakeholders, including all participating 
UKEPSS units, the Association of Early Pregnancy Units, the Royal College of 
Obstetricians and Gynaecologist, the Early Pregnancy Clinical Studies Group, the 
Miscarriage Association. the Ectopic Pregnancy Trust and the Scottish Early 
Pregnancy Network.  
Annual Report: This report will outline the studies undertaken during the preceding 
year and will provide a summary of the key outcomes. It will be widely distributed to 
all stakeholders. 
Peer reviewed publications: Study investigators will give an undertaking to submit full 
results for publication in a peer-reviewed journal within 1 year of the completion of 
data collection. References to all completed studies will be listed both in the annual 
report and on the UKEPSS Website. We will disseminate completed papers to the 
Department of Health, the Scientific Advisory Committees of the Royal College of 
Obstetricians and Gynaecologists (RCOG), the Royal College of Nurses (RCN) and 
the Association of Early Pregnancy Units. 
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Teaching and training material: We will produce these for EPU clinicians, nurses, 
sonographers and trainees. 
Media: Where the Steering Committee judges it appropriate, in consultation with the 
investigators and appropriate journal, a press release may be made to the media 
upon publication of particularly notable results. 
UKEPSS Website: UKEPSS already has an active website (www.ukepss.org) which 
will become an important instrument for dissemination. 
Data for systematic reviews and meta-analysis: The Study Steering Committee will 
aim to release data for synthesis by external researchers with a credible protocol. 
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CHAPTER 5 
CAESAREAN SCAR PREGNANCY IN THE UK: INCIDENCE 
AND MANAGEMENT OUTCOMES. A NATIONAL, 
PROSPECTIVE, COHORT STUDY 
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ABSTRACT 
 
Objective 
To estimate the incidence of caesarean scar pregnancy (CSP) in the UK and to 
describe the outcomes for women according to treatment approach 
 
Design 
A national prospective cohort study using the UK Early Pregnancy Surveillance 
Service (UKEPSS) 
 
Setting 
Eighty six UK early pregnancy and gynaecology units 
 
Population 
Sixty women diagnosed with caesarean scar pregnancy between February 2014 and 
February 2015, and 211 comparison women who have previously had at least one 
caesarean section and who have an intrauterine pregnancy 
 
Methods 
Prospective cohort identification through the UKEPSS monthly mailing system 
 
Main outcome measures 
Incidence, success rates, complications. Unadjusted (OR) and adjusted (aOR) odds 
ratio estimates. 
 
  
  
 
108 
 
 
Results 
The estimated UK incidence of CSP was 1 per 10 000 maternities [95% confidence 
interval (CI), 0.71 – 1.19]. Age, smoking, parity and number of caesarean sections 
were strongly associated with a risk of having a caesarean scar pregnancy. The 
mean age at presentation was 35 years (±4.8). The most common symptom at 
presentation was vaginal bleeding (46%) and the mean gestational age at 
presentation was 9 weeks (range 6-18 weeks).   Transvaginal ultrasound scan was 
used as first line diagnostic tool in all cases where mode of investigation was 
reported (44/44, 100%). Expectant treatment was associated with the highest failure 
rate (66%) when compared with medical (53%) and surgical treatment (7%). 50% of 
women having medical management needed further intervention.  Surgical treatment 
with dilatation and curettage was the most commonly used treatment approach,  and 
was associated with the highest rate of successful treatment (93%) following primary 
management.  Expectant management had the highest complication rate (50%) 
when compared with medical (37.5%) and surgical (37.9%) management.  
 
Conclusion 
Surgical management appears to be the most effective treatment approach, and is 
associated with less need for additional intervention and early discharge from care.  
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INTRODUCTION 
 
A caesarean scar pregnancy is an ectopic pregnancy which is partially or completely 
surrounded by myometrium and fibrous tissue of the scar of the prior lower uterine 
segment. It is estimated to occur in 0.15% of women with a history of at least one 
caesarean delivery. (17) The number of reported cases has increased over recent 
years, possibly reflecting the rising number of caesareans performed and the more 
widespread use of transvaginal ultrasonography. 
 
There is currently no agreement on the management for caesarean scar 
pregnancies. There are three main management approaches; expectant, medical 
and surgical treatment. Women are counselled about the management options and 
are given the choice to either continue with their pregnancy, to watch and wait or to 
terminate the pregnancy.  
 
No population-wide prospective incidence studies of caesarean scar pregnancy have 
been undertaken previously and the UK incidence is unknown.  
 
The aim of this study was to use the UK Early Pregnancy Surveillance Service to 
identify all women in the UK diagnosed with caesarean scar pregnancy. This study 
describes the reported cases, management and outcomes for both women and 
babies, and draws comparison with women delivering in the same units who have 
had an intrauterine pregnancy following previous caesarean section delivery.  
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METHODS 
This was a national prospective cohort study. The cohort was defined as all women 
in the UK diagnosed with caesarean scar pregnancy between February 2014 and 
February 2015. For all women in the study, baseline data were recorded for age, 
ethnic background, smoking status at presentation, history of medical problems, 
parity, and caesarean section history. Moreover details on presentation with CSP, 
ultrasound scan findings, additional investigations, management approach, 
outcomes, complication and follow up duration was collected. The primary outcome 
of the study was to identify the incidence of caesarean scar pregnancy. The 
secondary outcome was successful treatment following primary management. 
Success was defined as completed treatment without the need for additional 
interventions. Other outcomes included time to discharge and complications 
according to management approach. Furthermore, the clinician reporting each case 
of CSP was asked to supply data for at least two controls, obtained from the same 
units and defined as women with an intrauterine pregnancy who have undergone at 
least one previous caesarean section. This was to enable the identification of 
predictive factors for developing a caesarean scar pregnancy, The UKEPSS general 
methodology and this study were approved by the North Wales Research Ethics 
Committee (REC reference 13/WA/0318).  
 
Data collection 
Cases were identified on a national basis through the monthly mailing of UKEPSS 
between February 2014 and February 2015. Clinicians were asked to report any 
woman diagnosed with caesarean scar pregnancy. The UKEPSS methodology has 
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been described in Chapter 2. In brief, every month UKEPSS electronic case 
notification cards were sent to nominated reporting clinicians in each hospital in the 
UK with a consultant-led early pregnancy unit, with a simple box to indicate whether 
they had seen a woman with CSP. They were also asked to return cards indicating a 
‘‘nil report‘‘, in order that we could monitor card return rates and confirm the 
denominator to calculate the incidence rate. When a clinician returned a card 
indicating a case, they were then asked to complete an online data collection form 
asking for details of disease presentation, management and outcomes.  All data 
collected were anonymous. Up to five reminders were sent if forms were incomplete. 
 
Additional case ascertainment 
To ensure all cases were identified, we independently contacted all early pregnancy 
and radiology departments, who were asked to report any cases of CSP, reporting 
only their year of birth and date of diagnosis. Where a case was identified which had 
apparently not been reported through UKEPSS, the relevant reporting clinician was 
contacted and asked to complete a data collection form. No additional new cases 
were identified through these three other sources. 
 
Statistical analyses 
Statistical analysis was carried out according to a pre-specified study protocol. I 
calculated incidence with 95% confidence intervals by using denominator data from 
the most recently available birth registration data as a proxy for the period between 
February 2013 and February 2014. Odds ratios (ORs) and adjusted odds ratios 
(aORs) with 95% confidence intervals (CI) were estimated for outcomes using logistic 
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regression. Survival analysis for time interval from presentation with caesarean scar 
pregnancy to resolution of CSP was performed using the Cox proportional hazards 
model. Survival was calculated for the cases according to treatment group using 
Kaplan-Meier estimates. (60;61) For the analysis of predictive variables, I used the 
Mann-Whitney U tests. 
 
RESULTS 
86 hospitals with consultant-led early pregnancy units (EPAU) maternity units 
contributed data to UKEPSS during the study period with 85% participation. Data 
collection was complete for 48/60 (80%) of cases. Additional reports were received 
from 3 (4%) radiology departments, although no new cases were identified through 
this source.  
 
Sixty cases of caesarean scar pregnancy were reported through UKEPSS in a 
reported 646, 904 maternities, giving an incidence of 1 per 10 000 maternities (95% 
CI, 0.71 – 1.19). 
 
Demographics 
Table 4 shows the characteristics of women diagnosed with CSP and provides a 
comparison with controls. Univariate analysis of baseline characteristics in women 
with and without caesarean scar pregnancy showed that age, number of previous live 
births, smoking and previous number of caesarean section are associated with an 
increased risk of developing a caesarean scar pregnancy. No difference was noted in 
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ethnicity, previous uterine surgery (surgical termination of pregnancy and surgical 
management of miscarriage), and medical history. 
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Table 4. Univariate analysis for prediction of caesarean scar pregnancy in women 
who have had at least one previous caesarean section  
 
*live births 
**Data presented and analysed according to available data (missing data not included)  
Prognostic variable Cases  Controls Odds ratio (95% 
CI) 
 
 P 
Age in years 
< 35 
> 35 
N=(45)  
21 (47%) 
24 (53%) 
N=70 
22 (31%) 
48 (69%) 
2.02  
(1.05- 3.86) 
0.04 
Parity* 
1 
2 
≥3 
N=48 
16 (33%) 
15 (32%) 
17 (35%) 
N=70 
98  (50%) 
64  (33%) 
33  (17%) 
3.42  
(1.39 – 8.4) 
0.03  
Ethnicity 
White 
Black 
Asian 
Chinese 
Mixed 
N=60 
45 (75%) 
2  (3%) 
9  (15%) 
3  (5%) 
1  (2%) 
N=70 
39 (56%) 
70 (10%) 
20 (29%) 
1   (1%)  
3   (4%) 
0.96 
(0.34 – 2.99) 
0.06 
Smoking status 
Smoker 
Non-smoker 
N=38 
9   (24%) 
29 (76%) 
N=194 
  6   (3%) 
188 (97%) 
3.99  
(1.58 – 10.05) 
0.003 
Number of previous caesarean 
sections 
1                                                            
2 
≥ 3 
 
N=48 
 
23 (48%) 
17 (35%) 
8   (16%) 
 
 
N=193 
 
147 (76%)  
 32  (16.5%) 
 14   (7.5%) 
   
1.83  
(1.29 – 2.59) 
0.001 
Previous uterine surgery 
Yes 
No 
N=47 
5   (11%) 
42 (89%) 
N=183 
42   (8%) 
168 (91%) 
0.78  
(0.41 – 3.33) 
0.569 
Medical problems 
Yes 
No 
59 
14 (23%) 
45 (76%) 
67 
27 (40%) 
40 (60%) 
0.46 (0.21-0.99) 0.05 
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Diagnosis 
The mean age at presentation was 35 years (±4.8). The most common symptom at 
presentation was vaginal bleeding (46%), followed by vaginal bleeding and pain 
(27%), pain (6%) and the remaining were asymptomatic (Table 5). The mean 
gestational age at presentation was 9 weeks (range 6-18 weeks).   
 
      Table 5. Presenting features in women diagnosed with a CSP 
 Presentation (n=41) 
 Gestation at presentation Mean 9 weeks (range= 6-18) 
 
 Symptoms 
     Vaginal bleeding 
     Pain 
     Vaginal bleeding and pain  
     Asymptomatic 
  
 
19  (46%) 
 6   (15%) 
11  (27%) 
5    (12%)  
 
Ultrasonography was performed in 44/48 (92%) women. Data was missing for 4 
women.  Thirty three (75%) women had a transvaginal ultrasound scan, 10 (23%) 
had transabdominal ultrasound scan, and 1 (3%) woman had both transavaginal and 
transabdmonial ultrasonography. The main findings on ultrasound scan are 
summarised in Table 6. 
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Table 6. Ultrasound findings in women diagnosed with CSP 
 
Ultrasound features 
(n=44)* 
       Seen      Not seen Not assessed/ 
not reported 
Presence of gestational sac 
Pregnancy invading into the 
myometrium 
Sustained peritrophoblastic 
circulation 
Negative sliding organ sign 
Herniation of gestational sac 
Cardiac activity present 
Uterine cavity empty 
Closed internal os 
Intact endometrium 
Concomittant IUP 
40 (91%) 
33 (75%) 
 
21 (48%) 
 
25 (57%) 
9 (21%) 
14 (32%) 
25 (57%) 
34 (77%) 
23 (52%) 
3 (7%) 
4(9%) 
10 (23%) 
 
3 (7%) 
 
1 (2%) 
34 (77%) 
26 (59%) 
16 (36%) 
3 (7%) 
5 (11%) 
40 (91%) 
0 
1 (2%) 
 
20 (45%) 
 
18 (41%) 
1 (2%) 
4 (9%) 
3 (7%) 
7 (16%) 
16 (36%) 
1 (2%) 
IUP=Intrauterine pregnancy. * Cases with complete data (Total number of women n= 48, 
details in 4 women not reported).  
 
Additional investigations 
24 women had serial BhCG measurement(s), 6 women had MRI assessment, 8 
women had 3D ultrasonography, and 3 women had diagnostic laparoscopy. 
Diagnostic hysteroscopy was not used in any of the women. Furthermore, none of 
the cases were investigated by CT scan.  
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Outcomes 
The treatment outcomes are presented in Table 7. Sixty one percent (30/49) of 
women presenting with CSP had surgical treatment as primary management of 
caesarean ectopic pregnancy. This was followed by expectant management (10/49, 
20.4%) and medical management (9/49, 18.4%).  
 
Dilatation and curettage (including those reported as suction curettage) was the 
predominant surgical approach (29/30).  In 22/29 (76%) cases additional haemostatic 
measures were used, including misoprostol (15/22, 68%), syntometrine (10/22, 45%), 
foley catheter (3/22, 14%), shirodkar suture (5/22, 23%), embolization (2/22, 9%).  
 
Methotrexate (MTX) was used in all (9/9, 100%) cases treated by medical 
management. In 8/9 women methotrexate was given by the intramuscular route at a 
dose of 85 – 110mg. In one case, MTX was given intrasac at a dose of 20mg.  
 
Treatment success 
Surgical management resulted in successful treatment of caesarean scar pregnancy 
in 26/28 (93%) cases (OR 0.07, 95% CI 0.01 – 0.49, p=0.007). Outcome data were 
missing for two women were reported to have had surgical treatment.  Only half (4/8, 
50%) of the cases who underwent primary medical treatment were successfully 
managed (OR 0.8, 95% CI 0.12 -5.4, p=0.8) with the rest (4/8) requiring further 
interventions; three women had surgical management as secondary treatment and 
one woman had repeat medical treatment. Data was missing for one woman and it is 
not clear whether additional treatment was given. Expectant management was 
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associated with the highest failure rate, with 66% of women requiring further 
treatment. Multivariate analysis of successful outcome by treatment approach, 
controlling for number of previous caesarean sections and parity, showed a 
statistically significant increase in the success rate in women treated with surgical 
treatment (aOR 0.03, 95% CI 0.001 – 0.5, p= 0.02). 
 
Complications 
Expectant management had the highest rate of complications (5/8, 50%) when 
compared with medical (3/8, 37.5%) and surgical treatment (11/29, 37.9%).  
 
Bleeding was the most common complication (3/8, 37.5%) associated with expectant 
management. One woman was managed conservatively with BhCG follow-up.  BhCG 
at presentation was 34,947 mIU/ml and fell to 166mIU/ml after 8 weeks. Due to 
persistent spotting, and multiple hospital visits as a result of retained products of 
conception, evident on ultrasound scan, a decision between the clinician and the 
woman was made to perform a surgical dilatation and curettage under ultrasound 
guidance. In theatre, the patient had an estimated blood loss of 2500ml and was 
given FFP, tranexamic acid and transfused 2 units of blood. She also underwent 
bilateral uterine artery emobilisation. She was given 48 hours of IV antibiotics and 
completed a course of oral antibiotics. Another woman was managed conservatively 
and underwent a planned caesarean section at 33 weeks gestation. The baby was 
born alive and healthy. In theatre she was diagnosed with a placenta percreta and 
suffered an estimated 2200ml blood loss. An emergency hysterectomy was 
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performed. A vascular surgeon was also called to theatre and a uterine artery 
embolization was performed. Postoperative haemoglobin was 6g/dl.  
 
Medical treatment was associated with the highest rate of retained products of 
conception (25%) compared with surgical (0%) and expectant (12.5%). The most 
frequent complication following surgical management was bleeding (8/29, 27.5%), 
followed by infection (2/29, 6.9%). Two women who were reported to have had 
bleeding as a complication of surgical treatment had in fact undergone emergency 
caesarean sections as primary surgical management for ongoing scar pregnancy. 
One woman presented with sepsis and bleeding at 34 weeks and underwent an 
emergency caesarean section. The estimated blood loss was 500ml. The baby was 
born alive and healthy. The other woman had an emergency caesarean section at 30 
weeks gestation with premature rupture of membranes and sepsis secondary to 
chorioamnionitis. She was found to have placenta percreta at caesarean section had 
a 9500ml blood loss, requiring 20 units of blood transfusion. A subtotal hysterectomy 
was performed. The baby was born alive with apgars of 1 and 6 at 1min and 5mins 
respectively, and required admission to neonatal unit.  
 
None of the women suffered uterine scar rupture following treatment. Logistic 
regression using expectant management as baseline showed no difference in the risk 
of bleeding between the groups. It was not possible to adjust for the rest of the 
complications due to the small sample size.  
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        Table 7. Outcome data for each treatment group 
Outcomes 
 
Expectant Medical Surgical Unadjusted 
OR (95% CI) 
 
P  
Adjusted* 
OR (95% CI) 
 
P 
 
Treatment success** 
     Expectant vs Medical  
     Expectant vs Surgical 
 
4/9 (44.4%) 
 
 
4/8 (50%) 
 
26/28 (93%) 
 
 
0.8  (0.12–5.4) 
0.07 (0.01–0.49) 
 
 
0.8 
0.007 
 
 
1.02 (0.09 – 11.97) 
0.03 (0.001 – 0.51) 
 
 
0.1 
0.02 
Complications  
    Overall 
       Expectant vs Medical 
       Expectant vs Surgical 
    Bleeding 
       Expectant vs Medical 
       Expectant vs Surgical 
    RPOC 
    Infection 
    Uterine scar rupture 
    Hysterectomy 
Discharge from care 
       Expectant vs Medical 
       Expectant vs Surgical 
5/8 (50%) 
 
 
 
3/8 (37.5%) 
 
 
1/8 (12.5%) 
0/8 (0%) 
0/8 (0%) 
1/8 (12.5%) 
7/10 (70%)*** 
 
3/8(37.5%) 
 
 
 
1/8(12.5%) 
 
 
2/8 (25%) 
0/8 (0%) 
0/8 (0%) 
0/8 (0%) 
9/9 (100%) 
11/29(37.9%) 
 
 
 
8/29 (27.5%) 
 
 
0/29 (0%) 
2/29 (6.9%) 
0/29 
1/29 (3.4%) 
29/29 (100%) 
 
 
 
1.67 (0.23-12.22) 
1.64 (0.34-7.91) 
 
4.2 (0.33 – 53.1) 
1.58 (0.30 – 8.17) 
NA 
NA 
NA 
NA 
 
NA 
0.08 (0.01-0.51) 
 
 
0.62 
0.54 
 
0.27 
0.59 
NA 
NA 
NA 
NA 
 
NA 
0.008 
 
 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
0.15 (0.02-1.44) 
 
 
 
 
 
 
 
 
 
 
 
 
N/A 
0.1 
Follow-up duration**** 
       Expectant vs Medical                 
       Expectant vs Surgical 
96 (82-83) 27 (21-27) 35 (3-111)  
3.3 (1.05 -10.42) 
3.6 (1.34 - 9.69) 
 
0.04 
0.01 
 
NA 
NA 
 
*Adjusted for parity and number of CS. **Defined as resolution of CSP without the need for additional interventions. *** 3 women remain 
under follow up for ongoing pregnancy. **** in days, (IQR).  NA= Not Applicable (where it was not possible to compute due to small 
numbers)   
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Follow-up 
The median length of follow-up (figure 26) in women treated with expectant 
management was 96 days (IQR 82 - 83, range 38-233), compared with 26.5 days 
(IQR 21 - 27, range 5-56) in medical management and 34.5 days (IQR 3 - 111, range 
1-180) following surgical management. 70% (7/10) of women managed expectantly 
have been discharged from care; five women had resolution of pregnancy and two 
women had live births following planned caesarean sections at 33 and 39 weeks. 
Three women remain under follow up for ongoing pregnancy.  All women (9/9, 100%) 
treated with medical management as well as all women treated surgically (28/28, 
100%) have been discharged from care. Although reported to have had surgical 
treatment as primary management, one woman had in fact been managed 
conservatively for 8 weeks with BhCG follow up prior to surgical management, and 
this is likely to have skewed the follow-up interval.         
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Figure 26. Kaplan-Meier survival curve for resolution of CSP according to treatment 
group 
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DISCUSSION 
This study estimates a UK incidence of caesarean scar pregnancy of 1 per  
10 000 maternities (95 % CI, 0.71 – 1.19). This equates to one case every two years 
in a unit delivering 5000 women. Although rare, CSP is not confined to tertiary 
centres and is managed in many district general hospitals. 
 
The main findings of this study are that maternal age (>35 years), previous 
caesarean sections (≥2), smoking and parity (2 or more live births) are prognostic 
predictors of having a caesarean scar pregnancy. The current treatment options of 
expectant, medical and surgical treatment are widely used in practice for the 
management of caesarean scar pregnancy. Surgical management is the first line 
approach in the majority of cases. Expectant management is opted for more 
frequently by women than medical management. Expectant management is 
associated with a high risk of bleeding, need for emergency surgery and 
hysterectomy. Medical treatment appears to be ineffective, with 50% of cases 
requiring further interventions for persistent mass (retained products of conception). 
Surgical management was found to have a high success rate but appeared to have a 
higher risk of bleeding than medical management although this was not statistically 
significant and the overall complication rates were comparable in both groups.  
 
The findings of this study in this chapter are limited by a number of factors. The study 
protocol defines the study methodology, and details the strategies used for the 
identification of cases as well as the methods for data collection. Issues regarding the 
ascertainment of diagnosis have been previously discussed.  
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Despite multiple attempts to request the original data from reporting units, it was not 
possible to obtain complete data for all reported cases. This was a limitation which 
arose from reporting centres across the UK, and not limited to a specific region or 
unit. It is possible that analyses with the missing data may have shown a difference 
in the study findings. However, the analyses based on the available data were 
unbiased, although based on a smaller sample size than the original data set. The 
use of a smaller sample size could show an underestimate or overestimate of effects. 
Continued attempts will be made to obtain this data prior to study publication.  
 
Our data showed an increased risk of major obstetric haemorrhage (4/4, 100%), 
delivery prior to 37 weeks gestation (3/4, 75%), emergency caesarean section for 
delivery (2/4, 50%) and emergency hysterectomy (2/4, 50%) in women with ongoing 
pregnancy. All babies were born alive, with 1/4 (25%) requiring admission to neonatal 
unit.   
 
Where diagnostic modality was reported, all women (44/44) had an ultrasound scan. 
It is possible that false positive cases have been reported as a caesarean scar 
pregnancy. Indeed 2 cases were excluded from the study as they were initially 
thought to be CSP but later confirmed to be a failing pregnancy in one case and a 
cervical pregnancy in another.  Included cases were assessed objectively against a 
diagnostic criteria for CSP proposed by Jurkovic et al.(41)  In 6 women, MRI was 
used in addition to transvaginal scanning, however, the benefit of MRI assessment 
for the diagnosis of CSP is unclear. Serum BhCG was measured in 24 women, and 
was predominantly used for monitoring purposes in the follow up period.  
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Analysis showed that a history of 2 or more previous caesarean sections is strongly 
associated with a risk of having a scar pregnancy. As the numbers were limited, it 
was not possible to assess the risk of having a CSP by number of previous CS. 
Nonetheless, with increasing number of caesarean deliveries the risk of abnormal 
placentation increases with subsequent pregnancy. Placenta accreta was reported in 
2/48 (4%) women in our cohort, diagnosed at the time of caesarean section in 2 of 
the 4 women (50%) who chose to continue with their pregnancy. At present, making 
an antenatal diagnosis of placenta accreta is not reliable. A national cohort study (62) 
conducted by UKOSS on multiple repeat caesarean section (MRCS) in the UK found 
that 73% of women who had placenta praevia also had placenta accreta. The 
recommendation was that clinicians should regard any woman having MRCS 
diagnosed with an anterior placenta praevia as having a placenta accreta, unless 
otherwise demonstrated.  
 
As with any medical condition, women should be fully counselled about the benefits 
and risks of all treatment options, and their decision should be respected and 
supported by the care provider. Pre-pregnancy counselling is important and should 
be given to all women with a history of caesarean section delivery regarding the risks 
of future pregnancies. Although the number of cases in this study are limited, this is 
the only population-wide prospective study of caesarean scar pregnancy in the UK 
and it is hoped that the findings of this study will aid women and clinicians in the 
decision on best treatment option. 
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SECTION 2 
SYSTEMATIC REVIEWS OF PRIORITY QUESTIONS 
IN MISCARRIAGE 
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CHAPTER 6 
PROGESTOGEN FOR THE TREATMENT OF EARLY 
PREGNANCY BLEEDING: A SYSTEMATIC REVIEW AND 
META-ANALYSIS 
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OBJECTIVES 
 
1. To determine the effectiveness of progestogens to reduce miscarriage in women 
presenting with early pregnancy bleeding 
2. To identify adverse effects associated with progestogen use 
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ABSTRACT 
 
Objective 
To determine the effectiveness of progestogen treatment for the reduction of 
miscarriage in women presenting with early pregnancy bleeding. 
Methods 
Studies were identified without language restrictions from MEDLINE (1966-2013), 
EMBASE (1980-2013), Cochrane Library, and manual searching of bibliographies of 
known primary and review articles. Studies were selected if progestogen treatment 
was given to women presenting with early pregnancy and if studies reported 
miscarriage rate. Only studies of randomised trials were included. Data were 
extracted on study characteristics, quality and the primary outcome of interest. 
Relative risks from individual studies were meta-analysed using random and fixed 
effects model as. Heterogeneity evaluated graphically using forest plots and 
statistically using the I2 statistic. 
Results  
The search identified 7 randomised trials comprising 744 women. Meta-analysis of 
these seven studies showed a statistically significant reduction in miscarriage rate 
with progestogen use (RR 0.53, 95% CI: 0.39 to 0.73). There was no heterogeneity 
across the studies (I2=0%, p=0.81), suggesting consistency across the studies. 
Quality assessment of the studies showed poor methodological quality, with none of 
the studies reporting the method of allocation concealment, only 3/7 were placebo-
controlled, and 5/7 studies were not blinded.  
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Conclusion 
There is evidence to suggest that progestogen treatment in women presenting with 
early pregnancy bleeding can reduce the risk of miscarriage. Existing trials are small 
and of poor methodological quality limiting the confidence in the findings of this 
review. A large high quality randomised trial is needed to robustly address this 
question.  
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INTRODUCTION 
Threatened miscarriage is the most common complication of early pregnancy, 
occurring in approximately 20% of pregnant women before 20 weeks of gestation. 
(63)  
Miscarriage remains an important cause of morbidity and mortality, especially in low-
income countries. (64) The great majority of miscarriages occur early before 12 
weeks, and less than 5% occur after fetal heart activity is identified. (65) 
Approximately half of all miscarriages are associated with fetal chromosomal 
abnormality, particularly in those of earlier gestational demise, however the cause in 
the remainder is unclear. (66;67) 
Low progesterone levels have been linked to an increased risk of first trimester 
miscarriage. (68) Progesterone is a natural hormone, which is secreted in women 
principally by the corpus luteum in the ovaries during the normal menstrual cycle as 
well as during the first two months of pregnancy, after which production shifts to the 
placenta. Progesterone is derived from cholesterol steroids. It has different actions 
depending on the stage in the oestrous cycle. Progesterone regulates maturation of 
the oocytes, ovulation, myometrial quiescence, mammary gland growth and 
endometrial enzymes. (69;70) Progesterone exerts other wide-ranging actions 
including effects on metabolism, (71) respiratory system (72) and central nervous 
system (73).  
Progesterone is a well-established drug substance that has been used clinically since 
the 1980s. It is used widely in assisted conception. (74;75) 
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Studies have shown that low progesterone is found in women with failing 
pregnancies and it is in these women that progesterone might be expected to have 
an effect. Given the recognised role of progesterone in maintaining pregnancy, 
progestogens have been used for many decades in an attempt to salvage threatened 
pregnancies. (76) This rationale is supported by the effectiveness of progesterone 
antagonists like mifepristone to terminate pregnancies. (77) 
Recently, Haas et al (78) conducted a meta-analysis of progestogen use for the 
prevention of miscarriage. The findings of their review suggested that progestogen is 
not effective in the prevention of miscarriage. The population they included was 
heterogeneous, including women who predominantly presented without vaginal 
bleeding, and who were given progestogen treatment for the prevention rather than 
the treatment of threatened miscarriage. The majority of the included women had a 
history of recurrent miscarriages, and did not present with early pregnancy bleeding. 
Therefore their review did not address the question of whether progestogen is 
effective in reducing miscarriage risk in women presenting with early pregnancy 
bleeding.  
The aim of this review is to systematically review studies on the effectiveness of 
progestogens for the treatment of threatened miscarriage. 
 
METHODS 
Identification of studies 
I searched MEDLINE (1966-2014), EMBASE (1980-2014), Cochrane Library, and 
Conference Proceedings (ISI Proceedings, 1990-2014) for relevant citations. In 
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MEDLINE, a combination of Medical Subject Headings (MeSH) and textwords were 
used to generate two subsets of citations, one including studies of progestogen ( 
‘progesterone’, ‘progestogen’ , ‘dydrogesterone’ , ‘duphaston’) and the other studies 
of miscarriage (miscarriage, abortion, ‘early pregnancy’, bleeding). These subsets 
were combined using ‘AND’ to generate a subset of citations relevant to the research 
question. Where necessary, this search strategy was adapted for use in the other 
electronic databases. The reference lists of all known primary and review articles 
were examined to identify cited articles not captured by electronic searches. Articles 
frequently cited were used in the Science Citation Index to identify additional 
citations. I also made enquiries about unpublished studies from researchers 
investigating in this field.  
 
Study selection 
Studies in which progestogen therapy was used for the treatment of early pregnancy 
bleeding were selected in a two-stage process. First, the electronic searches were 
scrutinised and full manuscripts of all citations that were likely to meet the predefined 
selection criteria were obtained. Second, final inclusion or exclusion decisions were 
made on examination of these manuscripts. In case of duplicate publication, the most 
recent and complete versions were selected. There were no language restrictions but 
studies with case-control or cohort design were excluded. Information was extracted 
from each selected article on study characteristics, quality and miscarriage rate.  
 
Methodological quality assessment 
All manuscripts meeting the selection criteria were assessed for their methodological 
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quality. Quality was defined as the confidence that the study design, conduct and 
analysis minimised bias. Quality assessment was carried out using the Cochrane 
collaboration tool, which assesses the risk of bias through examining the following 
items; random sequence generation, allocation concealment, blinding of participants 
and personnel, and of the outcome assessment, completeness of outcome data, 
selective reporting and anyother bias within the studies. 
 
Each trial was assessed on the method of randomisation, whether it was double blind 
and whether there was a description of withdrawals and dropouts. Additionally, I 
assessed the quality of allocation concealment. A study was considered to be of 
good quality if participants were appropriately randomised, if blinding of participants 
and study personnel was adequate, if the method of allocation concealment was 
adequate, and if all participants were accounted for. 
 
 
Data extraction 
I designed a data extraction form to extract relevant data. A second reviewer (AC) 
extracted data using the agreed form. Any discrepancies were resolved by 
discussion.  
 
Data synthesis 
I carried out statistical analyses using the Review Manager software (RevMan 5.3). 
Relative risks with 95% confidence intervals from each study were combined for 
meta-analysis using the Peto-modified Mantel-Haenszel method. The fixed-effect 
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model for combining data was used where it was reasonable to assume that studies 
were estimating the same underlying treatment effect: i.e. where trials are examining 
the same intervention, and the trials’ populations and methods were judged 
sufficiently similar. Where clinical heterogeneity was deemed significant to expect 
that the underlying treatment effects differ between trials, or where I detected 
substantial statistical heterogeneity, I used random-effects meta-analysis to produce 
an overall summary of an average treatment effect across trials.  
 
Heterogeneity was assessed graphically using forest plot and statistically using chi-
squared test.  To detect publication and related biases, I undertook funnel plot 
analysis using Egger’s tests to evaluate for asymmetry.  
 
RESULTS 
 
Literature identification 
Figure 27 provides a summary of the process of literature identification and selection. 
The search strategy yielded 150 citations.  Of these, 117 publications were excluded 
as it was clear from the title or abstract that they did not fulfill the selection criteria.  I 
obtained full manuscripts for the remaining 33 articles.  Following scrutiny of these, 6 
studies were excluded as they were not randomized trials, 3 studies did not report 
original data, in 4 studies treatment was commenced in the second or third trimester, 
7 studies reported different outcomes, 2 studies had duplicate data and 4 studies 
used combined progestogen treatment (3 with oestrogen, 1 with immunotherapy).  
Therefore the total number of studies included in the review was 7.  
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Study characteristics 
The seven studies (76;79-84) included a total of 744 women. The study 
characteristics, including number of women, type, dose and route of progestogen 
used, whether the trial was placebo controlled, and the reported outcomes are 
summarized in Table 8.  
 
Quality of included studies 
The quality of the included studies is summarised in Table 9.  The studies were 
randomised or quasi-randomized trials which compared progestogens with placebo 
or no treatment, given for the treatment of miscarriage. These studies were small and 
of poor quality, with none reporting the method of allocation concealment. Only 3/7 
studies were placebo-controlled, and 5/7 studies were not blinded.  
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Total number of citations retrieved from electronic searches and from examination of 
reference lists of primary and review articles: n = 150
Citations excluded after screening title and/or abstracts: n = 117
Full manuscripts retrieved for detailed evaluation: n = 33 
Primary articles fulfilling inclusion criteria for systematic review: n=7
Articles excluded after review of full text with reasons.
Not a randomised trial n= 6 
Literature review n= 3
Treatment started in 2nd or 3rd trimester n= 4
Different treatment outcome n= 7
Duplicate publication N= 2
Combined treatment n=  4
Total excluded n=26
 
 
 
 
Figure 27. Study selection process for systematic review of progestogen therapy for 
early pregnancy bleeding 
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Table 8. Randomised trials of progestogens versus placebo or no treatment 
Study Population                       Intervention Comparison  Outcome 
  Route Dose  Duration   
Misto 1967 
n=25 
Women presenting at 
different gestational age 
with threatened 
miscarriage 
 
Oral 
(Dydrogesterone) 
20-40mg Once daily for 6-15 
sometimes for longer 
periods and for several 
cycles  
Placebo Miscarriage  
 
Ehrenskjold 1967 
 
n=153 
Women who wanted to 
continue their pregnancy, 
had a positive pregnancy 
test at admission or the 
day after and not aborted 
within the first treatment 
day included 
 
Oral 
 
(Dyrdrogesterone) 
20mg 20mg then staggered dose 
(20mg after 12hours/20mg 
every 8 hours until 
symptoms ceased/10mg 
am and pm for 5 days/5mg 
am and pm for at least 7 
days 
 
No treatment Miscarriage rate 
Premature births 
Live births 
 
Gerhard 1987 
 
n=34 
Women with confirmation 
of fetal viability by 
ultrasound before 
commencement of 
treatment 
 
Vaginal suppository 25mg twice 
daily 
Until the woman either 
miscarried or 14 days after 
bleeding stopped 
 
Placebo Miscarriage 
Birth weight 
Preterm labour 
Palagiano 2004 
 
n=50 
Women with previous 
diagnosis of inadequate 
luteal phase, threatened 
miscarriage, 
and confirmed fetal 
viability. Gestational age  
6-12 weeks 
 
Vaginal suppository 
(Crinone 8%) 
90mg OD 5 days 
Women followed up for 60 
days for the occurrence of 
miscarriage and for 5 days 
for the other outcomes 
Placebo Pain relief 
Miscarriage 
Frequency of uterine 
contractions 
Blood loss 
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Omar 2005 
 
n=154 
Women presenting at 13 
weeks or less with 
vaginal bleeding or 
spotting and USS 
confirmed foetal viability 
 
Oral 
 
(Dydrogesterone) 
40mg stat 40mg stat dose followed by 
10mg twice daily until 
bleeding stopped 
No treatment Miscarriage  
 
El-Zibdeh 2009 
 
n=146 
 
 
Women presenting at 5-8 
weeks gestation, with 
mild to moderate vaginal 
bleeding 
 
Oral  
 
(Dydrogesterone) 
10mg twice 
daily 
Continued until 1 week after 
bleeding stopped 
No treatment Miscarriage, preterm 
labour, congenital 
malformations, 
antepartum 
haemorrhage, 
preeclampsia, 
and intrauterine 
growth restriction 
 
Pandian 2009 
 
n=191 
Women presenting 
between 5 and 16 weeks 
gestation 
Oral  
 
(Dydrogesterone) 
40mg stat 40mg stat followed by 
10mg twice daily and 
continued until 16 weeks of 
gestation 
 
No treatment Miscarriage, preterm 
labour, congenital 
anomalies, 
antepartum 
haemorrhage, 
placenta praevia, 
caesarean section 
rate, pre-eclampsia, 
and intrauterine fetal 
death 
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Random sequence 
generation 
Allocation 
concealment 
Blinding of participants 
and personnel 
Blinding of outcome 
assessment 
Incomplete outcome 
data 
Selective 
reporting 
Misto 1967      
    Unclear Low Low Unclear Unclear Unclear 
Ehrenskjold 1967      
    Unclear Low Low Low Unclear Unclear 
Gerhard 1987      
    Unclear Unclear Low Low Low Unclear 
Palagiano 2004      
    Unclear Low High High Unclear High 
Omar 2005      
    Unclear High High High Unclear Unclear 
El-Zibdeh 2009      
    High High Unclear Unclear Low Low 
Pandian 2009      
    Low Low High High Unclear Unclear 
    
 
       Table 9. Risk of Bias in RCTs using the Cochrane  collaboration risk of bias tool 
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Primary outcome 
Miscarriage 
Pooling of seven studies of progestogen use in women with early pregnancy bleeding 
showed a statistically significant reduction in miscarriage rate in the progestogen 
group when compared with placebo or no treatment (RR 0.53, 95% CI: 0.39, 0.73, 
p= 0.0001, Figure 28). There was no heterogeneity across the studies (I2=0%, 
p=0.81), suggesting consistency across the studies.  
 
Secondary outcomes 
Congenital malformations 
Pooling of results from 3 studies of progestogen use in women with early pregnancy 
bleeding did not show a difference in congenital malformations when compared to 
placebo or no treatment (RR=0.96, 95% CI 0.09–10.20, p=0.97, Figure 29).  
 
Preterm labour 
Pooling of results from 3 studies of progestogen use in women with early pregnancy 
bleeding did not show a difference in preterm labour when compared to placebo or 
no treatment (RR=0.91, 95% CI 0.39–2.09, p=0.82, Figure 30). There was little 
variation across studies as indicated by an I2 value of 0% (p=0.41). 
 
Neonatal death 
Pooling of results from 2 studies of progestogen use in women with early pregnancy 
bleeding did not show a difference neonatal death when compared to placebo or no 
treatment (RR=0.96, 95% CI 0.09–10.20, p=0.97, Figure 31).  
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Study
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Figure 28. Meta-analysis of studies of progesterone in women with early pregnancy bleeding for the outcome of miscarriage 
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  Figure 29. Meta-analysis of studies of progesterone in women with early pregnancy bleeding for the outcome of congenital    
   anomalies 
 
 
    
 
144 
 
 
 
 
  Figure 30. Meta-analysis of studies of progesterone in women with early pregnancy bleeding for the outcome of  preterm labour 
 
 
 
 
Study
El-Zibdeh 2009
Gerhard 1987
Pandian 2009
Total (95% CI)
Heterogeneity: Chi² = 1.75, df = 2 (P = 0.42); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Events
5
0
6
Total
71
23
96
190
Events
3
2
4
Total
34
21
95
150
0.80 [0.20, 3.15]
0.18 [0.01, 3.61]
1.48 [0.43, 5.09]
0.91 [0.39, 2.09]
Progesterone Placebo or no treatment Risk Ratio Risk Ratio
Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental] Favours control
    
 
145 
 
 
 
Figure 31. Meta-analysis of studies of progesterone in women with early pregnancy bleeding for the outcome of neonatal 
death 
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Secondary outcomes (continued) 
Progestogen for the prevention of miscarriage in women with a history of 
recurrent miscarriages 
 
History of 2 or more previous miscarriages  
Pooling of results from 7 studies of progestogen treatment in pregnant women with a 
history of 2 or more recurrent miscarriages did not show a difference in miscarriage 
rate when compared to placebo or no treatment (RR=0.73, 95% CI 0.52–1.04, 
p=0.08). There was little variation across studies as indicated by an I2 value of 5% 
(p=0.38). 
 
History of 3 or more previous miscarriages 
Pooling of results from 4 studies of progestogen treatment in pregnant women with a 
history of 3 or more recurrent miscarriages showed a statistically significant reduction 
in miscarriage in the progestogen group when compared with placebo or no 
treatment (RR=0.39, 95% CI0.21–0.72, p=0.003). There was consistency across 
studies as indicated by an I2 value of 0% (p=0.98). 
 
DISCUSSION 
This systematic review, which included 7 studies, found that the use of progestogens 
for the treatment of early pregnancy bleeding is associated with a relative risk 
reduction in miscarriage by 47%. No difference was found in the risk of congenital 
anomalies, preterm birth or neonatal death. 
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There are several reasons that give strength to the findings of this study. Firstly, I 
performed an extensive search strategy and used valid data synthesis methods.  No 
language restrictions were placed on the search or included study. Moreover, only 
studies of randomised design were included. 
 
The weaknesses in the study are mainly related to the poor quality of the included 
studies. Although reported as randomised trials, the method of randomisation was 
unclear in 5 out of the 7 studies. In one study, participants were randomised 
according to the day of the week they presented to hospital. None of the studies 
reported the method of allocation concealment. Only 3/7 studies were placebo-
controlled, and 5/7 studies were not blinded. Moreover, there was clinical 
heterogeneity between the trials. Women were treated for different durations; one 
study did not have a strict protocol for the duration of treatment, with some women 
having treatment for 6-15 days, whilst others were on progesterone for a longer 
unspecified period. Palagiano (76) treated women for 5 days, whilst other studies 
used bleeding cessation as the time point for ending treatment. Moreover, the 
dosage and routes varied between trials, with one trial using as little a dose as 25mg 
twice daily of progesterone vaginal suppositories. Furthermore, few of the studies 
used ultrasonography to confirm the pregnancy or fetal viability prior to enrolment to 
the study.  
 
Despite the weaknesses of the included studies, a significant reduction in the risk of 
miscarriage was demonstrated in the progestogen group. Progesterone is thought to 
have an immune-modulatory effect on the uterus, and has a role in preventing 
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rejection of the embryo, enhancing uterine quiescence and suppressing uterine 
contractions. (70) Progesterone is used widely in the field of assisted conception. 
There have been some reports of an increase in hypospadias, however recent 
reviews have not demonstrated this. (85;86) 
 
The findings of this review are consistent with the Cochrane review conducted by 
Wahabi et al. (86) Their review, which included 4 studies, found a reduction of up to 
50% in women receiving oral progesterone (dydrogesterone). There was a trend 
towards a reduction in women receiving vaginal progesterone, however this did not 
reach statistical significance, probably due to the small sample size. Based on the 
findings of this review, NICE called for “A very large multicentre randomised 
controlled trial of women treated with either progesterone/progestogen or placebo 
should be conducted.” 
 
The conclusions of this systematic review are limited by the poor methodological 
quality of the included studies and the small number of participants. In agreement 
with the call by NICE, a high quality randomized controlled trial is needed to robustly 
address this question. 
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Clinician and patient surveys 
 
To understand how the existing evidence is viewed by clinicians, I conducted  UK 
and International Clinician surveys, the findings of which are provided below.  
 
UK and International Clinician surveys 
I conducted a UK clinician survey (n=222) in Oct 2012. In the UK, the vast majority of 
clinicians (212/222, 95.5%) do not use progesterone to prevent miscarriage in 
women with early pregnancy bleeding  (Figure 32).  The key reason for non-use is 
the lack of robust evidence. It is therefore not surprising that the majority (201/222, 
91%) called for a definitive trial.  
 
Figure 32. UK clinician survey findings 
 
 
A survey of international practitioners was also conducted at FIGO (International 
Federation of Gynecology and Obstetrics) 2012 Conference, Rome. Surprisingly, this 
survey found the majority of clinicians (61/68, 90%) already use progesterone in 
women with early pregnancy bleeding, although the vast majority (56/66, 85%) were 
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willing to recruit into a randomised trial, (Figure 33) presumably indicating lack of 
confidence in the available evidence.  
 
Figure 33. International clinician survey findings 
 
UK patient survey 
 
I conducted a survey to seek the opinion of women seen in the Early Pregnancy Unit 
(n=79) at Birmingham’s Womens Hospital, in December 2012. The majority of 
women (57/79, 72%) said they would consider taking part in the trial, and 70% 
(55/79) found the vaginal route of administration acceptable. Furthermore, an 
independent survey was conducted by the Miscarriage Association to identify 
women’s opinions on a double-blind placebo-controlled trial in early pregnancy and 
the acceptability of administering vaginal or rectal medications. The findings of this 
survey of 128 women showed that 91% (116/128) would enter or consider entering 
the trial. The vaginal route of administration of medicines was acceptable to 100/111 
(90%) of women, and the rectal route acceptable to 91/111 (82%) of women.  
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CHAPTER 7 
THE EFFECT OF PRESENCE AND TREATMENT OF 
HYDROSALPINX ON MISCARRIAGE: A SYSTEMATIC 
REVIEW AND META-ANALYSIS 
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OBJECTIVES 
 
1. To evaluate the relationship between presence of hydrosalpinx and miscarriage  
2. To evaluate the effects of management of hydrosalpinx on the risk of miscarriage  
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ABSTRACT 
 
Objectives 
To evaluate the association between the presence and management of hydrosalpinx 
on the risk of miscarriage (as opposed to the chances of conception of a pregnancy). 
 
Search strategy 
Searches were conducted on MEDLINE, EMBASE, Cochrane Library and Web of 
Science (inception- October 2014) in all languages, together with reference lists of 
retrieved papers. Studies comparing miscarriage rate in women with hydroaslpinx to 
women without hydrosalpinx were included. Furthermore, studies reporting 
miscarriage in women who underwent treatment of hydrosalpinx compared to no 
treatment were also included. Study selection was conducted independently by two 
reviewers. The Cochrane scale for randomised controlled trials and the Newcastle-
Ottawa Quality Assessment Scale for cohort studies were used for quality 
assessment. Data extraction was conducted independently by two reviewers. 
Relative risks from individual studies were meta-analysed. 
 
Results 
Twenty three studies were identified, of which 7 were randomised controlled trials 
and 16 were observational studies, all in the IVF population. The studies scored well 
on the Cochrane and Newcastle-Ottawa scales for quality assessment. Meta-
analysis of 14 observational studies showed a 64% relative increase in the risk of 
miscarriage in women with hydrosalpinx compared to women without hydrosalpinx 
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(RR=1.64, 95% CI 1.27, 2.12, p=0.0002, I2=31%). Pooling of results from 5 
randomised controlled trials of treatment of hydrosalpinx with salpingectomy showed 
a halving in the risk of miscarriage in women who had salpingectomy for hydrosalpinx 
treatment when compared to women with untreated hydrosalpinx (RR=0.44, 95% CI 
0.23- 0.83, p=0.01, p=0%). Similarly, pooling of results from 5 observational studies 
showed halving in the risk of miscarriage in women who had salpingectomy for 
hydrosalpinx in comparison to women with untreated hydrosalpinx (RR=0.49, 95% CI 
0.34- 0.71, p=0.0002, I2=0%). No difference was found in women having ultrasound 
guided drainage (RR= 0.68, 95% CI 0.24- 1.95, p=0%). 
 
Conclusion 
There is evidence to suggest that the presence of hydrosalpinges increases the risk 
of miscarriage in IVF/ICSI pregnancies. Treatment for hydrosalpinges with 
salpingectomy can reduce the risk of miscarriage. These findings may have 
implications for women with a history of recurrent miscarriage, and raises the 
question whether routine screening for hydrosalpinx should be performed in this 
population. Further research is needed to assess this question. 
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INTRODUCTION 
Hydrosalpinx is a fluid-filled distension of the fallopian tube in the presence of distal 
tubal occlusion. The incidence of hydrosalpinx within infertile women is between 10 
to 13% when diagnosed by ultrasound.  This figure increases to 30% with the use of 
hysterosalpingogram or laparoscopy (5).  The most common pathogens associated 
with tubal damage is Chlamydia trachomatis . In vitro fertilization was first introduced 
as a method to overcome tubal infertility(1).   
 
It has been widely established that the presence of hydrosalpinx is associated with 
lower implantation and pregnancy rates.   Multiple studies have demonstrated that 
the presence of hydrosalpinges adversely affects IVF outcomes, with a reduction in 
live birth rates by approximately 50% (2, 3). Several mechanisms have been 
postulated to explain the adverse effects of hydrosalpinges on the live birth rate 
achieved with IVF, including direct embryotoxicity (5), a reduction in endometrial 
receptivity, and mechanical flushing of the embryo. Moreover, tt has also been 
demonstrated that treatment for hydrosalpinx can improve clinical pregnancy and live 
birth rate.  
 
However, the question whether hydrosalpinx has a detrimental effect on an already 
established pregnancy, that is, when an intrauterine pregnancy is seen on 
ultrasonography has yet to be robustly reviewed. Moreover, the potential 
effectiveness of treatment in reducing miscarriage risk in such women is currently 
unknown. The aim of this review is to assess the effect of the presence and 
treatment of hydrosalpinx on miscarriage.  
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METHODS 
 
Identification of literature and study selection  
The population for this review is women with hydrosalpinx. The following electronic 
databases were searched: MEDLINE, EMBASE, Cochrane Central Register of 
Controlled Trials and Web of Science (inception - October 2014). A search strategy 
was carried out based on the following key words and/or medical subject heading 
(MeSH) terminology: hydrosalpinges, hydrosalpinx, abortion, spontaneous fetal loss, 
miscarriage, salpingectomy, salpingostomy, ultrasound guided aspiration. The 
reference lists of all known primary and review articles were examined to identify 
cited articles not captured by electronic searches. No language restrictions were 
placed in any of the searches or study selection. 
 
I excluded articles where women had causes of infertility other than hydrosalpinx and 
where miscarriage was not reported as an outcome.  Studies were selected in a two-
stage process. First, the titles and abstracts from the electronic searches were 
scrutinised by two reviewers independently (HH and FR) and full manuscripts of all 
citations that were likely to meet the predefined selection criteria were obtained. 
Second, final inclusion or exclusion decisions were made on examination of the full 
manuscripts. In cases of duplicate publication, the most recent and complete 
versions were selected. Any disagreements about inclusion were resolved by 
consensus.  
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Quality assessment 
All manuscripts meeting the selection criteria were assessed for their methodological 
quality. Quality was defined as the confidence that the study design, conduct and 
analysis minimised bias. Quality assessment was carried out using the Cochrane 
collaboration tool, which assesses the risk of bias through examining the following 
items; random sequence generation, allocation concealment, blinding of participants 
and personnel, and of the outcome assessment, completeness of outcome data, 
selective reporting and any other bias within the studies. 
  
The Newcastle-Ottawa Quality Assessment was implemented for quality assessment 
of the included observational studies. This scale assesses eight components, 
including representativeness of the exposed cohort, selection of non-exposed cohort, 
ascertainment of exposure, outcome at start, comparability by design or analysis, 
outcome assessment, duration and adequacy of follow up . One star is awarded as 
maximum for all items except for comparability where a maximum of two stars can be 
awarded. I used an arbitrary score based on the assumption of equal weight of all 
items included in the Newcastle-Ottawa Scale. This was used to give a quantitative 
appraisal of overall quality of the individual studies. The score ranged from 0 to 9, 
with a score of either 0 or 1 for each item. From each study, outcome data were 
extracted in 2 x 2 tables by two reviewers HH and FR.  
 
Data extraction 
I designed a data extraction form to extract relevant data. A second reviewer (FR) 
extracted data using the agreed form. Any discrepancies were resolved by 
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discussion.  
 
Data synthesis 
For the analysis of miscarriage rates I analysed data per total number of 
pregnancies. I carried out statistical analyses using the Review Manager software 
(RevMan 5.3). Relative risks with 95% confidence intervals from each study were 
combined for meta-analysis using the Peto-modified Mantel-Haenszel method. The 
fixed-effect model for combining data was used where it was reasonable to assume 
that studies were estimating the same underlying treatment effect: i.e. where trials 
are examining the same intervention, and the trials’ populations and methods were 
judged sufficiently similar. Where clinical heterogeneity was deemed significant to 
expect that the underlying treatment effects differ between trials, or where I detected 
substantial statistical heterogeneity, I used random-effects meta-analysis to produce 
an overall summary of an average treatment effect across trials.  
 
Heterogeneity was assessed graphically using forest plot and statistically using chi-
squared test.  To detect publication and related biases, I undertook funnel plot 
analysis using Egger’s tests to evaluate for asymmetry. 
 
RESULTS 
Literature identification 
The search strategy yielded 2680 citations (Figure 34) of which 2512 publications 
were excluded because it was clear from the title or abstract that they did not fulfil the 
selection criteria. I obtained full manuscripts for the remaining articles. 145 
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publications were excluded because they did fulfil the inclusion criteria. Therefore the 
total number of studies included in the review was 23 (25;26;87-107). 7 of the 
included studies were of randomised controlled design (RCT) and 16 were 
observational studies.  
 
Study characteristics 
The characteristics of the studies are presented in Tables 10 and 11.  
 
Quality assessment 
The Cochrane and Newcastle-Ottawa scales for Quality Assessment are presented 
in Tables 12 and 13. The studies scored well on both scales. There was no evidence 
of publication bias on funnel-plot assessment. 
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 Total number of citations retrieved from electronic searches and from examination of  
reference lists of primary and review articles: n = 2680 
 Citations excluded after screening title and/or abstracts: n = 2571 
 
 Full manuscripts retrieved for detailed evaluation: n = 78  
 
 Primary articles fulfilling inclusion criteria for systematic review n= 23 
 Articles excluded after review of full text with reasons: 
Review article/opinion/case reports n=28 
Miscarriage not reported n=11 
No control group n= 9 
Data not extractable n= 3 
Duplicate publication n= 4 
Total excluded n= 55 
Figure 34. Study selection process for the systematic review of hydrosalpinx and miscarriage  
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Study  Population Study groups Outcomes  Study design 
Blazar et al 
1997 
 
All patients who had undergone IVF for 
tubal factor at Brown University school of 
Medicine, Providence, Rhode Island  
between May 1988 and October 1994 
Total 250 women  
Hydrosalpinx n= 
67 
 
Without 
Hydrosalpinx n= 
183 
Diagnosed on 
USS 
Implantation rate, 
miscarriage and clinical 
pregnancy rate  
Retrospective 
observational study 
Akman et al 
1996 
 
 
All patients at The Women's Hospital 
Fertility Center at the Greater Baltimore 
Medical center, MD, USA, with tubal 
disease undergoing embryo transfer of 
previously cryopreserved embryo during 
a natural cycle between September 1993 
and November 1995 
Total 84 women  
 
Hydrosalpinx n= 
10 
 
Without 
Hydrosalpinx n= 
74 
Implantation rate, 
clinical pregnancy, 
miscarriage 
Retrospective 
observational study 
Table 10. Characteristics of studies of hydrosalpinx versus no hydrosalpinx in women undergoing IVF  
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Diagnosed on 
USS or HSG 
Andersen et al 
1994 
 
Results of first IVF treatment cycles in 
144 patients from 1 January 1993 to 31 
December 1995, who had tubal infertility 
only at ACU of Queen Mary Hospital, 
Hong Kong 
Total 741 women  
 
Hydrosalpinx n= 
62 
 
No Hydrosalpinx 
n= 493 
 
Diagnosed on 
USS 
Implantation, 
miscarriage Pregnancy 
rate and delivery rate 
Retrospective 
observational study 
Hung-Yu Ng et 
al 1997 
 
Women with tubal factor infertility who 
underwent IVF treatment at The New 
York Hospital –Cornell Medical Center 
between January 1989 to December 
1995 
Total 144 women  
 
Hydrosalpinx n= 
43 
 
Without 
Hydrosalpinx n= 
Implantation rate, 
clinical pregnancy rate, 
miscarriage 
Retrospective 
observational study 
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101 
Diagnosed on 
USS, HSG or 
laparoscopy 
 
Barmat et al 
1999 
 
Women with tubal factor infertility who 
underwent IVF-embryo transfer cyles at  
Nashville Fertility Center, USA between 
January 1993 and June 1996  
Total 1000 
women  
 
Hydrosalpinx n= 
60 
 
Without 
Hydrosalpinx n= 
940 
 
Diagnosed on 
Diagnosed on 
USS  
Clinical pregnancy 
rate, miscarriage and 
live birth 
 
 
Retrospective 
observational study 
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Freeman et al 
2005 
 
Women with and without who 
hydrosalpinx underwent IVF treatment in 
a university-based assisted reproduction 
programme  
Total 286 women  
 
Hydrosalpinx n= 
35 
 
Without 
Hydrosalpinx n= 
83 
Diagnosed on 
USS or HSG 
 
Implantation rate, 
clinical pregnancy rate, 
miscarriage 
Retrospective 
observational study 
Cohen et al 
1999 
 
Women with tubal factor infertility 
underwent IVF treatment at Micheal 
Reese Hospital and Fertility Center 
between January 1990 and December 
1994 
Total 110 women  
 
Hydrosalpinx= 10 
 
Without 
Hydrosalpinx n= 
100 
 
Pregnancy, 
implantation, 
miscarriage and ectpic 
pregnancy rates. 
Retrospective 
observational study 
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Diagnosed on 
USS 
 
Sharara et al 
1996 
 
Women with tubal factor infertility who 
underwent IVF trearment at the 
Sahlgrenska University Hospital, 
Sweden between January 1990 and 
June 1993. 
Total 123 women  
 
Hydrosalpinx= 63 
 
No Hydrosalpinx 
n= 60 
 
Diagnosed on 
USS 
Implantation, 
pregnancy and 
miscarriage rates 
Retrospective 
observational study 
Strandell et al 
1994 
 
Women with tubal disease initiated on a 
stimulation cycle for eventual IVF 
between October 12 1987 and March 31 
1995 at The women’s fertility center,  
Greater Baltimore Medical Centre 
Total 254 women  
 
Hydrosalpinx=  
 
Without 
Hydrosalpinx =  
 
Pregnancy, 
miscarriage and 
delivery rates. 
Retrospective 
observational study 
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Diagnosed on 
USS and HSG 
Katz et al, 1996 
 
Women with tubal disease who 
underwent IVF treatment at University of 
Bristol IVF unit at the BUPA Hospital 
Bristol from July 1989 to June 1993 
Total 891 women  
 
Hydrosalpinx n= 
79 
Diagnosed on 
USS, HSG or 
laparoscopy 
Pregnancy, 
miscarriage and 
Implantation rates. 
Retrospective 
observational study 
Fleming et al, 
1996 
 
Women with hydrosalpinx who 
underwent IVF treatment at Free 
University Brussels, Belgium between 
March 1989 and June 1993 
Total 277 women  
Hydrosalpinx n= 
79 
 
 
Without 
Hydrosalpinx n= 
198 Diagnosed 
on USS 
 
Clinical Pregnancy, 
miscarriage and live 
birth rates 
Retrospective 
observational study 
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Vandromme et 
al, 1995 
Women with hydrosalpinx undergoing 
IVF treatment compared with women 
tubal infertility from other causes.  
Total 78 women 
 
Hydrosalpinx n= 
37 
 
Without 
hydrosalpinx 
n=41 
 
Diagnosed on 
USS 
Clinical pregnancy, 
miscarriage, ongoing 
pregnancy 
Retrospective 
observational study 
Sims et al, 
1993 
 
Abstract 
Not available from published abstract Hydrosalpinx 
n=118 
 
Without 
hydrosalpinx 
n=823 
Diagnosed on 
USS 
Clinical pregnancy, 
miscarriage, ongoing 
pregnancy 
Retrospective 
observational study 
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Table 11. Characteristics of studies of treatment vs no treatment of hydrosalpinx in women undergoing IVF 
Study Population Intervention Comparison Outcome Study design 
Kassabji et al 
1994 
 
n=275  
 
Women undergoing IVF 
treatment at The Jones 
Institute for Reproductive 
Medicine, East Virginia 
Medical school, USA 
between 1988 and 1992 
 
Bilateral Salpingectomy  
n= 157 
 
 
No treatment n=118 
 
oocyte retrieval and 
implantation and 
pregnancy outcome 
Retrospective 
cohort study 
Shelton et al 
1996 
 
n=23  
 
Women with hydrosalpinx 
and have had a repeated 
implantation failure and 
have had unilateral or 
bilateral salpingectomy  
 
Unilateral or bilateral 
salpingectomy 
n= 8 
No treatment n=15 
 
Implantation, clinical 
pregnancy and 
ongoing pregnancy 
rates 
Retrospective 
cohort study 
Murray et al 
1998 
 
n= 38 
 
All IVF-ET cycles in 
women with tubal factor 
infertility at The Shady 
Grove Fertility Centre, 
Rockville, USA 
 
Unilateral or bilateral 
salpingectomy n= 12 
 
No treatment n= 26 
 
Implantation, clinical 
pregnancy, 
miscarriage, live birth 
rates 
Retrospective 
cohort study 
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Strandell et al 
1999 
 
n=204  
 
Women with hydrosalpinx 
were randomised to 
laproscopic salpingectomy 
or no intervention before 
IVF treatment in 
Scandinavia 
 
Unilateral or bilateral 
salpingectomy n=116 
 
 
 
 
No intervention n= 88 
 
Clinical pregnancy, live 
birth 
 
 
Randomised 
controlled 
study 
Hammadieh et 
al 2008 
 
n=66   
66 women with 
hydrosalpinx were 
randomised before IVF 
treatment to U/S guided 
aspiration or no aspiration  
 
Ultrasound aspiration 
n = 32 
 
 
No aspiration n= 34 
Pregnancy, 
implantation, 
spontaneous abortion, 
ectopic pregnancy and 
pelvic infection rates 
Randomised 
controlled 
study 
Zolghadri et al 
2006 
 
n=13  
 
Women with recurrent 
miscarriage and a unilateral 
hydrosalpinx( diagnosed by 
U/S) randomised to tubal 
surgery and no intervention 
  
 
Laparoscopic 
fulguration n= 7 
 
 
No intervention n= 6 
Continuation of 
pregnancy over the 
first trimester 
Randomised 
controlled 
study 
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Dechaud et al 
1998 
 
n= 60 
Patients with tubal factor 
infertility 
(laparoscopic 
salpingectomy and no 
salpingectomy ) and had 
IVF treatment 
 
 
Laparoscopic 
salpingectomy n=30 
 
 
No salpingectomy  
n= 30 
 
Implantation rate and 
ongoing pregnancy 
rate 
Pilot 
randomised 
study 
Goldstein et al,  
n=31 
Women aged 22 to 38 
years with hydrosalpinx 
undergoing IVF treatment  
Surgical treatment 
(selective 
salpingostomy-
salpingectomy) n= 15 
No surgical treatment 
n= 16 
 
Pregnancy, 
spontaneous abortion, 
ectopic pregnancy and 
live birth rates 
Randomised 
controlled 
study 
Fouda and 
Sayed, 2010 
 
n=110 
Women with ultrasound 
visible hydrosalpinges 
who underwent IVF 
treatment at Ahmed 
Elgazzar Hospital, Cairo, 
between October 2006 
and May 2010 
Ultrasound guided 
aspiration of 
hydrosalpingeal fluid 
n=55 
No treatment n= 55 Implantation, clinical 
pregnancy and 
ongoing pregnancy 
rate  
Randomised 
controlled 
study 
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Kontoravdis et 
al 2006 
n= 65 
Women with unilateral or 
bilateral hydrosalpinges 
who underwent IVF 
treatment.  
Salpingectomy = 50 No salpingectomy 
 n= 15 
Implantation, clinical 
pregnancy, ongoing 
pregnancy, 
miscarriage, and 
ectopic pregnancy 
rate. 
Randomised 
controlled 
study 
 
 
 
 
 
 
 
 
 
 
 
    
 
172 
 
 
 Random sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete outcome 
data 
Selective 
reporting 
Dechaud 1998 
  Unclear Low High Low Low Low 
Strandell 2001 
  Low Low High Low Low Low 
Zolghadri 2006 
  Low Low High Low Low Low 
Kontoravdis 2006 
  Low Low High Low High Low 
Hammadieh 2008 
  Low High High Low Low Low 
 
Table 12. Risk of Bias in RCTs using the Cochrane collaboration risk of bias tool 
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Study                                            Case-cohort 
representative 
Selection of 
non-exposed 
control 
Ascertainment 
of exposure 
Outcome 
negative at 
start 
Comparability 
by design§ 
Comparability 
by analysis 
Outcome 
assessment 
Duration 
of follow-
up 
Score 
 
Akman, et al (1996) 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
8 
 
Andersen, et al. (1994) 
 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
8 
Barmat et al. (1999) 
 
* * * * * * * * 8 
Blazar, et al. (1997) 
 
* * * * * * * * 8 
Cohen, et al. (1999) 
 
* * * * * * * * 8 
Freeman, et al. (1998)                                        
 
* * * * * * * * 8 
Hung-Yu Ng, et al , (1997) 
 
* * * * ** * * * 9 
Sharara, et al, (1996) 
 
* * * * * * * * 8 
Kassabji, et al, (1994) 
 
* * * * * * * * 8 
Murray, et al,(1998) 
 
* * * * * * * * 8 
Shelton,et al, (1996) 
 
* * * * * * * * 8 
Strandell, et al, (1994) 
 
* * * * * * * * 8 
Vandromme et al, (1995) * * * * ** * * * 9 
Table 13. Appraisal of methodological quality (Newcastle-Ottawa Scale) of included studies 
 
* - Indicates that feature is present;  x- feature is absent. §-For comparability by design this checklist awards a maximum of two stars (**), one (*) or none 
if the feature is completely absent (x). 
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Primary outcome 
Miscarriage (hydrosalpinx vs no hydrosalpinx) 
Pooling of results from 14 observational studies showed a two-fold increase in the 
risk of miscarriage in women with hydrosalpinx compared to women without 
hydrosalpinx (RR=1.64, 95% CI 1.27, 2.12, p=0.0002, Figure 35). There was 
moderate variation across studies as indicated by an I2 value of 31% (p=0.13). 
 
Treatment vs no treatment (all interventions)  
Pooling of results from 7 randomised controlled trials showed halving in the risk of 
miscarriage in women who had treatment for hydrosalpinges when compared to 
women with untreated hydrosalpinx (RR=0.49, 95% CI 0.29- 0.85, p=0.01, Figure 
36). There was consistency across studies as indicated by an I2 value of 0% 
(p=0.78). 
 
By intervention 
Salpingectomy 
Pooling of results from 5 randomised trials that reported miscarriage as an outcome 
showed a 56% relative reduction in miscarriage in women who had salpingectomy for 
hydrosalpinx when compared with women with untreated hydrosalpinx (RR=0.44, 
95% CI 0.23- 0.83, p=0.01, Figure 37). There was consistency across studies as 
indicated by an I2 value of 0% (p=0.62).  
 
Pooling of results from 5 observational studies showed a reduction in miscarriage in 
women who had salpingectomy for hydrosalpinx in comparison with women with 
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untreated hydrosalpinx (RR=0.49, 95% CI 0.34- 0.71, p=0.0002, Figure 38). There 
was consistency across studies as indicated by an I2 value of 0% (p=0.75).  
 
Ultrasound guided drainage 
Pooling of results from 2 randomised controlled trials did not show a difference in 
miscarriage risk in women who had ultrasound guided drainage for hydrosalpinges 
when compared to women with untreated hydrosalpinx (RR= 0.68, 95% CI 0.24- 
1.95, p=0.47%, Figure 39). There was consistency across studies as indicated by an 
I2 value of 0% (p=0.96). 
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Study
Akman 1996
Andersen 1994
Barmat 1999
Blazar 1997
Cohen 1999
Fleming 1996
Freeman 1998
Hung -Yu Ng 1997
Katz 1996
Murray 1998
Sharara 1996
Sims 1993
Strandell 1994
Vandromme 1995
Total (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 18.90, df = 13 (P = 0.13); I² = 31%
Test for overall effect: Z = 3.78 (P = 0.0002)
Miscarriages
0
14
9
6
3
3
5
1
6
0
11
18
6
0
1
20
37
45
4
18
18
9
16
4
101
43
14
7
337
Miscarriages
4
95
99
14
13
4
12
5
114
12
8
80
26
1
24
265
486
132
87
57
62
11
467
56
89
341
89
14
2180
95% CI
1.39 [0.11, 17.65]
1.95 [1.41, 2.71]
1.19 [0.66, 2.16]
1.26 [0.51, 3.08]
5.02 [2.36, 10.69]
2.38 [0.59, 9.63]
1.44 [0.58, 3.54]
0.24 [0.03, 1.73]
1.54 [0.80, 2.95]
0.46 [0.03, 6.62]
1.21 [0.51, 2.88]
1.78 [1.19, 2.66]
1.47 [0.74, 2.91]
0.63 [0.03, 13.65]
1.64 [1.27, 2.12]
Hydrosalpinx No hydrosalpinx Risk Ratio Risk Ratio
MRandom, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
Total Total
 
         Figure 35. Meta-analysis of studies comparing miscarriage risk in women with hydrosalpinx to women with no       
           hydrosalpinx  
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Study
Dechaud 1998
Fouda 2011
Goldstein 1996
Hammadieh 2008
Kontoravdis 2006
Strandell 2001
Zolghadri 2006
Total (95% CI)
Heterogeneity: Chi² = 3.25, df = 6 (P = 0.78); I² = 0%
Test for overall effect: Z = 2.54 (P = 0.01)
Miscarriages
1
2
2
4
2
6
1
30
17
6
14
26
37
6
136
Miscarriages
1
1
3
3
1
5
5
Total
30
6
4
7
2
19
5
73
1.00 [0.07, 15.26]
0.71 [0.08, 6.45]
0.44 [0.13, 1.57]
0.67 [0.20, 2.19]
0.15 [0.02, 1.05]
0.62 [0.22, 1.76]
0.23 [0.06, 0.99]
0.49 [0.29, 0.85]
Treatment No treatment Risk Ratio Risk Ratio
Fixed, 95% CI
0.02 0.1 1 10 50
Favours treatment Favours no treatment
Total
 
 
Figure 36. Meta-analysis of studies comparing miscarriage rate in women who had treatment (all interventions) for    
           hydrosalpinx  to women who did not undergo treatment for hydrosalpinx  
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Study
Dechaud 1998
Goldstein 1996
Kontoravdis 2006
Strandell 2001
Zolghadri 2006
Total (95% CI)
Heterogeneity: Chi² = 2.63, df = 4 (P = 0.62); I² = 0%
Test for overall effect: Z = 2.51 (P = 0.01)
Miscarriages
1
2
2
6
1
30
6
26
37
6
105
Miscarriages
1
3
1
5
5
30
4
2
19
5
60
95% CI
1.00 [0.07, 15.26]
0.44 [0.13, 1.57]
0.15 [0.02, 1.05]
0.62 [0.22, 1.76]
0.23 [0.06, 0.99]
0.44 [0.23, 0.83]
Salpingectomy No salpingectomy
Risk Ratio Risk Ratio
Fixed, 95% CI
0.01 0.1 1 10 100
Favours [experimental] Favours [control]
Total Total
 
 
 
Figure 37. Meta-analysis of randomised studies comparing miscarriage rate in women who had salpingectomy for the 
treatment of hydrosalpinx to women who did not undergo treatment for hydrosalpinx  
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Study
Freeman 1998
Kassabji 1994
Murray 1998
Shelton 1996
Strandell 1994
Total (95% CI)
Heterogeneity: Chi² = 1.21, df = 3 (P = 0.75); I² = 0%
Test for overall effect: Z = 3.70 (P = 0.0002)
Miscarriages
12
14
0
2
20
62
70
4
5
74
215
Miscarriages
5
20
0
1
6
18
40
15
1
12
86
95% CI
0.70 [0.28, 1.72]
0.40 [0.23, 0.70]
Not estimable
0.56 [0.16, 1.92]
0.54 [0.27, 1.07]
0.49 [0.34, 0.71]
Salpingectomy No salpingectomy
Risk Ratio Risk Ratio
Fixed, 95% CI
0.01 0.1 1 10 100
Favours [experimental] Favours [control]
Total Total
 
 
Figure 38. Meta-analysis of observational studies comparing miscarriage rate in women who had salpingectomy for the 
treatment of hydrosalpinx to women who did not undergo treatment for hydrosalpinx  
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Study
Fouda 2011
Hammadieh 2008
Total (95% CI)
Heterogeneity: Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.72 (P = 0.47)
Miscarriages
2
4
17
14
31
Miscarriages
1
3
6
7
13
95% CI
0.71 [0.08, 6.45]
0.67 [0.20, 2.19]
0.68 [0.24, 1.95]
USS guided drainage No drainage
Risk Ratio Risk Ratio
Fixed, 95% CI
0.01 0.1 1 10 100
Favours [experimental] Favours [control]
Total Total
 
       
Figure 39. Meta-analysis of randomised studies comparing miscarriage rate in women who had ultrasound guided aspiration 
for the treatment of hydrosalpinx to women who did not undergo treatment for hydrosalpinx  
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DISCUSSION 
 
This meta-analysis, which included 23 studies, found that the presence of 
hydrosalpinx is associated with an increased risk of miscarriage. Surgical treatment 
by salpingectomy can halve the risk of miscarriage in women with hydrosalpinx 
when compared to no treatment. 
 
This review was strengthened by several factors.  I performed an extensive search 
strategy and used valid data synthesis methods. I used the Cochrane and 
Newcastle-Ottawa quality assessment Scales to rate the quality of the included 
studies and the included studies scored well, suggesting low risk of bias. 
Furthermore, no language restrictions were applied.  
 
Studies looking at miscarriage in women with hydrosalpinx following spontaneously 
conception were sparse with limited data, therefore all of the included studies were 
in pregnancies resulting from IVF/ICSI treatment. There was significant clinical 
heterogeneity between studies which differed in the diagnostic methods used to 
confirm the presence of hydrosalpinx; in some studies ultrasonography was used 
whilst others confirmed diagnosis by hysterosalpingography or on diagnostic 
laparoscopy. Whether all hydrosalpinges result in adverse outcomes or are only 
limited to those that are larger and visible with transvaginal ultrasonography 
remains uncertain (4). Furthermore, authors did not consistently report disease 
severity and whether included women had unilateral or bilateral tubal pathology. It is 
possible that women with bilateral disease may have had worse outcome than 
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those with unilateral disease. Similarly, disease severity could have had more 
adverse effect on a developing pregnancy and a potentially higher miscarriage rates 
would have been observed in this group. It was therefore not possible to analyse 
according to disease severity and the effect of unilateral versus bilateral disease 
could not be taken into account.  
 
Miscarriage occurs most often due to chromosomal anomalies. The proportion of 
miscarriages due to chromosomal abnormalities varies dramatically with maternal 
age. Under the age of 35 years, 36% of miscarriages are due to trisomies; between 
35 and 39 years, the rate rises to 46%, and > 40 years of age, trisomies are 
associated with 70% of miscarriages. (108) A more recent study (109) confirmed 
these findings, with an aneuploidy rate of 34.8% in women aged < 35 years, and 
45.7% in women aged ≥ 35 years. Therefore age is a strong confounding factor. 
The median age for the included women was 33, therefore the findings of this 
review are unlikely to have been significantly affected by this factor.  
 
It is widely established that hydrosalpinx is associated with poor implantation and 
clinical pregnancy rate. (91;94;98;103;105;106)  Moreover, it has been 
demonstrated that treatment for hydrosalpinx can improve pregnancy chances. 
(28;28;95;97) However, this review addresses the question of whether hydrosalpinx 
has a detrimental effect on an established pregnancy, and looks at the effect of 
treatment on miscarriage outcome. 
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This review found that the presence of hydrosalpinx is associated with a 64% 
relative increase in the risk of miscarriage when compared to women who do not 
have hydrosalpinx. The exact mechanisms behind the observed increase in 
miscarriage rate are not yet well understood. Hydrosalpinx fluid is known to be 
embryotoxic and contains growth factor inhibitors.  Moreover, it has been suggested 
that hydrosalpinx fluid contains lower levels of proteins and bicarbonate than does 
serum and may also contain cellular or infectious debris, lymphocytes, and other 
components, such as cytokines, prostaglandins, leukotrienes and catecholamines 
(7), all of which may have deleterious inflammatory, infectious, or immunological 
effects on the developing embryo(10) and can make the endometrium hostile to 
embryo development(6).  
 
Another explanation is mechanical flushing of the implanted embryo, especially in 
patients with recurrent hydrorrhea. Moreover, endometrial blood flow is important 
for the continuation of an implanted pregnancy; one study (9) has investigated the 
blood flow in patients with and without hydrosalpinges and found that the 
endometrium and subendometrium of patients with hydrosalpinges have a 
significantly lower blood flow, compared with patients without hydrosalpinges. 
 
This review has demonstrated that treatment for hydrosalpinx can reduce the risk of 
miscarriage. Meta-analysis of five randomised controlled trials found that when 
salpingectomy was performed, the risk of miscarriage was halved when compared 
to no treatment. Ultrasound guided aspiration of hydrosalpinges was performed in 
two trials of randomised trials which individually found a reduction in the miscarriage 
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rate, however the studies were small and meta-analysis did not reach statistical 
significance, leaving the need for more trials assessing aspiration of 
hydrosalpinges. 
 
Recurrent miscarriage is defined as the loss of three or more consecutive 
pregnancies, and affects 1% of couples trying to conceive. Current RCOG 
guidelines do not routinely recommend tubal assessment as part of the 
investigations offered to women suffering from recurrent miscarriage. (20) It is 
possible that women with unilateral hydrosalpinx are suffering recurrent pregnancy 
loss and the findings of this review raise the question whether introducing screening 
for tubal pathology and treatment can reduce the risk of miscarriage in this 
population. This is further supported by a randomised controlled trial which 
assessed the benefit of unilateral proximal tubal fulguration in cases of unexplained 
early recurrent miscarriage. In this study, included women were those women 
screened for known causes of recurrent miscarriage and a diagnosis of unilateral 
hydrosalpinx by hysterosalpingography was the only positive finding. The study 
findings showed that pregnancy outcome in terms of early miscarriage improved 
significantly after proximal tubal fulguration of the tube affected by hydrosalpinx. 
Further research is needed to assess benefit of screening by 
hysterosalpingography in women affected by recurrent miscarriage.  
 
To conclude, there is evidence to suggest that the presence of hydrosalpinx is 
associated with an increased risk of miscarriage. Treatment for hydrosalpinx can 
reduce the risk of miscarriage in these women.  
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     CHAPTER 8 
THE EFFECT OF ETHNICITY ON MISCARRIAGE: A 
COHORT STUDY AND META-ANALYSIS 
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Objectives 
 
1. To explore the association between ethnicity and miscarriage 
2. To identify at risk groups  
3. To determine whether natural or assisted conception is associated with an 
increase in miscarriage risk in women of different ethnicity 
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ABSTRACT 
Objectives 
To investigate the association between ethnicity and miscarriage  
Methods 
A cohort study of all women undergoing their first IVF cycle at CARE (110) (Centres 
for Assisted Reproduction) clinic in the UK, with a systematic review and meta-
analysis which incorporates the findings of the cohort study. For the cohort study, 
data were retrieved from 12 CARE (Centres for Assisted Reproduction) clinics from 
across the UK and Ireland, from 2008 to 2012.  For the systematic review 
MEDLINE, EMBASE and CINAHL databases (inception – October 2014) were 
searched electronically.  Studies were included where women underwent their first 
non-donor cycle of IVF (including intracytoplasmic sperm injection [ICSI] cycles). 
The primary outcome was miscarriage; secondary outcome was clinical pregnancy. 
Results 
For the cohort study a total of 5110 clinical pregnancies were analysed.  The ethnic 
groups were; White (3970), Black (48), Asian (409), Chinese (27), Mixed (175), 
Other (48) and Not stated (591). 15 observational studies were included in the 
systematic review, of which 5 studies were in naturally conceived pregnancies and 
10 studies in the IVF population. Quality assessment of the studies in the meta-
analysis showed a low risk of bias.  
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In the cohort study, women of Asian ethnicity were found to have an increased 
miscarriage risk when compared with White women (OR 1.63 [1.05-2.54] p=0.03) 
after adjusting for age, BMI, previous live birth, previous miscarriage.   
The meta-analysis found a statistically significant increase in miscarriage in women 
of Black ethnicity when compared with White women (RR 2.15 [1.07-4.34] p=0.03) 
in naturally conceived pregnancies. Incorporating the findings of the cohort study, a 
similar finding in IVF pregnancies was observed showing an increased risk of 
miscarriage in Black women when compared to White women (RR 1.50 [1.42-1.57] 
p< 0.00001). Furthermore, women of Asian ethnicity undergoing IVF had an 
increased risk of miscarriage than their White counterparts (RR 1.37 [CI 1.10-1.71] 
p=0.007), however this finding was not demonstrated in naturally conceived 
pregnancies (RR 0.78 [0.26-2.29] p=0.65).  
Conclusions 
The results of both the cohort study and the meta-analysis strongly suggest that 
ethnicity has an effect on miscarriage risk.  Black and Asian women have an 
increased risk of miscarriage when compared to White women, and this difference 
is not explained by the commonly known confounders.  Further research is needed 
to understand the reasons for the observed difference and to allow a targeted 
approach to investigations and management. 
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This chapter is divided into two sections: 
1- Observational study of miscarriage in women undergoing their first non-donor 
cycle of IVF/ICSI treatment 
2- Systematic review and meta-analysis of studies of ethnicity and miscarriage, 
incorporating the findings of the cohort study 
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COHORT STUDY 
 
Methods 
Study Design 
This observational cohort study included all women undergoing their first non-donor 
cycle of IVF or Intra-cytoplasmic Sperm Injection (ICSI) at Centres for Assisted 
Reproduction (CARE) clinic in the UK, from 2008 to 2012.  CARE is the UK’s 
largest independent provider of fertility services.  
Data were obtained from 5 main fertility clinics within the CARE consortium; 
London, Nottingham, Manchester, Northampton and Sheffield and a further 7 
nationally spread satellite centres; Bolton, Boston, Derby, Leicester, Mansfield, 
Northampton and Peterborough.   
Within the CARE database ethnicity is divided into 17 specific groups which we 
grouped into 7 broader categories; White (White British, White Irish, any other 
White), Asian (Indian, Pakistani, Bangladeshi, any other Asian background), Black 
(Black Caribbean, Black African, other Black), Chinese, Mixed (White and Black 
Carribean, White and Black African, White and Asian, any other mixed), any other 
and not stated. 
Statistical analysis 
Data were analysed using SPSS (ver. 21.0; SPSS Inc., Chicago).   The baseline 
patient characteristics were described giving frequencies with percentages, or 
means with standard deviations, where appropriate.   To estimate the independent 
contribution of ethnic group to miscarriage, regression and multiple logistic 
regression analyses were performed to calculate odds ratios and corresponding 
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95% confidence intervals.  A stepwise technique was used for multiple logistic 
regression.  Variables used within the model were age, body mass index, previous 
live birth and previous miscarriage.   
Results 
A total of 5110 clinical pregnancies (defined as the presence of a gestational sac or 
foetal pole on ultrasound scan) were reported between 2008 and 2012 at the CARE 
clinics in the UK.  The ethnic groupings were as follows; White (3970), Black (48), 
Asian (409), Chinese (27), Mixed (175), Other (48) and Not stated (591).  The crude 
miscarriage rates were as follows; White 9.5%, Black 12.5%, Asian 11%, Chinese 
3.7%, Mixed 10.3%, Other 6.3% and not stated 8.3%. 
 
Tables 14-17 display an overall description of the results including univariate and 
multivariate analysis. 
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 White 
(n=3970) 
Black 
(n=48) 
Asian 
(n=409) 
Chinese 
(n=27) 
 
Mixed 
(n=175) 
Other 
(n=48) 
Not stated 
(n=591) 
Age (in years) 
    <35 
    35.1-40 
    40.1-45 
    >45.1 
 
2575 (64.9%) 
1069 (26.9%) 
263 (6.6%) 
63 (1.6%) 
 
 
36 (75%) 
7 (14.6%) 
5 (10.4%) 
0  
 
323 (79%) 
72 (17.6%) 
12 (2.9%) 
2 (0.5%) 
 
16 (59.3%) 
9 (33.3%) 
2 (7.4%) 
0 
 
120 (68.6%) 
37 (21.1%) 
15 (8.6%) 
3 (1.7%) 
 
29 (60.4%) 
18 (37.5%) 
1 (2.1%) 
0 
 
353 (59.7%) 
162 (27.4%) 
52 (8.8%) 
24 (4.1%) 
 
 
Body mass index 
    >18.5 
    18.6-25 
    25.1-30 
    30.1-35 
    >35.1 
(n=1962) 
32 (1.6%) 
1178 (60.0%) 
587 (29.9%) 
152 (7.7%) 
13 (0.7%) 
(n=23) 
1 (4.3%) 
8 (34.8%) 
9 (39.1%) 
5 (21.7%) 
0 
 
(n=198) 
4 (2.0%) 
110 (55.6%) 
72 (36.4%) 
10 (5.1%) 
2 (1.0%) 
(n=17) 
0  
15 (88.2%) 
1 (5.9%) 
0 
1 (5.9%) 
(n= 290) 
16 (5.5%) 
160 (55.2%) 
81 (27.9%) 
30 (10.3%) 
3 (1.0%) 
(n=24) 
0 
13 (54.2%) 
11 (45.8%) 
0  
0 
(n=41) 
0 
30 (73.2%) 
8 (19.5%) 
2 (4.9%) 
1 (2.4%) 
 
Cause of infertility 
     Male factor 
     Tubal factor 
     Anovulation 
     Female other  
     Unexplained       
 
 
2315 (58.3%) 
589 (14.8%) 
513 (12.9%) 
1034 (26.0%) 
1170 (29.5%) 
 
 
24 (52.1%) 
9 (18.8%) 
4 (8.3%) 
14 (29.2%) 
19 (39.6%) 
 
 
222 (54.3%) 
49 (12.0%) 
81 (19.8%) 
80 (19.6%) 
145 (35.5%) 
 
 
16 (59.3%) 
8 (29.6%) 
2 (7.4%) 
2 (7.4%) 
9 (33.3%) 
 
 
117 (66.9%) 
26 (14.9%) 
25 (14.3%) 
49 (28.0%) 
45 (25.7%) 
 
 
27 (56.3%) 
7 (14.6%) 
6 (12.5%) 
7 (14.6%) 
18 (37.5%) 
 
 
222 (37.6%) 
82 (13.9%) 
91 (15.4%) 
111 (18.8%) 
173 (29.3%) 
 
 
Duration of 
infertility (years) 
Mean ±SD 
 
 
2.6  ±2.0 
 
2.6 ±1.4 
 
3.4 ±2.7 
 
2.1 ±1.1 
 
2.5 ±2.3 
 
3.4 ±2.2 
 
4.4 ±3.0 
Previous live birth 
 
734 (18.5%) 1 (2.1%) 76 (18.6%) 3 (11.1%) 37 (21.1%) 5 (10.4%) 131 (22.2%) 
Previous 
miscarriage 
 
746 (18.8%) 
 
10 (20.8%) 
 
65 (15.9%) 
 
2 (7.4%) 
 
29 (16.6%) 
 
8 (16.7%) 
 
36 (6.1%) 
 
Table 14.  Baseline characteristics across each ethnic group 
 
 
 
Table 15. Cycle data 
 
 White  
(n=3970) 
Black 
(n=48) 
Asian 
(n=409) 
Chinese 
(n=27) 
 
Mixed 
(n=175) 
Other 
(n=48) 
Not stated 
(n=591) 
 
Treatment type 
 
IVF 
 
ICSI 
 
FET 
 
 
1198 (30.2%) 
 
2208 (55.6%) 
 
641 (16.1%) 
 
 
17 (35.4%) 
 
27 (56.3%) 
 
6 (12.5%) 
 
 
 
115 (28.1%) 
 
238 (58.2%) 
 
65 (15.9%) 
 
 
11 (40.7%) 
 
10 (37.0%) 
 
6 (22.2%) 
 
 
41 (23.4%) 
 
100 (57.1%) 
 
37 (21.1%) 
 
 
14 (29.2%) 
 
26 (54.2%) 
 
10 (20.8%) 
 
 
 
184 (31.1%) 
 
273 (46.2%) 
 
146 (24.7%) 
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Table 16.  Outcome data 
 
 White 
(n=3970) 
Black 
(n=48) 
Asian 
(n=409) 
Chinese 
(n=27) 
 
Mixed 
(n=175) 
Other 
(n=48) 
Not stated 
(n=591) 
 
 
 
Miscarriage 
rate 
 
378 (9.5%) 
 
 
6 (12.5%) 
 
 
45 (11.0%) 
 
 
1 (3.7%) 
 
 
18 (10.3%) 
 
 
3 (6.3%) 
 
 
49 (8.3%) 
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Table 17.  Univariate and multivariate analyses 
 
Ethnic Group No. of cycles      Univariate analysis           Multivariate analysis*   
 
            OR (95% CI) P value  OR (95% CI) P value 
        
White 3980 Reference   Reference   
Asian 409 1.18 (0.85-1.63) 0.3  1.63 (1.05-2.54) 0.03 
Black 48 1.36 (0.57-3.21) 0.5  1.56 (0.44-5.44) 0.5 
Chinese 27 0.37 (0.05-2.70) 0.3  0.56 (0.07-4.28) 0.6 
Mixed 175 1.09 (0.66-1.80) 0.7  1.05 (0.54-2.03) 0.8 
Other 48 0.63 (0.20-2.05) 0.4  1.40 (0.41-4.81) 0.6 
Not stated 591 0.86 (0.63-1.17) 0.3  1.27 (0.48-3.31) 0.6 
              
*Adjusted for age, BMI, previous live birth, previous miscarriage 
                                                                                                                                          
 
 
SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Methods 
Identification of literature and study selection  
The population for this review was women of different ethnic groups that were 
reported to have a miscarriage. The study cohort consisted of non-White women 
identified within a specific ethnic group who have had a miscarriage and the 
comparison was White women who have had a miscarriage. The outcome was 
miscarriage rate in each group.  The following electronic databases were searched: 
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Web of 
Science (inception- October 2014). A search strategy was carried out based on the 
following key words and/or medical subject heading (MeSH) terminology: ethnicity, 
ethnic group, ethnic, racial aspects, miscarriage, recurrent miscarriage, fetal death, 
abortion and embryo. The reference lists of all known primary and review articles 
were examined to identify cited articles not captured by electronic searches. No 
language restrictions were placed in any of our searches or study selection. 
 
I excluded studies that did not specify ethnicity of included women, including studies 
which have grouped women as ‘non-White’ without specifying their ethnic group. 
Studies were selected in a two-stage process. First, the titles and abstracts from the 
electronic searches were scrutinised by two reviewers independently (HH and FR) 
and full manuscripts of all citations that were likely to meet the predefined selection 
criteria were obtained. Second, final inclusion or exclusion decisions were made on 
examination of the full manuscripts. In cases of duplicate publication, the most 
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recent and complete versions were selected. Any disagreements about inclusion 
were resolved by consensus.  
 
I completed the quality assessment with a second reviewer (FR).  The Newcastle-
Ottawa Quality Assessment was implemented for quality assessment of the 
included observational studies. This scale assesses eight components, including 
representativeness of the exposed cohort, selection of non-exposed cohort, 
ascertainment of exposure, outcome at start, comparability by design or analysis, 
outcome assessment, duration and adequacy of follow up . One star is awarded as 
maximum for all items except for comparability where a maximum of two stars can 
be awarded. I used an arbitrary score based on the assumption of equal weight of 
all items included in the Newcastle-Ottawa Scale. This was used to give a 
quantitative appraisal of overall quality of the individual studies. The score ranged 
from 0 to 9, with a score of either 0 or 1 for each item. From each study, outcome 
data were extracted in 2 x 2 tables by two reviewers HH and FR.  
 
Statistical analysis 
For the analysis of miscarriage rates I analysed data per total number of 
pregnancies for each ethnic group (Caucasian, Black, Asian and Hispanic). Data for 
spontaneously conceived pregnancies was analysed separately from pregnancies 
achieved by assisted reproductive techniques (IVF/ICSI).  I carried out statistical 
analyses using the Review Manager software (RevMan 5.3). Relative risks with 
95% confidence intervals from each study were combined for meta-analysis using 
the Peto-modified Mantel-Haenszel method. The fixed-effect model for combining 
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data was used where it was reasonable to assume that studies were estimating the 
same underlying treatment effect: i.e. where trials are examining the same 
intervention, and the trials’ populations and methods were judged sufficiently 
similar. Where clinical heterogeneity was deemed significant to expect that the 
underlying treatment effects differ between trials, or where I detected substantial 
statistical heterogeneity, I used random-effects meta-analysis to produce an overall 
summary of an average treatment effect across trials.  
 
Heterogeneity was assessed graphically using forest plot and statistically using chi-
squared test.  To detect publication and related biases, I undertook funnel plot 
analysis using Egger’s tests to evaluate for asymmetry.  
 
Data extraction 
I designed a data extraction form to extract relevant data. A second reviewer (FR) 
extracted data using the agreed form. Any discrepancies were resolved by 
discussion.  
 
Literature identification 
The search strategy yielded 4003 citations (Figure 40) of which 3947 publications 
were excluded because it was clear from the title or abstract that they did not fulfil 
the selection criteria. I obtained full manuscripts for the remaining 56 articles. 42 
publications were excluded because 10 did not specify ethnicity, 8 did not report 
miscarriage rate, 6 did not have a control group, 14 reported pregnancy loss beyond 
24 weeks gestation, and 4 presented duplicate data. Therefore the total number of 
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studies included in the review was 14 (111-124). All of the included studies were of 
observational study design.  
 
Figure 40. Study selection process for the systematic review of ethnicity and miscarriage  
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Study characteristics 
The characteristics of the studies are presented in Tables 19 and 20. 
 
Quality assessment 
The Newcastle-Ottawa scale for Quality Assessment is presented in Table 18. The 
studies scored well on the scale. There was no evidence of publication bias on 
funnel-plot assessment. 
 
Results 
 
Naturally conceived pregnancies 
Black vs Caucasian 
Pooling of results from 5 studies that reported miscarriage as an outcome found an 
increased risk of miscarriage in Black women when compared with White women 
(RR 2.15 [1.07-4.34] p=0.03, Figure 41). There was significant variation across 
studies as indicated by an I2 value of 98% (p < 0.00001). 
 
Asian vs Caucasian 
Pooling of results from 3 studies that reported miscarriage as an outcome showed 
no difference in the risk of miscarriage in women of Asian ethnicity when compared 
to women of White ethnicity (RR 0.78 [0.26-2.29] p=0.65, Figure 42). There was 
moderate heterogeneity across studies as indicated by an I2 value of 49% (p=0.14).
 
 
 
Study                                                      
 
Case-cohort
representative 
Selection of 
non-exposed 
control 
Ascertainment 
of exposure 
Outcome 
negative 
at start 
Comparability 
by design§ 
Comparability 
by analysis 
Outcome 
assessment 
Duration 
of 
follow-
up 
Score 
Goetzl (2004) * * * * ** * * * 9 
Lyon (1994) * * * * x * * x 6 
Hassan (2009) * * * * ** * * * 9 
Mukherjee (2012) * * * * ** * * * 9 
Seifer (2010) * * * * ** * * * 9 
Shahine (2009) * * * * ** * * * 9 
Sharara (2011) * * * * * * * * 8 
Csokmay (2011) * * * * * * * * 8 
Bendikson (2004) * * * * * * * * 8 
Sharara (1999) * * * * * * * * 8 
Palep-Singh (2006) * * * * ** * * * 9 
Mahmud (1995) * * * * * * * * 8 
Wyatt (2005) * * * * * * * * 8 
Feinberg (2006) * * * * ** * * * 9 
 Table 18. Appraisal of methodological quality (Newcastle-Ottawa Scale) of included studies 
* - Indicates that feature is present;  x- feature is absent. §- For comparability by design this checklist awards a maximum of two stars (**), one (*) or 
none if the feature is completely absent (x). 
 
 
 
Study Population Ethnic groups Outcome Study design  
 
Goetzl, 2004 
n=7932 
 
7932 pregnant women at 10 to 14 
weeks gestation were recruited 
from 12 US and Canadian centres 
African American = 
344 
 
Caucasian =6561  
Hispanic =445  
Asian =416  
Other =160  
 
 
 
Miscarriage  Rate 
 
Prospective cohort 
study 
Lyon, 1994 
 
n=11046 
The outcome of 11,046 infant, from 
20 weeks gestation, born to 
mothers of different ethnic origin 
within one London borough during 
the period from June 1990 to end 
of 1992 
White = 8281 
Asian = 1219 
African = 597 
West Indian = 949 
 
Miscarriage  Rate Retrospective cohort 
study 
 
Wyatt, 2005 
n=264,653 
 
Women undergoing routine 
screening for Down syndrome or 
neural tube defects between 1995 
and  2000 
 
White = 160, 567 
Asian = 45, 723 
Black = 13, 826 
 
Miscarriage rate 
 
Retrospective cohort 
study 
Table 19. Table of characteristics of studies of miscarriage in naturally conceived pregnancies  
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Hasan, 2009 
n=3658 
 
 
 
 
 
White = 2458 
Black = 767  
Hispanic = 268  
 
Other = 159 
Unknown = 6 
 
 
 
 
 
 
Miscarriage  Rate 
 
 
 
Prospective Cohort 
study 
Mukherjee, 2013 
n=3533 
 
 
 
Women wishing to conceive and 
women in early pregnancy who 
were followed up till pregnancy 
outcome in the period from 2000 to 
2009 
White = 2732 
Black = 801 
 
Miscarriage  Rate Prospective cohort 
study 
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Table 20. Characteristics of studies of miscarriage in IVF pregnancies 
Author, year and study design Sample population Outcomes measured Fresh/frozen 
cycles 
Patient numbers 
Csokmay et al 2011  
Retrospective Cohort Study  
All patients who underwent 
frozen blastocyst transfer 
between 2003 and 2008 in 
a University-based ART 
program. University of 
California at San Francisco 
Miscarriage rate, clinical 
Pregnancy rate and Live 
birth rate 
Frozen embryo 
cycles with 
autologous 
oocytes 
Total 169 women  
Caucasian = 119 
African American = 50 
 
Seifer et al 2010  
Retrospective Cohort Study  
Non-donor IVF cycles 
between 2004 and 2006 in 
White and Black women, 
identified using the SART 
database (USA) 
Miscarriage rate, Live birth 
rate per cycle started 
Fresh and frozen 
non-donor IVF 
cycles 
Total 158,693 cycles.  
Fresh cycles:  
Black = 10,354  
White = 120,994 
 
Frozen cycles:  
Black = 1,933  
White = 25,412  
Sharara et al 2000  
Retrospective Cohort Study  
Women undergoing IVF at 
an inner city, university-
based IVF programme 
(University of Maryland, 
USA) between April 1997 
and July 1999 and under 
the age of 40  
Miscarriage rate, 
Implantation rate, clinical 
pregnancy rate and 
ongoing/delivered 
pregnancy rate 
Fresh non-donor 
IVF cycles 
Total 168 cycles 
White = 121 cycles  
Black = 47 cycles 
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Sharara et al 2012 
Retrospective Cohort Study 
All white and South Asian 
Women <40years 
undergoing blastocyst 
transfers at Virginia Centre 
for Reproductive Medicine, 
USA. 
Miscarriage rate, Clinical 
PR and live birth rate 
Non-donor, initial 
fresh cycle, 
blastocyst 
transfer 
Total = 292 
White = 238 cycles 
South Asian = 54 
Shahine et al 2009  
Retrospective Cohort Study 
Indian and Caucasian 
Women undergoing 
blastocyst transfer between 
Jan ‘05 – July ‘07 in 
Stanford University fertility 
centre, USA 
Miscarriage rate, Live birth 
rate per cycle started 
 
 
Initial Fresh cycle, 
blastocyst 
transfer 
Total 225 women 
Caucasian = 145 
Indian = 80  
Bendikson et al 2005 
Retrospective Cohort study 
Women undergoing first 
IVF cycle between August 
1994 and March 1998 at 
Boston IVF, Brigham 
Womens Hospital and 
Boston Reproductive 
Science Centre (USA) 
Live birth rate, chemical 
and ectopic pregnancies, 
miscarriage rate 
First cycle, fresh 
non-donor 
transfer 
 
Total 1135 cycles 
White = 1039 
African American = 43, 
Hispanic = 18 
Asian = 35. 
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Palep-Singh, 2006 Women undergoing IVF/ICSI cycles between 
2000 and 2004 at Leeds 
Teaching Hospitals, Leeds 
(UK) 
Gonadotrophin dose, 
number of oocytes 
retrieved, miscarriage, 
ongoing clinical pregnancy 
Fresh IVF or ICSI 
cycles Total 608 cycles White = 420 
Asian = 188 
Mahmud, 1995 Women undergoing first 
IVF cycles between April 
1987 and December 1993 
at Oxford Radcliffe 
Hospital, Oxford (UK) 
Clinical pregnancy, 
miscarriage, live birth rate 
First IVF or ICSI 
cycles 
Total 132 cycles 
White = 88 
Asian = 44 
Feinberg, 2006 Women undergoing first 
cycle of fresh, non-donor 
ART from 1999 to 2003 
Within the DoD population, 
USA  
 
 
Implantation, clinical 
pregnancy, miscarriage, 
live birth rate 
First cycle of 
fresh, non-donor 
IVF or ICSI 
 
Total 1227 cycles 
White = 974  
Black = 273  
 
 
 
 
 
 
Figure 41. Meta-analysis of studies comparing miscarriage risk in Black and White women in naturally conceived pregnancies 
 
 
Study 
Lyon, 1994
Goetzl, 2004
Wyatt, 2005
Hasan, 2009
Mukherjee, 2013
Total (95% CI)
Heterogeneity: Tau² = 0.57; Chi² = 164.70, df = 4 (P < 0.00001); I² = 98%
Test for overall effect: Z = 2.15 (P = 0.03)
Miscarriages
10
4
249
124
131
Total
597
344
13826
767
801
16335
Miscarriages
29
32
755
347
406
Total
8281
6561
160567
2458
2732
180599
Random, 95% CI
4.78 [2.34, 9.77]
2.38 [0.85, 6.70]
3.83 [3.32, 4.42]
1.15 [0.95, 1.38]
1.10 [0.92, 1.32]
2.15 [1.07, 4.34]
Black White Risk Ratio Risk Ratio
Random, 95% CI
0.02 0.1 1 10 50
Favours experimental Favours control
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Study
Goetzl, 2004
Lyon, 1994
Wyatt, 2005
Total (95% CI)
Heterogeneity: Tau² = 0.50; Chi² = 3.91, df = 2 (P = 0.14); I² = 49%
Test for overall effect: Z = 0.46 (P = 0.65)
Miscarriages
1
1
288
Total
416
1219
45723
47358
Miscarriages
32
29
755
Total
6561
8281
160567
175409
95% CI
0.49 [0.07, 3.60]
0.23 [0.03, 1.72]
1.34 [1.17, 1.53]
0.78 [0.26, 2.29]
Asian White Risk Ratio Risk Ratio
Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
    Figure 42. Meta-analysis of studies comparing miscarriage risk in Asian and White women in naturally conceived 
   pregnancies 
 
 
 
 
 
 
 
 
 
 
 
 
 
IVF/ICSI pregnancies 
Black vs Caucasian 
Pooling of results from 6 studies that reported miscarriage as an outcome found an 
increased risk of miscarriage in women of Black ethnicity when compared to women 
of White ethnicity (RR 1.50 [1.42 - 1.57 ] p< 0.00001, Figure 43). There was 
consistency across studies as indicated by an I2 value of 0% (p=0.92).  
 
Asian vs Caucasian 
Pooling of results from 6 studies that reported miscarriage as an outcome in the 
found an increase in miscarriage risk in women of Asian ethnicity when compared to 
women of White ethnicity (RR=1.37, 95% CI 1.10 – 1.71, p=0.007, Figure 44). 
There was consistency across studies as indicated by an I2 value of 1% (p=0.41).  
 
 
 
 
 
 
 
 
 
 
 
 
Study
Bendikson, 2004
Harb 2015
Csokmay, 2011
Feinberg, 2006
Seifer, 2010
Sharara, 2000
Total (95% CI)
Heterogeneity: Chi² = 1.41, df = 5 (P = 0.92); I² = 0%
Test for overall effect: Z = 15.65 (P < 0.00001)
Events
1
6
7
25
1356
2
Total
43
48
50
100
6815
9
7065
Events
34
378
12
66
9894
4
Total
1039
3970
119
415
74390
51
79984
95% CI
0.71 [0.10, 5.07]
1.31 [0.62, 2.79]
1.39 [0.58, 3.32]
1.57 [1.05, 2.36]
1.50 [1.42, 1.57]
2.83 [0.61, 13.25]
1.50 [1.42, 1.57]
Black White Risk Ratio Risk Ratio
95% CI
0.5 0.7 1 1.5 2
Favours experimental Favours control
 
Figure 43. Meta-analysis of studies comparing miscarriage risk in Black and White women in IVF pregnancies 
 
 
 
    Figure 44. Meta-analysis of studies comparing miscarriage risk in Asian and White women in IVF pregnancies 
  
 
 
Discussion  
This systematic review found that women of Black ethnicity are at increased risk of 
miscarriage than White women in both naturally conceived and IVF pregnancies. 
Women of Asian ethnicity also have an increased risk of miscarriage in IVF 
pregnancies, however this finding was not demonstrated in naturally conceived 
pregnancies.  
 
 
There are several factors that strengthen our analysis. We performed an extensive 
search strategy and used valid data synthesis methods. We used the Newcastle-
Ottawa Quality Assessment Scale to rate the quality of the included studies and the 
included studies scored well on this scale, suggesting low risk of bias. Furthermore, 
no language restrictions were applied.  
 
The findings of this review are limited by the number of included studies. Only 5 
studies reported miscarriage risk for naturally conceived pregnancies in Black and 
White women, although they include a large sample size (n=196, 934). Similarly, 6 
studies report miscarriage risk in Asian women (3 studies in spontaneous 
pregnancy and 3 studies in the IVF population) but have a large sample size 
(n=222,767 and 6491 respectively). Furthermore, studies did not consistently 
distinguish first from second trimester miscarriages. Several of the studies included 
all pregnancy losses below 24 weeks gestation. Miscarriages occurring in the 
second trimester of pregnancy are uncommon with a reported incidence of 
approximately 0.5% in low risk women (Westin et al, 2007). Moreover, it is possible 
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that variation exists within ethnic groups and the findings of this review may not be 
generalizable.  
 
This review found that women of Black and Asian ethnicity appear to be at 
increased risk of miscarriage when compared to White women. A possible 
explanation for our findings is that women originating from certain ethnic groups are 
at more risk of having conditions which are associated with an increased risk of 
miscarriage. Firstly, uterine myoma are more prevalent in women of Black ethnicity, 
and tend to be multiple. (125;126)  It is not known exactly how fibroids can cause 
miscarriage. The possible mechanisms are increased irritability of the uterus, 
mechanical compression by the fibroid and damage to the blood supply to the 
growing placenta or foetus. Intramural myomas have also been shown to be 
associated with a high rate of spontaneous miscarriage. Moreover, women who 
undergo uterine artery embolization (UAE) for the treatment of fibroids are reported 
to be at higher risk of miscarriage due to interruption to the endometrial blood flow. 
(127) 
 
Secondly, diabetes mellitus and obesity is more prevalent in Black and Asian 
women than women of White ethnicity. (112) A four-fold increase in the risk of 
spontaneous miscarriage has been reported in diabetic pregnant women with poor 
glycaemic control in early pregnancy. (128) The risk of early miscarriage and 
recurrent miscarriage have been shown to be significantly higher among obese 
patients. (128-130)  The exact reason for the obesity-related increased risk of 
miscarriage is not known. The possibility of oocyte abnormality was refuted by a 
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recent study of obese women receiving oocyte donation who experienced a higher 
rate of spontaneous miscarriage compared with normal weight peers.  Undiagnosed 
pre-gestational diabetes may be linked with maternal obesity and increased 
miscarriage rate. (115) More interestingly some medical disorders that associated 
with increase miscarriage rate and pregnancy complications, like SLE, 
hypertension, and APS, are more prevalent, and even more severe in non-White, 
especially Black women, particularly in childbearing age, while auto-immune 
diseases are less prevalent in Hispanic and Asian women. (131) 
 
Both sporadic and recurrent miscarriage are recognised complications of systemic 
lupus erythematosus (SLE). One study has found a 20% increase in the miscarriage 
risk in women with SLE. The presence of antiphospholipid antibodies (found in 1-
3% of the healthy fertile population) whether primary or secondary to another 
condition such as systemic lupus, is associated with recurrent miscarriage. (20) 
Previous studies have shown that the prevalence and incidence of lupus is high in 
patients from certain ethnic groups including those of African descent in North 
America (Afro-Americans) or with a Caribbean background in the UK (Afro-
Caribbeans), those of Asian descent including those from the Indian subcontinent 
(those from India or Pakistan, known as South Asians or Indo-Asians), those of 
Hispanic origin in North America, and those of Chinese background. (132-136) 
 
The results of both the cohort study and the meta-analysis strongly suggest that 
ethnicity has an effect on miscarriage.  Black and Asian women have an increased 
risk of miscarriage when compared with White women, and this difference is not 
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explained by the commonly known confounders.  Further research is needed to 
understand the reasons for the observed difference to allow a targeted approach to 
investigations and management. 
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SECTION 3 
INTERPRETATION AND CONCLUSION 
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CHAPTER 9 
INTERPRETATION AND IMPLICATIONS FOR PRACTICE 
AND RESEARCH FOR CAESAREAN SCAR PREGNANCY 
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THE INCIDENCE AND MANAGEMENT OUTCOMES OF CAESAREAN SCAR 
PREGNANCY IN THE UK: A NATIONAL PROSPECTIVE COHORT STUDY 
 
Chapter 5 presents a national prospective cohort study using the UK Early 
Pregnancy Surveillance Service to identify all women in the UK diagnosed with 
caesarean scar pregnancy over a 12 months surveillance period. No population-
wide prospective incidence studies of caesarean scar pregnancy had been 
previously undertaken and the UK incidence was previously unknown.  
 
The study found that the estimated UK incidence of CSP is 1 per 10 000 maternities 
[95% confidence interval (CI), 0.71 – 1.19]. This equates to one case every two 
years in a unit delivering 5000 women. Maternal age greater than 35 years, 
smoking, parity (2 or more) and number of previous caesarean section (2 or more) 
were strongly associated with an increased risk of having a caesarean scar 
pregnancy. These findings are important for the counselling of women who have 
had previous caesarean section delivery and who may wish to plan for further 
pregnancy. For the purpose of calculating the incidence of caesarean scar 
pregnancy, maternity data was used as the denominator population. A long term 
study of women who have had caesarean section delivery is recommended to allow 
a more accurate calculation of the true incidence of this condition. 
The risk of CSP in a woman may be expected to increase with increasing number of 
previous caesarean sections , however this could not demonstrated in our study 
due to the limited sample size. Furthermore, it was not possible to determine 
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whether the indication for CS, the method for uterine closure (one vs two layers) 
and the choice of suture material are associated with risk of CSP as this information 
was poorly reported, often due to women delivering in another unit and their delivery 
details were not available to reporting clinicians. In this study, one woman (1/60, 
1.6%) diagnosed with CSP was previously treated for caesarean scar pregnancy. 
Long term follow up of women with caesarean scar pregnancy is needed to identify 
the risk of recurrence.  
 
Women should be fully counselled about all of the management options, including 
the benefits and risks associated with each treatment. The study found that the 
primary management most commonly used was surgical treatment, used in almost 
2/3 of cases. Dilatation and curettage was performed in the majority of these cases. 
Methotrexate was administered in all women undergoing medical management. 
Interestingly, the study found that expectant management is chosen more often 
than medical management. 
 
Women may choose to have expectant management for various reasons. Some 
women and clinicians may decide to watch and wait in the hope that the pregnancy 
will resolve spontaneously, which was the case in 4/10 women managed 
conservatively. Moreover in cases of diagnostic uncertainty conservative 
management may be more appropriate in the first instance. Some women may wish 
to preserve their pregnancy, whilst accepting the risks of maternal or fetal 
compromise. Indeed, four of the women in this study had a live birth following 
planned or emergency caesarean section; in all cases the women suffered massive 
    
 
 
 
220 
obstetric haemorrhage, necessitating an emergency hysterectomy in two women. 
Although most clinicians would probably prefer not to have to perform a caesarean 
section in a woman with a morbidly adherent placenta, ultimately it is the decision of 
the woman involved, and this should be respected. Regular antenatal visits, 
placental localisation during pregnancy and a plan for early delivery by caesarean 
section should be considered. Moreover, women should be cross matched prior to 
delivery, and it may be beneficial to involve a gynaecologist, vascular surgeon or 
interventional radiologist prior to, and preferably for them to be available at the time 
of delivery should emergency interventions for the control of haemorrhage be 
required. 
 
Fifty percent of medically managed caesarean scar pregnancies were treated 
successfully with methotrexate. For women wishing to have less invasive treatment, 
this might be a suitable option however they should be informed of the risk of failure 
(50%), and the need for further treatment with repeat medical management or 
surgical management. This is because one of the main complications associated 
with medical management is retained products of conception.  
 
Surgical treatment was the most commonly used treatment approach and is 
associated with the highest rate of successful treatment following primary 
management. This approach is associated with an increased risk of bleeding when 
compared with medical management, although this was not found to be statistically 
significantly.  
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We recommend that a shared management plan should be discussed and put in 
place early in pregnancy. The choice of treatment should be centred around the 
woman’s preferences following full counselling on the treatment options.  
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     CHAPTER 10 
INTERPRETATION AND IMPLICATIONS FOR PRACTICE 
AND RESEARCH FOR SYSTEMATIC REVIEWS OF 
MISCARRIAGE STUDIES 
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Progesterone for threatened miscarriage 
Chapter 6 presents a systematic review of progestogen use for threatened 
miscarriage. The findings of the review suggested that progestogens can reduce the 
risk of miscarriage by up to a half in women presenting with early pregnancy 
bleeding. The meta-analysis included seven studies which were small and of poor 
methodological quality. 
 
To understand how the existing evidence is viewed by clinicians, I conducted  UK 
and International Clinician surveys, as well as UK patient surveys.  
 
The UK clinician survey (n=222) in Oct 2012 found that, in the UK, the vast majority 
of clinicians (212/222, 95.5%) do not use progesterone to prevent miscarriage in 
women with early pregnancy bleeding.  The key reason for non-use is the lack of 
robust evidence. It is therefore not surprising that the majority (201/222, 91%) called 
for a definitive trial.  
 
A survey of international practitioners was also conducted at FIGO (International 
Federation of Gynecology and Obstetrics) 2012 Conference, Rome. Surprisingly, 
this survey found the majority of clinicians (61/68, 90%) already use progesterone in 
women with early pregnancy bleeding, although the vast majority (56/66, 85%) were 
willing to recruit into a randomised trial, (Figure 38) presumably indicating lack of 
confidence in the available evidence.  
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UK patient survey 
 
I conducted a survey to seek the opinion of women seen in the Early Pregnancy 
Unit (n=79) at Birmingham’s Womens Hospital, in December 2012. The majority of 
women (57/79, 72%) said they would consider taking part in the trial, and 70% 
(55/79) found the vaginal route of administration acceptable. Furthermore, an 
independent survey was conducted by the Miscarriage Association to identify 
women’s opinions on a double-blind placebo-controlled trial in early pregnancy and 
the acceptability of administering vaginal or rectal medications. The findings of this 
survey of 128 women showed that 91% (116/128) would enter or consider entering 
the trial. The vaginal route of administration of medicines was acceptable to 
100/111 (90%) of women, and the rectal route acceptable to 91/111 (82%) of 
women. 
 
Given the findings of my review, and the prioritisation of this important 
question by NICE, as well as the overwhelming support from national 
international clinicians, and patients, I applied for funding as a co-
investigator from the Health Technology Assessment, NIHR to address 
this important question. I was successful in being awarded a £1.8 
million grant to perform a randomised placebo-controlled trial (The 
PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial). 
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Aim: To evaluate the effects of progesterone treatment to prevent miscarriage in women with 
early pregnancy bleeding. 
Primary objective: 
 
1. To test the hypothesis that in women presenting with vaginal bleeding in the first trimester, 
progesterone (400mg pessaries, twice daily), started as soon as possible after a scan has 
demonstrated a visible intrauterine gestation sac and continued to 16 completed weeks of 
gestation, compared with placebo, increases maternities with live births beyond 34 
completed weeks by at least 5%. 
Secondary objectives: 
 
2. To test the hypothesis that progesterone improves other pregnancy and neonatal 
outcomes, including gestation at birth and survival at 28 days of neonatal life. 
3. To test the hypothesis that progesterone, compared with placebo, is not associated with 
substantial adverse effects to the mother or the neonate, including chromosomal anomalies 
in the newborn.  
4. To explore differential or subgroup effects of progesterone in prognostic subgroups, 
including age, fetal heart activity, gestation at presentation, amount of bleeding and body 
mass index. 
5. To perform a cost-effectiveness analysis, with cost per additional birth over 34 weeks’ 
gestation from an NHS and Personal Social Services perspective as the primary analysis. 
We will also model longer term outcomes to the extent the data permit. 
PRISM Progesterone In Spontaneous Miscarriage 
 
Figure 45. PRISM Trial aims and objectives 
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THE EFFECT OF PRESENCE AND TREATMENT OF HYDROSALPINX ON 
MISCARRIAGE RISK 
 
Chapter 7 presents a systematic review of 23 studies which found that the presence 
of hydrosalpinx increases the risk of miscarriage in women who have an intrauterine 
pregnancy. Meta-analysis showed a 64% relative increase in the risk of miscarriage 
in women with untreated hydrosalpinx. Furthermore, the review suggested that in 
women who underwent salpingectomy, the risk was decreased by 56%.  
The findings of this review demonstrate a continued harmful effect even after 
successful implantation and an established intrauterine pregnancy is confirmed on 
ultrasonography. It would support the current approach of treating women with 
hydrosalpinx prior to commencing IVF treatment. Although individual studies found 
a reduction in miscarriage in women who underwent ultrasound guided aspiration of 
hydrosalpinx, meta-analysis did not shown an overall effect, probably due to the 
size and number of included studies. A large study to determine the benefit of the 
latter tube conserving treatment can offer additional options for women who do not 
wish to have tubal disconnection. Moreover, the benefit of alternative surgical 
management with salpingostomy for the treatment of hydrosalpinx needs further 
assessment.  
Furthermore, the findings of this review also raise the question whether women who 
have recurrent miscarriage should be routinely screened for the presence of 
hydrosalpinx. Women who have unilateral hydrosalpinx may be at increased risk of 
miscarriage after spontaneous conception. Currently, tubal assessment is not 
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routinely performed. Further research is needed to determine the benefit of tubal 
assessment through the use hysterosalpingography.  
 
 
THE EFFECT OF ETHNICITY ON MISCARRIAGE 
 
Chapter 8 presents a cohort study and meta-analysis of pregnancy outcome in 
women of different ethnic backgrounds. The findings suggest that women of Black 
and Asian ethnicity are at increased risk of miscarriage when compared to women 
of White ethnicity. This  was demonstrated in naturally conceived and IVF 
pregnancies in women of Black ethnicity, and was observed in Asian women 
conceived after IVF treatment.  
 
The reasons for these findings are not fully understood. We accounted for some of 
the known risk factors associated with miscarriage, such as age and BMI, however 
a difference was still demonstrated. It is known that fibroids, diabetes and obesity 
are more prevalent in women of Black and Asian ethnicity, and they are associated 
with an increased risk of miscarriage. Women should receive pre-pregnancy 
counselling on the benefits of optimising diabetes control and weight loss. 
Furthermore, evidence suggests that submucosal fibroids reduce implantation rates 
and increase miscarriage risk, and it has therefore been recommended that these 
should be removed prior to IVF treatment. Moreover, it has been suggested that 
intramural fibroids which distort the uterine cavity should be removed to potentially 
improve IVF outcome.   
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There is a need to understand why some groups are at greater risk of miscarriage 
than others, to enable the identification of targeted investigations and management 
for women at greater risk of miscarriage.  Further research to assess whether these 
differences are genetically induced or are caused by other variables such as 
nutrition is required. This can also help offer appropriate counseling to these 
women. 
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